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MECHANISTIC AND FUNCTIONAL CHARACTERIZATION OF B AND T 
LYMPHOCYTE ATTENUATOR (BTLA) IN CD8 TUMOR INFILTRATING 
LYMPHOCYTES 
Krit Ritthipichai, D.V.M., M.S.  
Supervisory Professor: Patrick Hwu, MD 
This dissertation project focused on understanding the functional role of BTLA 
on CD8+ Tumor Infiltrating Lymphocytes (TIL) from metastatic melanoma patients. 
Clinical trials of adoptive T-cell therapy (ACT) using autologous ex vivo expanded TIL 
have demonstrated the great potential of this immunotherapy with an overall clinical 
response rate 40-50% for stage IV metastatic melanoma patients. We have investigated 
a number of biomarkers in both the infused TIL and the tumor microenvironment for 
their association with clinical response. Surprisingly, a subset of CD8+ TIL expressing 
the co-inhibitory molecule BTLA (B-and-T lymphocyte attenuator) was highly 
associated with clinical response, while expression of other co-inhibitory molecules 
such as PD-1, TIM-3, and Lag3 did not associate with response. BTLA is expressed by 
T cells, B cells, and NK cells and serves as a T cell differentiation maker whereby high 
expression of BTLA associates with less differentiated T cell phenotype. While the 
suppressive function of the ITIM and ITSM motifs of BTLA are well described, the 
Grb2 motif’s function remains understudied.  
In this study, we sought to determine the functional characteristics of the 
CD8+BTLA+TIL subset and define the contribution of the Grb2 motif of BTLA in T 
cell co-stimulation. We have uncovered a survival advantages of the BTLA+ subset that 
allows for serial killing of target tumor cells, which may explain our previous 
vi 
 
correlation between this subset and response to TIL ACT.  BTLA-HVEM interaction 
during T cell activation led to the specific activation of SRC kinase. In addition, our 
results unveiled a role for the BTLA-associated Grb2-binding motif in T cell 
proliferation and IL-2 production following TCR engagement that was independent of 
the inhibitory function of ITIM/ITSM motifs.  
Overall, our study first unveil the dual role of BTLA as both a co-stimulatory 
and co-inhibitory molecule. The integration of the positive and negative signals 
transduced by BTLA promotes IL-2 secretion while reducing certain effector function 
of T cell. Altogether, the combination of both BTLA signaling and inherent attributes 
of less differentiated T cells could promote T cell survival, persistence, and anti-tumor 
function.  
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General Introduction 
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1.1 Cancer Immunotherapy 
  Recently, the second edition of hallmarks of cancer proposed by Robert 
Weinberg and Douglas Hanahan have included evading immune system destruction as 
one of the biological properties that transformed cells require during multistep 
carcinogenesis (1, 2). In the past two decades, our extensive gain in knowledge of 
cancer immunology has solidly proved that the immune system plays both a positive 
and negative role during cancer development.  The first evidence of the immune 
system’s role in tumor control was demonstrated by William B. Coley in 1893 when 
he treated inoperable malignant sarcoma with inactivated bacterial lysates that 
consisted of Streptococcus pyogenes and Bacillus prodigiosus, which triggered an 
immune response resulting in tumor regression in a patient for almost 26 years until his 
death (3). Although the finding suggested that the activated immune system could 
promote tumor regression, there was no strong evidence to support this clinical 
observation.  
In early 1909, Paul Ehrlich first postulated that the immune system could 
recognize and destroy cancerous cells (4). Five decades later, Lewis Thomas and 
MacFarlane Burnet proposed their immunosurveillance hypothesis, which suggested 
the existence of effector cells that can sentinel the transformed cells in the body and 
eliminate them through a specific mechanism (4-6). Later on, a number of extensive in 
vivo and in vitro studies have refined and included immunosurveillance as a part of 
“cancer immunoediting”, which more precisely defines the involvement of the immune 
system in tumor development in three phases; elimination, equilibrium, and escape. 
Elimination (or immunosurveillance) is the first step, in which immune cells recognize 
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tumor cells and destroy cancer cells. In the equilibrium phase, some tumor cells are not 
targeted by immune-mediated killing. Emerging new tumor cell variants are then 
selected to grow and flee from immune detection in the escape phase (7-9).  
1.1 a) Highlights of major discoveries in cancer immunotherapy 
 
1950:  Evidence from Llyod Old, and other scientists emphasized the importance of 
the immune system in tumor control (10, 11).  
1961 to 1970:  
- Hellstorm and colleagues demonstrated specific tumor recognition by immune 
cells (12). 
- Alpha fetoprotein (AFP) was identified as the first tumor-specific antigen by 
Irlin’s group (13). 
- Gershon and Kondo revealed the suppressive role of T cells, leading to 
immunotolerance theory (14). 
1971 to 1980 
- Discovery of dendritic cells by Ralph Steinman, leading to cancer vaccine study 
(15).  
- Identification of Natural killer cells by Eva Klein and Hans Wigzell, leading to 
the development of NK cell therapy (16). 
- Francis W. Ruscetti, Doris A. Morgan, Robert Gallo and colleague discovered 
Interleukin-2, the first effective immunotherapy in cancer treatment and also 
used in combination with other immunotherapies (17-19).  
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1981 to 1990  
- FDA approved Rituxan, the first monoclonal antibody for B cell lymphoma 
treatment developed and tested by Ronal Levy. A few years later, Greg Winter 
successfully generated the world’s first humanized antibody (20, 21). 
- Dr. Steven Rosenberg first used high-dose IL-2 as a single therapy for cancer 
patients with advanced diseases and treated the first melanoma patient with 
tumor infiltrating lymphocytes (TILs) (22). 
- Discovery of T cell receptor by Phillippa Marrack, John Kappler, and James 
Allison (23).  
- CTLA-4 was identified by Golstein and colleagues (24).  
1991 to 2000 
- Tyrosinase was the first tumor antigen on melanoma cells recognized by HLA-
A2 restricted tumor reactive T cells (25). 
- Drew Pardoll demonstrated the effectiveness of the cancer vaccine GVAX to 
stimulate a long-lasting anti-tumor response in a phase I clinical trial (26). 
- The first report of using dendritic cells as a cancer vaccine in melanoma by 
Bijay Mukherji (27) 
- James Allison and colleagues first revealed the effect of anti-CTLA-4 antibody 
in tumor control using murine model (28, 29). 
- FDA approved Transtuzumab (Herceptin) for metastatic breast cancer 
treatment (30). 
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2001 to 2010 
- Fully humanized monoclonal antibody (anti-human Epidermal Growth Factor 
Receptor, Ranitumumab) was approved by FDA for metastatic colorectal 
cancer (31). 
- FDA approved Gardasil and Cervarix vaccines protecting against the Human 
Papilloma Virus (HPV), which causes approximately 70% of cervical cancer 
cases (32).  
- Immunoscore was firstly introduced as a novel approach to evaluate cancer 
progression (33). 
- Strong evidence demonstrating the effectiveness of the anti-CTLA-4 antibody 
in tumor regression in human studies (34).  
2010 to present 
- First dendritic cell vaccine (Sipuleucel-T) was approved by FDA for the 
treatment of prostate cancer (35) 
- Clinical studies demonstrated an improved survival with ipilimumab metastatic 
melanoma patients that led to FDA approval (36, 37). 
- Clinical trials of using anti-PD-1 blockade successfully showed improved 
clinical outcomes in metastatic melanoma, renal cancer, lung cancer, and colon 
cancer which led to FDA approval for anti-PD-1 antibody, Nivolumab and 
Pembrolizumab (38, 39). 
- Success of CAR T cell therapy trials led by Carl June and Steven Rosenberg 
demonstrated approximately 90% objective clinical response in Hematological 
(40). 
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Current strategies in cancer immunotherapy  
On the basis of our current knowledge, the immune system plays a protective 
role in pathogen infection as well as cancer control. Although the immune system is 
powerful enough to protect and control tumors, the remaining question is why cancers 
still occurs in normal people with healthy immune system. Indeed, tumors are able 
create a microenvironment that inhibits immune mediated cancer cell killing. 
Overcoming the immunosuppressive environment requires the coordination between 
antigen-presenting cells and T cells. Antigen-specific T cells need to receive an optimal 
priming in order to develop robust effector functions as well as long-lasting immune 
response. Several strategies have been extensively investigated to improve the function 
of immune cells including enhancing tumor antigen presentation and promoting 
effector function and memory development of antigen-specific T cells. Several types 
of tumor immunotherapy have been investigated and employed to foster innate and 
adaptive immune system. Here, four major types of cancer immunotherapy are 
discussed including; cytokine, checkpoint blockade inhibitor, vaccine, and cell-based 
therapy (Figure 1.1) 
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Figure 1.1. Schematic diagram demonstrates four major types of cancer 
immunotherapy.  
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1.1 b) Checkpoint blockade inhibitors 
The effector functions of T cells, including cytokine production, proliferation, 
and target cell killing are regulated by the coordination between co-stimulatory and co-
inhibitory molecules after encountering tumor antigens (41). Immune checkpoints are 
pivotal for the maintenance of self-tolerance and preventing an overreacting immune 
response (42, 43). However, excessive function of co-inhibitory molecules can benefit 
tumor cells to escape the immune response. Blockade of co-stimulatory molecules 
potentially breaks the physiological tolerance and enhances the anti-tumor response 
(42). Using antagonist antibodies against T cell co-inhibitory molecules has proved 
promising in cancer therapy.  Targeting checkpoint molecules does not directly affect 
tumor cell death itself, instead this strategy prevents T cell from receiving inhibitory 
signal from tumor cells, resulting in improvement of its effector function in mediating 
tumor killing (42, 43). Currently, the effect of immune checkpoints’ blockade on 
immune response has been widely investigated at both pre-clinical and clinical models. 
Targeting different inhibitory molecules have provided a great potential to manipulate 
immune response by different mechanisms such as enhancing effector T cell function, 
depleting regulatory T cells from tumor microenvironment, and facilitating T cell 
migration. Thus, combinatorial blockade is a worthwhile strategy for cancer 
immunotherapy.  
CTLA-4 
CTLA-4 was initially reported following the discovery of the first co-
stimulatory molecules, CD80 and CD86, in 1991 (24). Due to the high sequence 
similarity between CTLA-4 and CD28 it was initially believed that CTLA-4 was a 
positive T cell co-stimulatory receptor (44). However, the inhibitory function of CTLA-
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4 on T cells was revealed by James Allison’s laboratory later in 1995 (45). CTLA-4 
was shown to strongly suppress T cell proliferation by outcompeting CD28 from 
binding CD80 and 86 expressed by APCs during antigen stimulation (46). Thus far, the 
specific signaling pathway of T cells targeted by CTLA-4 has not been identified. Some 
studies suggest that the downstream pathway of CD28 might be dampened by CTLA-
4 via activation of SHP2 proteins, a phosphatase protein that attenuates proximal TCR 
signals (47). In addition, the cytotoxic lymphocytes (CTL) proliferative dysregulation 
observed in in CTLA-4 knock-out mice confirmed its inhibitory role(48). The 
inhibitory function of CTLA-4 strongly affects the effector function of CD8+ T cells, 
however CTLA-4 was found to directly enhance the suppressive function of 
CD4+CD25+Foxp3+ T reg (Regulatory T cell, Treg). Thus, blockade of CTLA-4 can 
improve effector function of CD8+ and attenuate the inhibitory function of T regulatory 
T cells (49). This results in boosting anti-tumor immunity in the tumor 
microenvironment. Preclinical studies demonstrated improvement of the antitumor 
response in partially immunogenic tumor-bearing mice when treated with anti-CTLA-
4 as a single therapy (28). However, in poorly immunogenic tumor models, vaccination 
in conjunction with anti-CTLA-4 blockade was required to achieve a similar anti-tumor 
response (28, 50).  
Based on preclinical evidence, two pharmaceutical companies have developed 
antibodies targeting CTLA-4, including Bristol Myer Squibb (ipilimumab) and Pfizer 
(tremelimumab). In phase III clinical trials, approximately 20% of patients with 
metastatic melanoma had achieved long-term-survival of at least two years when 
combined CTLA-4 treatment with gp100 vaccination (36, 51). Interestingly, ten-year 
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survival was also reported in some patients. On the basis of overall survival benefit for 
patients with advanced melanoma, ipilimumab was approved by FDA in 2011 (52). 
However, phase I and II clinical trials for melanoma with tremelimumab were 
discontinued in 2008 due to no statistical significance for improving overall survival 
(53). The successful story of CTLA-4 blockade has strengthened the concept of 
checkpoint blockade in cancer immunotherapy and fostered the needs for further 
studies on other checkpoint inhibitors such as PD-1, TIM-3, and LAG-3.  
PD-1    
PD-1 is characterized as a co-inhibitory molecule expressed by T cells. PD-L1 
and PD-L2 are the two identified PD-1 ligands. Recruitment of phosphatase (SHP1 and 
2) into ITIM and ITSM motifs is responsible for an inhibitory function of PD-1 (54, 
55). It has been shown that PD-1 specifically targeted Akt and cell cycle pathways to 
suppress T cell proliferation (56). Although PD-1 and CTLA-4 are both negative 
stimulatory molecules, it is believed that their downstream targets are relatively 
distinct. CTLA-4 predominantly inhibits T cells during early activation, supposedly 
during T cell priming phase, while PD-1 mainly suppresses effector functions of T cells 
primarily residing in peripheral tissues and tumor bed due to the presence of its ligand 
(PD-L1) highly expressed by tumor cells.   
PD-1 is widely expressed by several immune cells including B and NK cells, 
and its ligand is expressed by tumors. In contrast, expression of CTLA-4 is limited in 
T lymphocytes, and its ligand is mostly expressed by APCs (54). Thus, blockade of the 
PD-1 pathway is likely to affect more broad-range targets than CTLA-4. PD-1 
blockade, considered to enhance effector T cell function, may also improve the function 
11 
 
of natural killer cells in mediating tumor regression, and indirectly boost humoral 
immunity against tumors mediated by B cells as well (57).  
In several chronic diseases such as some viral infections and cancers, T cells 
are repetitively stimulated by antigens due to the persistence of diseases. This condition 
can induce high expression of PD-1 on T cells, resulting in T cell anergy or exhaustion 
(58). In murine models, it has been shown that blockade of PD-1 partially reversed the 
effector function of T cells during chronic viral infection (59).  
Expression of PD-L1 has been indentified in several human tumors including 
melanoma, breast cancer, glioblastoma, and ovarian cancer. IFN-γ secreted by CTL 
was found to up-regulate PD-L1 on tumor cells, epithelial cells, and stromal cells (60). 
It was thought that the PD-L1 ligand itself had no role in tumor cell signaling based on 
the fact that the cytoplasmic domain is relatively short. However, a recent report in 
glioblastoma has demonstrated that PD-L1 enhanced PTEN degradation resulting in 
constitutive activation of the AKT pathway (61).  
Suppression of anti-tumor immunity upon ligation between PD-L1 and PD-1 
has been noted in several murine models. Defects in T cell-mediated tumor immunity 
were observed upon overexpression of PD-L1 in mouse tumor cells (62, 63). The use 
of PD-L1 expression as a prognostic marker in clinical trials using PD-1 blockade 
antibody has been controversial. This might be due to some difficulties in performing 
cross comparisons with variations in technique, type and stage of cancers, and prior 
treatment.  
Strong evidence from mouse models demonstrating the effect of PD-1 blockade 
in improving tumor control combined with the observation of high expression of PD-
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L1 in several cancers has led to the development of several human therapeutic 
antibodies targeting the PD-1 pathway including anti-PD-1 antibodies; (nivolumab 
(BMS) and pembrolizumab (Merck)),  and anti-PD-L1 antibodies; (BMS-936558 
(BMS), MPDL3280A (Genentech), MEDI4736 (Medimmune), MSB0010718C (EMD 
serono)) (38, 64). In phase I studies, nivolumab successfully improved the three-year 
survival rate to 40% among 107 treated melanoma patients (65). In 2014, FDA has 
approved nivolumab for the treatment of patients with metastatic melanoma with no 
response to prior treatment as well as squamous non-small cell carcinoma. Comparison 
of nivolumab and conventional chemotherapy (dacarbazine) in phase III clinical trails 
has successfully confirmed the phase 1 result with a superior response rate (40% versus 
13%) (65).   
1.1 c) Cancer vaccine  
A knowledge of tumor antigens recognized by the immune system has shed 
light on developing vaccines as an alternative approach for cancer therapy. On the basis 
of vaccine components, it can be classified into three categories: cell-based, peptide-
based, and genetically-based vaccines.  
Cell based vaccine 
Tumors derived from patients were first used as a vaccine to test the proof of 
principle that providing tumor antigens with an adjuvant (BCG) can boost the anti-
tumor response. The patients vaccinated with irradiated autologous tumors alone did 
not achieve a favorable clinical response (66). However, tumors engineered to secrete 
granulocyte-macrophage colony-stimulating factors (GM-CSF) was found to trigger 
tumor regression when combined with anti-CTLA-4 antibodies (50). Autologous tumor 
cell preparation is labor intensive and limited to only some solid tumors. Hence, an 
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alternative approach of using an allogenic whole tumor cell vaccine was developed to 
overcome this limitation. The use of canavaxin, irradiated whole cells from three 
melanoma cell lines in combination with BCG, has been evaluated in phase III clinical 
trials and witnessed slightly improved overall survival rate in metastatic melanoma 
patients as compared to the control (49% versus 37%) (67). However, this approach 
was discontinued later on since two independent randomized trials failed to prove anti-
tumor efficacy. Because tumor antigens from tumor cell lysate require effective antigen 
processing and presentation, another strategy of using dendritic cells for active 
immunotherapy has been developed. Sipuleucel-T (Dendreon Corporation) is the first 
dendritic cell vaccine approved by FDA for the treatment of asymptomatic and 
minimally symptomatic metastatic castration-resistant prostate cancer (35).  Phase III 
trials have demonstrated a slightly improved median overall survival in patients treated 
with Sipuleucel-T as compared with a placebo control (25.8 months versus 21.7 
months) (68). In our TIL therapy program  at M.D. Anderson Cancer Center, we have 
observed that the combination of TIL therapy using TIL products containing MART-1 
reactive CD8+ TIL with the infusion of autologous dendritic cells pulsed with MART-
1 peptide did not improve the efficacy of treatment from what is seen with the infusion 
of TIL alone in a small cohort of 19 patients (data not shown, personal communication 
from the TIL program).  
Peptide vaccine 
Several tumor-associated antigens (TAAs) are identified in many types of 
cancers such as MAGE, NY-ESO-1, gp100, MART-1, E75, and so forth. TAAs can be 
up-taken, processed, and presented on the cell surface of mature APCs (69). It is crucial 
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for dendritic cells to receive appropriate signals for maturation, migration to the 
regional lymph node, and presentation of TAAs to naïve T cells. Thus, the adjuvant is 
required for appropriate TAAs priming by APCs. Mimicking innate immune alarm 
using synthetic pathogen-associated molecular patterns (PAMPs) such as TLR agonists 
can activate APCs and enhance the desired anti-tumor response. Investigating the use 
of TLR agonists for cancer vaccine is currently under way in clinical trials, including 
TLR3, TLR4, and TLR9. So far, only three TLR agonists are approved by FDA for 
therapeutic use in humans including BCG (TLR 2, and 4 agonists), monophosphoryl 
lipid A (MPL, TLR4 agonist), and imiquimod (TLR7 agonist) (70). Identification of 
melanoma TAAs recognized by T cells including gp100, MART-1, NY-ESO-1, and 
survivin strengthens the use of vaccine as an alternative therapy for cancer. In phase III 
clinical trials, a combination of gp100 and IL-2 has demonstrated improved response 
rate in relative to IL-2 alone (16% versus 6%) (71). However, vaccination of melanoma 
stage III patients with MAGE-A3 failed to prolong disease-free survival in phase III 
clinical studies. Recent study on cocktail antigen vaccination with melanoma antigens, 
including gp100, MAGE-A1, MAGE-A2 and MART-1 and tyrosine kinase, exhibited 
extended survival time as compared with placebo controls (21 months versus 8 months) 
(72). In pancreatic adenocarcinoma (PDA), phase III clinical studies of telomerase 
vaccine (GV1001) with chemotherapy demonstrated no improvement in survival as 
opposed to chemotherapy alone (73). Immunization with IMA901 vaccine in 
conjunction with cyclophosphamide and GM-CSF increased overall survival rate in 
patients with reactive T cells against peptide IMA901, but did not benefit patients who 
had no pre-existing immune response (74).  
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Genetically based vaccines 
Recombinant DNA vectors are carriers for protein overexpression in 
mammalian cells. This gene delivery approach can be used to deliver and express TAAs 
to enhance antigen recognition by T cells. Using optimization of codon usage can 
improve TAA expression when its gene-containing codons have rare tRNA. The major 
advantages of DNA vaccines are simple and flexible design, lack of adverse effects, 
heat labile, and cost effectiveness. In addition, DNA structure itself can also act as an 
adjuvant to activate innate immune systems through TLR, which can provide optimal 
priming to elicit potent adaptive immune (75). The introduction of DNA vaccines 
through intradermal and intramuscular injections was shown to have limited DNA up-
taking, and resulted in low transfection efficiency. A novel technology using the Gene 
Gun to deliver DNA coated with gold particles can increase DNA uptake, which makes 
it feasible for clinical applications. Another approach to increase the uptake of DNA 
plasmid is the use of electroporation which works by permeabilizing the cell membrane 
with electric pulses. By this mean, not only does the efficiency of DNA delivery can 
increase approximately 1,000-fold, but also lead to the recruitment of APCs at the 
vaccination site due to tissue damage (76).  
The first successful DNA vaccine (Oncept, Merial) was initially tested in canine 
spontaneous melanoma using a human tyrosinase recombinant DNA vector. The use of 
Oncept has demonstrated prolonged survival in dogs with advanced melanoma without 
toxicity. Thus far, Oncept is one-and only DNA vaccine approved by USDA. In human, 
DNA vaccine for cancer treatment has not yet been approved by FDA (77). However, 
several clinical trials are being extensively conducted in different types of cancers. In 
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melanoma, using the gp100 DNA vaccine has shown no benefit in progression-free 
survival regardless of patient immune response. Only a subtle increase in IFN-γ in 
CD8+gp100+ T cells has been observed in some patients (78). A number of studies of 
tumor antigens in other cancers are currently ongoing including human epidermal 
growth factor receptor 2 (HER2), carinoembryonic antigen (CEA), prostate acid 
phosphatase (PAP), and E6/E7 (human papilloma viral proteins). An increase in 
effector function of tumor-specific antigen reactive T cells was found in breast cancer 
and colorectal cancer patients, but failed to prolong the survival time (79).  
An application of mRNA vaccines is another approach used extensively in 
small animal models. RNA structure can be recognized by TLR and help prime an 
innate immune response. Because RNA is vulnerably instable and prone to degrade 
upon delivery, several strategies have been focused on protecting RNA from 
degradation such as RNA-loaded nanoparticles, protamine-condensed RNA, and 
encapsulated RNA. Instead of immunization with naked RNA, adoptive transfer of 
autologous dendritic cells transfected with the RNA of target antigens has also been 
studied in several types of cancers including melanoma, lung cancer, colorectal cancer, 
prostate cancer, and pancreatic cancer. In a study in humans, transfection of DCs with 
RNA directly isolated from autologous tumors has demonstrated the expansion of 
tumor-reactive T cells mediating autologous tumor cell lysis (80). Currently, the 
clinical study of RNA vaccines is still limited to phase I/II trials. In melanoma, using 
naked RNA purified from an autologous tumor improved clinical response rates, mixed 
response (15%) and no evidence of disease (23%) (81). In renal cell carcinoma, patients 
immunized with a cocktail of RNA of tumor antigens (MUC1, CEA, HER-2/neu, 
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telomerase, surviving, and MAGE-1) has illustrated only 7% partial response and 40% 
stable disease, and an increase in the effector function of CD8+ and CD4+ T cells was 
also observed in some patients (82).  
1.1 d) Cytokine therapy for cancers 
Cytokine, a small molecule secreted from cells, can act as a mediator for 
intercellular communication. Engagement of cytokine and receptors on immune cells 
can rapidly stimulate cell signaling and function in multiple facets including cell 
proliferation, migration, and cytotoxicity. In cancer immunology, cytokines are very 
critical to enhance maturation of innate immune cells such as dendritic cells as well as 
the effector function of cytotoxicity T cells (CTLs). Nevertheless, some cytokines such 
as IL-10 and TGF-β can inhibit effector function of CTLs. Currently, only two 
cytokines have been approved by FDA through the use of cancer therapy, including IL-
2 and IFN-α (83). In addition, a number of several cytokines such as IL-7, IL-15, IL-
18, and IL-21 are being focused in both preclinical and clinical studies for cancer 
treatment. 
IL-2  
IL-2 is a cytokine mainly secreted by activated CD4+ T cells. IL-2 mediates T cell 
proliferation similar to the cytokines that share common gamma chain receptors such 
as IL-4, IL-7, IL-9, IL-15, and IL-21. The IL-2 receptor consists of three subunits; alpha 
(CD25), beta (CD122), and gamma (CD132). The alpha subunit is involved in binding, 
while the other subunits play an important role in downstream signaling. Unlike T cells, 
IL-2 receptor in NK cells and B cells contains only gamma and beta subunits, thus 
mediate less binding affinity than T cells (84). Engagement of IL-2 and its receptor on 
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T cells does not only stimulate cell proliferation, but also promotes T cell 
differentiation into different subsets such as memory, effector, and terminally-
differentiated subsets (85).  
Discovery of IL-2 has unleashed new possibilities for in vitro expansion of T cells for 
functional study. Successfully shown to be effective in tumor control in murine model, 
the use of IL-2 was then quickly applied into cancer therapy (19). High dose IL-2 was 
given intravenously at 600,000 to 720,000 IU/kg every eight hours for two cycles; first 
and second cycle began on D1 to D5 and D15 to D19 respectively. Clinical response 
was evaluated within a month following the second cycle of treatment. It has been 
demonstrated that IL-2 treatments in melanoma patients with advanced stages achieved 
approximately 20% clinical response, and intriguingly 5 to 7% had a durable complete 
response (86).  The success of high dose IL-2 therapy in metastatic melanoma and renal 
cell carcinoma has eventually led FDA approval in 1998. Currently, the use of high 
dose IL-2 treatment becomes a conventional therapy used concurrently with other types 
of immunotherapy such as T cell therapy and cancer vaccination. Patients administered 
IL-2 require an intensive monitoring due to its toxicity, including febrile, hypotension, 
and capillary leak syndrome (87). Although major toxicities of IL-2 can be harmful, 
this effect is completely reversible following the completion of treatment. With proper 
management, IL-2 can be safely used either as a single treatment or in conjunction with 
other immunotherapies.  
IL-7 
IL-7 is known as a cytokine promoting the growth of hematopoietic cells. It is majorly 
produced by epithelial cells in thymus and stromal cells in bone marrow, but not 
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lymphocytes. Its receptor contains a gamma subunit commonly shared with IL-2.  IL-
7 plays a critical role in promoting differentiation of hematopoietic stem cells into 
lymphoid lineage cells (88). It has been also shown that IL-7 enhanced cell survival 
and proliferation of B cells and NK cells (89, 90). In T cells, IL-7 is critical for early 
development of thymocytes during double-negative stage (91). Together with stem cell 
factor (SCF), IL-7 promotes proliferation of TN precursors and provides survival 
signals through regulation of bcl-2 family members (92). It is known that IL-7 also 
enhances T cell activation, particularly in suboptimal conditions. IL-7 preferentially 
stimulates a type I immune response resulting in an increased IFN-γ and IL-2. A recent 
report also indicated that IL-7 directly boosts the cytolytic capacity of CTL as well as 
NK cells, NKT cells, and γδ T cells (93). Functional studies of IL-7 are still limited to 
in vitro settings and preclinical murine models. Two clinical trials are currently 
underway regarding the role of IL-7 in cancer immunotherapy. Early results have 
shown the promise of IL-7 in enhancing T recovery following chemotherapy treatment 
with minimal toxicity (94-96).  
IL-15 
IL-15 is a unique cytokine that is secreted in a complex form of IL-15 and IL-15 
receptor alpha (IL-15Rα) (97). Monocytes are a major source for IL-15 production (98). 
Upon activation with the IFN or engagement of the CD40 ligand, dendritic cells can 
upregulate IL-15 and IL-15Rα expression, and to trans-present to CD8+ memory T cells 
or NK cells expressing IL2/IL-15 receptor beta (IL-15Rβ) (99). Similar to other 
cytokines in the gamma receptor family, IL-15 stimulates proliferation of T cells and 
NK cells, and also enhances immunoglobulin production in activated B cells. 
20 
 
Downstream signal of IL-15 through the JAK/STAT pathway can promote 
phosphorylation of Src family proteins and the PI3K/Akt pathway (100). This results 
in an increased Bcl-2 and Bcl-xL proteins, which help protect memory CD8 T cells 
against apoptosis from activation-induced cell death mechanism (AICD) (101).   
IL-21 
IL-21 is a type I cytokine predominately produced by NKT cells, T follicular helper 
cells (Tfh), and Th17 cells (102). Unlike other cytokines in the type I receptor 
superfamily, IL-21 mainly activates STAT1 and STAT3 instead of STAT5 (103). IL-
21 has a pleotropic effect as its receptor is expressed by a broad range of several 
immune cells, including lymphoid lineage as well as myeloid cells. In B cells, IL-21 
can enhance immunoglobulin G production by promoting class switching (104). IL-21 
can also promote both NK cells and T cell proliferation and cytotoxic function without 
causing AICD, but suppresses FOXP3 expression in Treg cells (105). It has been 
evident that IL-21 promoted cytotoxic function of NK cells through antibody-
dependent cell cytotoxicity (ADCC), and effector function of T cells by enhancing 
granzyme and IFN-γ production (106). In our observation, IL-21 at low dose tends to 
preferentially promote CD8+TIL expansion, while attenuation of TIL proliferation has 
been observed with those expanded with IL-21 at high doses. Interestingly, recent 
findings showed that IL-27 can stimulate CD8+ T cells to secrete IL-21, which act as 
an autocrine regulator (107). In murine models, IL-21 has been shown to suppress the 
growth of melanoma and fibrosarcoma by enhancing the function of NK and CD8+T 
cells. Because IL-21 effectively promotes the function of CTL and NK cells, the use of 
IL-21 become attractive for an application in cancer treatment as either single therapy 
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or combination with other treatments. Systemic administration of IL-21 is likely to 
benefit tumor regression by enhancing the function of CD8+ and NK cells without 
vascular leakage, which provide an advantage over high dose IL-2 therapy. However, 
an adverse effect in enhancing pro-inflammation cytokine such as IL-6 and IL-17 might 
raise some concerns in clinical use. An alternative approach is adoptive transfer of 
autologous dendritic cells transfected with IL-21 transcript. Transferred dendritic cells 
can provide IL-21 locally to TIL in tumor microenvironments with minimal unwanted 
side effects (108). Another approach is to use IL-21 for ex-vivo expansion of TIL for 
Adoptive T cell therapy (ACT). Analysis of the immunophenotype of TIL expanded 
with IL-21 revealed a less differentiated phenotype (CD27hi and CD28hi) with 
increased cytotoxic capacity. Because poorly differentiated TIL is associated with 
persistence following TIL transfer, the expansion TIL with IL-21 could be a potential 
approach to improve TIL quality and clinical response (109).  
1.2 Cell based therapy for malignant diseases 
1.2 a) NK cell therapy 
Natural killer cells (NK) are innate immune cells derived from lymphoid progenitor 
cells in the bone marrow. As they are derived from a lymphoid lineage, NK cells can 
be defined as CD45+CD3-CD56+ cells. The expression level of CD56 can further 
classify NK cells into to two subsets; CD56brightCD16- and CD56dimCD16+. 
Peripheral blood is highly enriched for the CD56dimCD16+ subset, while 
CD56brightCD16- subset primarily resides in the lymph nodes and tonsils. Unlike T 
cells, NK cells recognize transformed cells such as virus-infected cells, stressed cells, 
and tumor cells in non-MHC-restricted settings. The mechanism of NK-mediated target 
cell killing relies on the balance between activating signals and inhibitory signals from 
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cell surface receptors (110). The activating receptor, such as NKG2D, NKp30, and 
DNAM-1, can trigger signals by phosphorylating the immunoreceptor tyrosine-based 
activating motif (ITAM) in the cytoplasmic domain. This results in recruitment of Syk 
and ZAP70, leading to degranulation of perforin and granzymes as well as cytotoxic 
cytokines such as IFN-γ and TNF-α. On the other hand, inhibitory receptors, such as 
Ly49C, KIR2DL1, and KLRG1, attenuate signals through immunoreceptor tyrosine-
based inhibitory molecules (ITIMs), resulting in sequestration of phosphatase SHP1 or 
2 and dephosphorylation of phosphoproteins in activating pathways. Under normal 
physiological condition, the cytotoxic activity of NK cells is suppressed by engagement 
of NK cell inhibitory receptors and MHC expressed by normal cells. Down-regulation 
of MHC expression in tumor cells and can relieve the suppressive function of the 
inhibitory receptor, which allows NK cells to become activated and destroy target cells. 
Moreover, up-regulation of danger signals by tumor cells can enhance the cytolytic 
capacity of NK through engagement of activating receptors (111). Under the selective 
pressure in tumor microenvironments, tumor cells tend to escape T cell recognition by 
down-regulation of MHC class I. This mechanism somehow aids NK cells to become 
more activated and attack tumor cells better. On the basis of its anti-tumor activity, 
several strategies have been developed to use adoptive transfer of NK cells for cancer 
treatment (112).  
NK cells can be generated from different sources such as peripheral blood, bone 
marrow, umbilical cord blood, and stem cells. The combination of IL-15 and 
hydrocortisone to propagate NK cells has become general practice guideline for ex vivo 
NK cell expansion. Although autologous NK can be successfully expanded for clinical 
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treatment, these expanded cells do not develop full cytolytic function following 
adoptive transfer, resulting in an unfavorable clinical outcome (113). It has been 
suggested that some tumor cells still maintain MHC class I expression, which is 
effective enough to suppress cytotoxic function of NK cells. Thus, another strategy is 
the use of allogenic NK cells with KIR mismatch which could circumvent the 
suppressive effect of MHC I and allow activating receptors to exhibit positive signals 
mediating tumor killing. It has been demonstrated that the KIR haplotype of the donor 
is associated with a survival benefit. Patients who received donor KIR haplotype group 
B have been shown to have improved overall survival as compared to those who 
received the KIRT haplotype group, mainly due to the high enrichment for activating 
receptors in the KIRT haplotype. Nevertheless, allogenic NK cells are eventually 
eliminated by the host immune system due to MHC mismatch (114). Currently, early 
clinical trials in adoptive NK cell therapy are under way in several countries, including 
the United States, Korea, France, Spain, and Singapore. The efficacy of NK cell therapy 
is evaluated mainly in hematological malignancies including leukemia, lymphoma, and 
multiple myelomas. A clinical trial conducted at Masonic Cancer Center in acute 
myeloid leukemia (AML) demonstrated that 26% of patients receiving haploidentical 
NK cells exhibited durable clinical outcomes. Recent studies have also demonstrated 
NK cell therapy in some solid tumors such as non-small cell carcinoma, hepatocellular 
carcinoma, and neuroblastoma. The clinical outcome of trials conducted in multiple 
institutions are promising for NK cells therapy (115). A more in-depth understanding 
of the signaling that regulates cytotoxic function is warranted for further improvements 
in NK cell therapy.   
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1.2 b) T cell therapy   
Discovery of the TCR in early 1980 has driven a leap in understanding T cell 
biology in the context of antigen recognition through MHC. This knowledge does not 
only foster basic immunology research, but also extends a great benefit for cancer 
immunotherapy. Based on the fact that T cells can recognize and destroy tumor cells, 
this notion has attracted scientists and physicians to utilize T cells for cancer treatment.  
Adoptive T cell therapy can be categorized on the basis of the source of T cells 
and type of gene modification approach used. T cells used for therapy can be derived 
from different sources, including the Tumor infiltrating lymphocytes (TIL), sorted 
antigen-specific T cells from peripheral blood, and normal peripheral blood 
mononuclear cells (PBMC). T cells can also be genetically modified to overexpress 
either chimeric antigen receptors or T cell receptors specific for tumor antigens by 
using bioengineering methods.   
TIL therapy (ACT) 
History of ACT 
In late 1987, a progress study on adoptive transfer of lymphokine-activated 
killer (LAK) cells with IL-2 was first investigated in 157 patients with metastatic 
melanoma. A combination of LAK and IL-2 was found to have advantages over IL-2 
alone due to the durable complete responses (22). The limited efficacy of LAK has 
suggested the used of TIL, which are already present in tumor bed and more enriched 
for tumor-reactivity (116).  
Several efforts were made to conduct adoptive transfer T cells for cancer 
therapy in murine models. One of the most successful murine models was established 
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in Dr. Alex Fefer’s lab in Fred Hutchinson Cancer Research Center.  Adoptive transfer 
of T cells from immunized mice with the Friend virus-induced leukemia, FBL-3 was 
shown to be effective following intravenous administration in both local tumors and 
disseminated metastasis (117). Although the concept of using adoptive transfer of 
tumor-specific T cells to destroy cancer was proved, incapability of expanding antigen-
specific T cells against spontaneously growing human cancers was a major hindrance. 
The approach of using adoptive transfer of TIL as an immunotherapy of cancer was 
proposed shortly after the success of using syngeneic TIL plus IL-2 therapy in murine 
model to eradicate established hepatic metastasis (118).   
The observation that specific tumor-reactive T cells can be grown from resected 
metastatic melanoma tumor with IL-2 was a critical step to support further investigation 
of large scale TIL expansion for therapeutic use. TIL expansion protocol initially used 
only IL-2 to grow TIL from digested tumor fragments. The fold expansion ranged from 
3 to 9 X 108-fold over 14 to 100 days (119). Shortly after, a pilot study using a 
combination of IL-2 and TILs was first reported from the Surgery Branch at the NCI 
(120). This report was considered as a huge leap for cancer immunotherapy and the 
beginning of the era of TIL ACT.                                                                                                                                                                                                                                                                                                   
Current TIL ACT therapy  
ACT is an effective immunotherapy for cancer using autologous tumor-
infiltrating lymphocytes (TIL) isolated from cancer patients. TIL can be generated from 
either small pieces of resected tumor fragments (approximately more than 1 cm) or 
tumor digestion followed by density gradient centrifugation. TILs are initially grown 
in 24-well plates with high dose IL-2 (6,000 IU/ml) for approximately three to five 
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weeks. The cells are then further propagated with a rapid expansion protocol (REP) 
using irradiated peripheral blood mononuclear feeder cells as feeders, anti-CD3, and 
high dose IL-2, for 14 days (Figure 1.2) (121). Recent studies have shown that 
genetically modified artificial antigen-presenting cells derived from K562 cells 
overexpressing CD19, CD64, CD86, and CD137L could be substituted for the feeder 
cells without perturbing REP fold expansion (122).  
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Figure 1.2. Schematic diagram of the TIL expansion (Pre-expansion and Rapid 
expansion) and TIL therapy.   
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Based on the studies in animal models, lymphodepletion in combination with 
ACT was shown to be critical for an effectiveness of transferred TIL. This helps 
eliminate the Treg cells and myeloid-derived suppressive cells (MDSCs) and preparing 
space for transferred cells (123). Currently, lymphodepletion prior to ACT has become  
a conventional practice widely used in multiple institutions including the Surgery 
Branch at NCI, M.D. Anderson Cancer Center, Moffit Cancer Center, and Sheba 
Medical Center in Israel. In non-myeloablative regimens (NMA), patients with 
metastatic disease undergo lymphodepletion with cyclophasphamide (30 or 60 mg/kg 
per day) and fludarabine (25 mg/m2 per day) for two and five days, respectively, prior 
to TIL transfer. High dose IL-2 (720,000 IU/kg) is administered starting one day after 
TIL infusion every 8 hours to tolerance (124). In myeloablative regimens, patients are 
given total body irradiation (TBI) in combination with cyclophosphamide and 
fludarabine followed by CD34+ hematopoietic stem cell transfer (125).  
TIL: tumor recognition in melanoma tumor cells  
Identification of tumor-specific cytolysis in human melanoma TIL was evident 
based on the existence of tumor-specific antigens recognized by T cells. The expression 
of T cell co-stimulatory molecules such as 4-1BB, ICOS and OX40, as well as co-
inhibitory molecules like PD-1, is triggered upon antigen stimulation and therefore is a 
marker of activation. The observation that TIL contain subpopulations of recently 
activated T cells (CD8+4-1BB+), and are enriched for chronically activated T cells 
(CD8+PD-1+) as compared to the blood suggests that a high fraction of TIL are 
recognizing tumor antigens. In addition, secretion of cytotoxic cytokines such as IFN-
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γ, TNF-α, and/or GM-CSF upon stimulation with autologous tumors also indicates 
tumor recognition by TIL (126).  
Most tumor-associated antigenic peptides identified are restricted by commonly 
shared HLA subtypes such as HLA-A1, -A2, -A24, -A31, -B8, and –Cw. However, 
HLA-2 is the most intensively studied due to high prevalence in Caucasian populations 
(approximate 45%) (127). It has been shown that TIL clones from HLA-A2+ patients 
were able to lyse HLA-A2+ melanoma cell lines derived from different patients, but did 
not lyse non-melanoma cells lines and other types of cancers. This suggested that 
melanoma tumor-associated antigen peptides in melanoma cells are commonly shared 
among patients in a HLA-A2 restricted fashion. In addition, overexpression of HLA-
A2 in HLA-A2 negative melanoma cell lines enables HLA-A2+ TIL to mediate tumor 
cytolysis (128). Melanoma associated antigen 1 (MAGE) was identified as the first 
melanoma antigen recognized by HLA-A1 restricted melanoma TIL. Although 
MAGE-1 is also expressed by non HLA-A1 melanoma tumors, HLA-A2 specific CTL 
has never been reported.  In addition, HLA-A2 antigen specific TIL were found not to 
lyse HLA-A2+ fibroblast cell lines overexpressing the MAGE-1 gene. Several HLA-
A2-restricted melanoma cytotoxic T lymphocytes derived from TIL recognizing other 
tumor antigens were also identified, including MART-1, gp100, and tyrosinase. 
Although most tumor antigen-specific CTLs were described in the HLA-2 restricted 
subtype, the MAGE-3 antigen expressed by melanoma and other types of cancers such 
as breast cancer, colon cancer, and lung cancer, was also recognized by the HLA-1 
restricted CTLs (129).   
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Effectiveness of ACT in melanoma and other cancers 
ACT is one of the most effective treatments in metastatic melanoma in inducing 
durable clinical responses as compared with other types of immunotherapy. The first 
preliminary report in 1988 of adoptive transfer of TIL was conducted in 12 patients 
with metastatic melanoma at the Surgery Branch, NCI. Objective tumor regressions 
occurred in 60% (9/15) of patients who had never been treated with IL-2 and 40% (2/5) 
of patients who were refractory to IL-2 therapy (130). In another trial in 2002 at the 
NCI, it was shown that 13 HLA-A2+ metastatic melanomas treated with TIL ACT had 
40% (6/13) objective clinical response to treatment. Rapid clonal repopulation of 
MART-1 reactive T cells was observed in two patients, resulting in the off-target 
destruction of normal cells expressing the MART-1 antigen (131). Several studies both 
in murine models and humans suggested that lymphodepletion is a critical factor for 
the positive clinical outcome of ACT (124). The NMA regimen using 
cyclophosphamide and fludarabine treatment prior to adoptive transfer was included in 
the standardized ACT protocol (132). In a recent study, myeloabalation using total 
body irradiation (TBI) concurrently with ACT has been investigated in 93 patients at 
the Surgery Branch, NCI. The clinical trial was assigned to patients into three cohorts; 
1) NMA regimen (n=45), 2) myleoablation with TBI 2 Gy (n=25) 3) myeloablation 
with TBI12 Gy (n=25).  Overall objective response rates in each cohorts were 49% 
(21/49), 52% (13/25), and 72% (18/25) respectively. In the NMA cohort, the complete 
response rate was around 10%, however in the TBI groups, over 20% of the patients 
achieved a complete response 20% underwent a complete remission more than 3 years. 
In a subsequent randomized study with more patients (101 patients; NMA (n=51) and 
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NMA plus TBI (n=50), the addition of TBI to the regimen did not improve the 
incidence of complete responses (133). Overall objective clinical response across 
multiple institutions is relatively similar to NCI, including M.D. Anderson Cancer 
Center (Houston, TX) (48%, 15/31 patients), Moffitt Cancer Center (Tampa, FL) (38%, 
5/13), and Sheba Cancer Research Center, (Israel) (40%, 23/34) (121). 
Functional role of TIL subsets in ACT: Tumor reactivity and persistence 
Different T cell lineage in TIL  
A high proportion of CD8+ TIL in infused TIL has been shown to associate with clinical 
response in melanoma TIL-treated patients (134). It is known that CD8+ T cells have a 
predominant role in the cell-mediated cytotoxic capability to induce cell death in 
pathogen-infected cells and transformed cells. The superior advantage of T cells over 
innate immune cells, which also mediate cell death, such as NK cells, is due to their 
specificity, adaptability, and durability. These properties allow CD8+ TIL to recognize 
both tumor specific antigens and mutated peptides and provide long lasting immune 
response. The mechanism used by CD8+ TIL to mediate tumor killing in has been well 
characterized. Following TCR recognition of peptide presented by tumor cells, both 
perforin (a membrane disrupting protein) and granzymes (serine proteases) secreted 
from effector TIL can cooperatively activate caspase-3 mediating tumor cell death 
(135). Occasionally, we have observed that TIL-treated patients somehow respond to 
the therapy even though the proportion of CD4+TIL is relatively high. CD4+T cells are 
generally not considered as  key players in cell-mediated cell death, but coordinately 
facilitate CD8+ function by providing cytokines such as IL-2, TNF-α, and IFN-γ that 
are critical for proliferation and effector functions of CD8+TIL. On the other hand, Treg 
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can also suppress the anti-tumor function of CD8+ by secreting immunosuppressive 
cytokines such as IL-10 and TGF-β (135).  
We have occasionally observed outgrowth of γδ TIL during initial expansion, but the 
dominant outgrowth of this subset following REP is rarely observed. Zoledronate was 
reported to facilitate expansion of γδ TIL. A Phase I ACT clinical trial in several cancer 
patients with metastasis using γδ TIL expanded with zoledronate has shown no clinical 
response even though the migration of transferred T cells into the tumor bed was 
observed due to high expression of chemokine receptors such as CXCR3, CXCR5, 
CCR5, and CCR7 (136). This suggests that these cells were capable of  trafficking into 
the tumor site, but might not be able to recognize tumor cells or might lack the effector 
function.  
T cell differentiation and T cell persistence following adoptive transfer. 
Although the CD8+ TIL subset is pivotal for tumor-mediated regression, only a subset 
of TIL-treated patients with a high number of CD8+ achieved a complete remission. It 
remains inconclusive as to what exact CD8+TIL subset(s) is/are responsible for the 
clinical response. After encountering tumor antigens presented by APC, naïve T cells 
undergo clonal expansion and further differentiate into effector T cells (TEF), followed 
by the development of effector memory T cells (TEM) and central memory T cells 
(TCM) for long-term recall response. Effector T cells will then undergo further 
differentiation and become terminally differentiated and eventually undergo clonal 
deletion. It has been controversial whether memory development involves a transition 
to effector phase prior to memory commitment or if memory cells are exclusively 
arising from pluripotent effector cells (137). It remains unclear what signals control the 
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decision fate in memory development, but recent studies suggest that the strength of 
antigen stimulation and cytokines might be critically involved (138). In human CD8+ 
T cells, the combination of CD45RA and CCR7 markers is most commonly used  to 
distinguish different memory T cells into the following subsets: naïve 
(CD45RA+CCR7+), effector memory (TEM) (CD45RA-CCR7-), terminally 
differentiated (TEMRA) (CD45RA+CCR7-), and central memory (TCM) (CD45RA-
CCR7+) (139). In addition, the combination of co-stimulation molecules such as CD28 
and CD27 is also used to further characterize the differentiation status of CD8 into three 
stages; undifferentiated (CD28+CD27+), intermediate differentiated (CD28-CD27+), 
terminally differentiated (CD28-CD27-) (140). Recently, we and others demonstrated 
that B and T lymphocyte attenuator, a co-inhibitory molecule, also serve a T cell 
differentiation marker, where high expression of BTLA is observed in less 
differentiated T cell (141, 142). Persistence of infused TIL in the peripheral blood one 
month following adoptive transfer has shown to be associated with clinical response 
(134, 143). A recent study unveiled the phenotype of a memory T cell subset with stem 
cell-like properties (TSM) which exhibited a least differentiated phenotype with 
enhanced proliferative capacity (144). Adoptive transfer of this T cell subset showed 
improved memory T cell survival and superior anti-tumor immunity. A report from the 
NCI indicated that the CD28+CD27+ TIL subset had longer telomeres with enhanced 
persistence in circulation after adoptive transfer (140). In line with this observation, we 
found that a high proportion of CD8+BTLA+ (less differentiated CD8+ TIL phenotype) 
in infusion product positively correlate with improved clinical response of TIL ACT 
treated patients (134).  
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Chimeric antigen receptor T cell therapy (CAR) 
TIL from several tumors have been shown to recognize and destroy the 
autologous tumor cells, but very few tumor-reactive T cells recognizing more broadly 
antigens have been identified. Most tumor antigens appear to be unique to the patients. 
This limitation strongly hampers the selection and enrichment of tumor-specific T cells 
for adoptive T cell therapy. Several shared cell surface tumor-associated antigens in 
several types of cancer have been more extensively identified. This type of antigen can 
be targeted by an antibody. One approach to improve recognition of these antigens is 
to couple the high affinity recognition of an antibody to the killing machinery of a T 
cell by engineering an artificial T cell receptor on a T cell made up of an antibody 
linked to the intracellular domains of the TCR and its co-stimulation molecules. 
Therefore, the use of genetic engineering method to overexpress chimeric antigen 
receptor (CAR) on T cells can be used to improve tumor specific antigen recognition 
and enhance tumor killing (145). 
Chimeric antigen receptors (CAR) contain two major parts; 1) an extracellular 
binding region of target proteins and 2) an intracellular signaling domain. The 
extracellular part contains a single chain variable fragment (scFv), variable regions of 
light chain and heavy chain of immunoglubin. scFV is designed to interact with the 
potential tumor antigen targets expressed by tumor cells. The intracellular signaling 
domain consists of a CD3 ξ chain, which exhibit the downstream signal mimicking 
TCR activation signals during the engagement of the extracellular part and the potential 
target. In the second and third-generation of CAR, its intracellular domain has been 
further modified with additional of signaling domains of CD28 and co-stimulatory 
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molecules such as OX-40 (CD134) and 4-1BB (CD137). Second-generation CAR has 
been found to be more effective than the first-generation because co-stimulatory signal 
can enhance cell survival and prevent T cell exhaustion. Generation of CAR T cells is 
far more complicated than TIL therapy, as T cells are required to undergo genetic 
modification prior T cell expansion. Several approaches are used to deliver modified 
genes including viral transduction, sleeping beauty, and CRISPR/Cas9 gene editing. 
Once modified genes are inserted, T cells then undergo propagation with artificial 
antigen-presenting cells (aAPC), which can provide a proper co-stimulatory signal, 
prior to adoptive transfer into the patients (145, 146).  
CAR T cell therapy has been widely used in hematological malignancies, 
including B cell malignancy, T cell malignancy, and myeloma. The durable clinical 
outcome in B cell malignancy patients treated with anti-CD19 CAR T cell therapy has 
demonstrated a promising model for other types of cancer. A number of targets of CAR 
T cell therapy for acute myeloid leukemia (AML) that are currently under investigation 
in an early phase clinical trials include CD33 (myeloid specific lectin), CD123 (IL-3 
receptor alpha chain), CD44v6 (adhesion molecule expressed by some subset of AML 
and multiple myeloma) (147-149). Clinical trials of CAR T therapy also are currently 
expanding into solid tumors, including glioblastoma multiforme, mesothelioma, 
ovarian cancer, and pancreatic cancer (145). Selection of targets can be very 
challenging, as solid tumors are much more heterogenous as opposed to hematological 
cancers. Because of a few instances of treatment-related fatal toxicity, such as in colon 
cancer patients treated by anti-HER-2/neu CAR T cell therapy, off-target toxicity from 
36 
 
targeting antigens commonly present in normal tissue is also a major safety concern for 
CAR therapy (150).  
Endogenous T cell therapy  
Detection of tumor-reactive T cells in the peripheral blood of cancer patients has 
provided a rationale for attempting their selection and expansion for adoptive T cell 
therapy. Tumor-reactive T cells in circulation are present at a very low frequency (less 
than 0.5%), which presents a challenge (151). If the tumor antigen is known, the T cells 
can be stained with fluorescence conjugated peptide-MHC tetramer and sorted by flow 
cytometry. A current strategy used to amplify circulating antigen-specific T cells is to 
stimulate PBMCs with APCs or insect cells expressing MHC class II pulsed with the 
peptide of interest. This helps expand and enrich tumor-reactive T cells prior to further 
selection processes by cell sorting, cloning, or performing immuonmagnetic selection 
(152).. If amplification of unselected tumor-reactive T cells is desired, hundreds of T 
cell clones can be screened for tumor reactivity and immunomagnetic selection 
methods can be performed to capture cytokine-secreting cells using dual-specific 
antibodies that can bind both CD45+ (lymphocyte marker) and IFN-γ (151). The 
enrichment and selection method can increase the number of cells to 1 to 5 millions of 
CD8+ T cells with the frequency greater than 80% of tumor-reactive T cells. The final 
expansion with high dose IL-2, anti-CD3, and feeders can rapidly increase the number 
of tumor-specific T cells to a billion cells with 90% specificity within two weeks. 
Unlike TIL adoptive transfer, patients are treated with low dose IL-2 without or 
minimal lymphodepletion, thus endogenous T cell therapy confer less adverse effects 
(153).  
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There have been several attempts to improve T cell quality with enhanced in 
vivo persistence. It is known that persistence of T cells following transfer is critical for 
positive clinical outcomes in adoptive T cell therapy. It has been shown that 
lymphodepletion with fludarabine alone or high dose cyoclophosphamide alone could 
improve engraftment and persistence of transferred T cells (133). Another report has 
indicated that central memory (TCM)-derived CTLs were the only phenotypes that 
exhibited in vivo long-term persistence (154). Consistently, a murine model also 
demonstrated that Tcm-derived CTLs were much more effective for tumor control due 
to superior replicative capacity when compared with effector and effector memory 
subset (144). In a recent study in human, CD8+MART+T cells expanded with IL-21 up-
regulated CD28 and IL-7R and maintained the expression for several weeks following 
adoptive transfer. In addition, cancer patients treated with endogenous T cells expanded 
with IL-21 exhibited better tumor control and some of those underwent a complete 
durable response (155). 
A major challenge of endogenous T cell therapy is to develop a novel approach 
to identify, select, and enrich tumor antigen-specific T cells that are of  very low 
frequency in circulation. T cells recognizing well characterized shared tumor antigens 
such as MART-1, gp100, NY-ESO can be selected for treatment. However, tumors 
may not uniformly express those antigens and therefore the development of  alternative 
methods such as cloning and immunomagnetic selection to enrich tumor-reactive T 
cells will be warranted. Moreover the transfer of T cells specific for one antigen may 
initiate an immunoselective pressure which allows immune escape through antigen loss 
and the development of resistance.  
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1.3 Biomarker of immune cell: Immunoscore 
The TNM (Tumor Node Metastasis) system, a standard criteria to evaluate the 
degree of tumor spread, has been widely used in cancer centers all over the world. This 
classification system aids physicians in planning treatment, making prognoses, and 
evaluating effectiveness of therapy. Disease progression used in TNM solely relies on 
the spreading of the tumor itself and does not include other factors in the tumor 
microenvironment. In recent years, it has become clear that the immune system plays 
a critical role in tumor control and progression (156). Thus, immune cells should also 
be included in evaluation of tumor progression criteria. Recently, Jerome Galon, a 
scientist at INSERM laboratory in France, has proposed a novel method to incorporate 
immune cells into the clinical assessment of cancer patients (157).  
The concept of “immunoscore” has emerged from a meta-analysis of more than 
120 independent studies on the impact of immune cells in tumor microenvironments. 
It has been demonstrated that the presence of CTL, memory T cells, and the CD4 Th1 
subset in all types of cancers is associated with extended survival time. On the basis of 
these analyses, the quantification of three surface markers on T cells including CD3, 
CD8, and CD45RO in combination with location in the tumor bed, the core of the tumor 
(CT) and the invasive margin (IM) are used to tabulate the immunoscore. The score is 
graded on the density of immune cells diffused in both the core tumor and the invasive 
margin from “no” or lowest (Immunscore 0, I0) to the highest (Immunoscore 4, I4) 
(157). A recent report from two independent cohort studies has demonstrated the ability 
to predict the recurrence of colorectal cancer in patients who had no detectable 
metastasis in either lymph nodes or distant organs. It appeared that patients with a high 
immune score (I4) exhibited a low chance of tumor recurrence (less than 5%), while 
39 
 
patients with a low immune score (I1) were very likely to develop recurrence 
(approximately 72%) (158). Based on the fact that Immunoscore is the only system that 
helps predict disease recurrence, the critical role of the immune system in the tumor 
microenvironment becomes very clear.  
Immunoscore is a task force established in collaboration with multiple 
institutions worldwide. The method standardization of immunohistochemistry and 
analysis software is currently being validated to ensure the accuracy and reproducibility 
across laboratories. Immunohistochemistry of immune markers is already routinely 
performed in the diagnostic pathology laboratory, it is possible that immunoscore will 
become a part of a conventional system for cancer treatment in the near future. Together 
with the TNM system, immunoscore can enhance the ability to evaluate disease 
progression, prognosis, as well as aid in developing a decisive plan for immunotherapy. 
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1.4 Co-signaling molecules on T cells  
Co-signaling molecules on T cells 
Engagement of TCR by peptide-MHC class I or II complexes determines the strength 
of TCR activation. Without additional co-signaling, T cells become unresponsive and 
undergo clonal deletion eventually. It is known that co-signaling molecules play a key 
role in steering the outcome of TCR signaling by either enhancing or inhibiting the 
downstream signals during TCR activation. This outcome is crucial for regulating the 
fate of T cell differentiation, effector function, cell proliferation and survival (159).   
1.4 a) Co-stimulatory molecules 
A co-stimulatory molecule is a receptor expressed on T cells whose signaling provides 
positive effect on T cell functions. On a structural basis, co-stimulatory molecules can 
be classified into two major groups; the Tumor Necrosis Factor Receptor superfamily 
(TNFRSF) and the Immunoglobulin super family (IgSF). TNFRSF requires a cluster 
formation of at least two molecules for the full activation, while only one molecule of 
IgSF is sufficient for the full function (159).    
Tumor Necrosis Factor Receptor superfamily (TNFRSF)  
TNFRSF family members consist of at least one subunit of extracellular cysteine-rich 
domains (CRDs).  Most TNFRSF members such as 4-1BB, CD40, OX40, and HVEM 
exhibit signals through NF-kB and mitogen-activated protein kinases (MAPK) 
pathways. However, some TNFRSF receptors contains dead domains (DD) such as Fas 
and TRAIL and are able to promote apoptosis. TNFRSF members expressed by T cells 
mostly synergize with T cell survival function rather than promote T cell apoptosis. A 
number of TNFRSF have been extensively studied in T cell and other cell types. Here, 
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only selected TNFRSFs that have potential in clinical application for cancer 
immunotherapy will be discussed (160). 
4-1BB 
4-1BB is an inducible molecule, which is up-regulated within only a few hours 
following T activation, and its expression declines within a few days. 4-1BB is 
preferentially expressed by activated CD8+, NK cells, and dendritic cells. Although 4-
1BB can be shed from the cell surface, the soluble form is not able to exert signals 
when engaged with its ligand (161). It has been shown that the soluble form of 4-1BB 
is highly associated with severity of patients with rheumatoid arthritis (162). In T cells, 
4-1BB mediates signals through NF-kB and activating protein-1 (AP-1), which triggers 
several downstream pathways including MEK, and JNK. 4-1BBL, identified as a 
binding partner for 4-1BB, is mainly expressed by antigen-presenting cells including 
dendritic cells, B cells, and macrophages. It has been demonstrated that the 4-1BB 
pathway in T cells enhances T cell proliferation and cell survival and prevents AICD 
(163). Although the 4-1BB pathway plays an important role in enhancing TCR 
activation signals, the 4-1BB pathway might not be a substitute for CD28 for long term 
protective tumor immunity. In murine lymphoma models, engagement of 4-1BB and 
4-1BBL did not rescue the killing capacity of T cells against T cell lymphoma cell line 
A20. When lacking CD28 signaling, cytotoxicity and survival of T cells were 
significantly impaired, resulting in a decrease in cytokine production, particularly IL-2 
(164). Thus far, 4-1BB is a key target for immunotherapy, with agonistic antibodies in 
clinical development for systemic use and for in vitro selection of antigen specific T 
cells. It has been shown that co-expression of PD-1 and 4-1BB serves as a marker for 
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tumor-reactive T cells, thus developing selection methods to expand CD8+4-1BB+PD-
1+ becomes critical to enrich tumor antigen-specific T cells for T cell therapy (126). In 
addition, agonistic anti 4-1BB antibody has also been used to expand T cells from 
tumor fragments as well as REP as it provides a great benefit in selective expansion of 
CD8+ subset expansion. TIL expanded with anti-4-1BB antibody also demonstrated 
protective capacity against AICD (165).  
CD40 
CD40 is TNFRSF receptor expressed by antigen-presenting cells, particularly 
in B cells and dendritic cells. CD40L expression, a ligand for CD40, is observed in 
activated T cells as well as non-immune cells such as endothelial cells, and epithelial 
cells. Interaction between CD40L and CD40 plays a critical role in the maturation of 
dendritic cells and the development of plasma cells and memory B cells. Like other 
TNFRSF members, engagement of CD40 and CD40L requires clustering of CD40 
receptors for the recruitment of TNFR-associated factors (TRAF) into the cytoplasmic 
domain, which leads to the activation of NF-kB, MAPK, PI3K, and PLCy pathways 
(166). In addition, JAK3 was shown to interact with the CD40 cytoplasmic region 
through the STAT5 pathway (167). CD40/CD40L engagement is known enhance both 
humoral and cell-mediated immune response. It has been shown that activated T helper 
cells promote B cell differentiation, antibody production, and memory development 
through CD40 signaling pathway (168). In addition, disruption of CD40L and CD40 
engagement was found to down-regulate expression of CD28 by dendritic cells, which 
directly attenuated T cell priming due to insufficient co-stimulatory signal (169). The 
CD40/CD40L pathway has been demonstrated to promote an optimal anti-tumor 
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responses both in vitro and in murine models. A number of studies have demonstrated 
that CD40 activation enhanced dendritic cell maturation and optimal priming, which is 
critical for developing a long term anti-tumor response (170).  
CD27 
CD27 is mainly expressed by T cells, NK cells, and memory B cells. CD70 
expression, known as a CD27 ligand in TNFSR, is constrained in only activated T or 
B cells, and mature dendritic cells (171). Although CD27 is expressed at the baseline 
level in naïve T cells, its expression is further up-regulated following T cell activation. 
In addition, CD27 can be shed from the cell surface of activated T cells and 
competitively prevent CD70 from binding the membrane-bound form of CD27. Upon 
engagement with CD70, CD27 recruits TRAF 2 and 5 into the cytoplasmic domain, 
which then activates the NF-kb and JNK pathways. CD27 plays an important role in 
promoting T cell priming, clonal expansion following recent activation, and memory T 
cell generation (172).  CD27/CD70 interaction prevents T cells from apoptosis through 
increasing anti-apoptosis protein expression, such as B cell lymphoma-extra large (Bcl-
xL) as well as suppressing FasL expression by CD4+T cells (173). In a murine model, 
engagement of CD27 and CD70 could harness Treg expansion, thus could suppress 
with the CTL function of CD8+ in the tumor microenvironment (174). Expression of 
CD70 by antigen-presenting cells such as B cells and dendritic cells was found to 
improve antitumor immunity against murine lymphoma (EL4) and murine melanoma 
(B16) (175). Based on studies conducted in a non-human primate model, anti-CD27 
(1F5) has shown no toxicity and caused a decrease in Treg subset. In humans, a fully 
humanized agonistic anti-CD27 antibody (1F5) is currently under investigation in 
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phase I clinical trials in several cancers including renal cell carcinoma, melanoma, and 
B cell malignancies (176).  
Immunoglobulin superfamily (IgSF) 
CD28 
CD28 is classified into the immunoglobulin superfamily and the CD28 
subfamily. It contains a single extracellular immunoglobulin variable-like domain with 
a  short cytoplasmic domain. This structure is also observed in other CD28 subfamilies 
including ICOS, CTLA-4, PD-1, VISTA, and BTLA. CD28 is abundantly expressed 
by naïve CD4+ and CD8+ and down-regulated following T cell activation. Two 
receptors in the B7 subfamily (CD80 and CD86) are identified as ligands of CD28. 
CD80 and CD86 are mainly expressed by activated antigen-presenting cells, but also 
observed in activated T cells as well (177).  The CD28 cytoplasmic region consists of 
YMNM and PYAP motifs. YMNM of CD28 was shown to interact with the SH2 
domain of PI3K, Grb2, and the Grb2-related adaptor downstream of Src (GADS). 
Recruitment of the p85 subunit of PI3K subsequently results in activation of protein 
kinase B (PKB) and the Akt pathway. The PKB pathway is involved in a broad range 
of downstream targets including mTOR, Glycogen synthase kinase 3 (GSK3), and anti-
apoptotic proteins (Bcl-XL and BAD). Moreover, interaction between PI3K with 
adaptor proteins VAv and SLP-76 can also enhance gene transcription and stabilization 
of IL-2 mRNA, which helps promote cell proliferation and survival. PYAP is known 
to interact with LCK, Grb2, and GADS. It has been shown that PYAP plays a role in 
cell proliferation and IL-2 production through the interaction of Vav and LCK (178). 
CD28 is considered one of the most important signals required during T cell priming. 
45 
 
Upon ligation with CD80/CD86, CD28 exhibits positive signals that enhance cell 
proliferation, cytokine production (particularly IL-2 and IL-4), and protection from 
activation-induced cell death (AICD) (179). In addition, CD28 also plays a critical role 
in T cell differentiation and T-cell subset generation.  
ICOS 
ICOS is a co-stimulatory molecule in the CD28 subfamily. Its expression is up-
regulated following T cell actvation. ICOS expression is found in activated T cells 
(particularly the CD4+subset), memory T cells, and activated NK cells, but not in naïve 
T cells. ICOS-L, an ICOS ligand, is expressed by immune cells such as CD33+ cells in 
bone marrow, B cells, dendritic cells, and T cells. Its expression was also found in non-
immune cells including epithelial cells, endothelial cells, and liver, kidney, and lung 
cells. IFN-γ can induce ICOS-L expression in B cells and dendritic cells, while GM-
CSF/TNF-α enhance ICOS-L expression in CD33+ cells in bone marrow. The 
cytoplasmic domain of ICOS contains the YMFM motif, which is also present in the 
CD28 and CTLA-4 (180). Engagement of ICOS and ICOS-L was shown to recruit p50 
alpha and p85 subunits of PI3K, which then activated PDK1, PKB, and GSK3 (181).  
Although the downstream pathway of ICOS shares some similarity with CD28, lacking 
Asn residue in the YMFM motif disables ICOS to activate JNK pathway and IL-2 
production through interaction with the Grb2 adaptor protein. Moreover, the TCR-
induced transcriptional profile of ligation of CD28 and ICOS receptors demonstrated 
that CD28 induced gene expression much more than ICOS. However, some genes were 
selectively induced by ICOS, but not CD28, such as unconventional myosin (MYL1) 
and T-lymphocyte maturation-associated protein (MAL), suggesting that the 
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downstream pathway of ICOS is somehow distinct from CD28 even though overlap in 
signaling pathways has been demonstrated (180).  
1.4 b) Co-inhibitory molecules  
Co-inhibitory molecule is considered as a checkpoint to negatively regulate T cell 
function including cell proliferation, cytokine production, and effector function.  
Because phosphorylation of downstream T cell signaling proteins is critical for T cell 
activation, the commonly shared suppressive mechanism by co-inhibitory molecules 
mainly through dephosphorylation by phosphatase. Unlike co-stimulatory molecules, 
the all co-inhibitory molecule belong to Immunoglobulin superfamily, consisting of an 
immunoglobulin variable (IgV)-like domain and immunoglobulin constant (IgC)-like 
domain in the extracellular region (182).  
PD-1 
PD-1 is an inhibitory molecule in the CD 28 subfamily of the Ig superfamily. 
PD-1 is up-regulated upon T cell activation. Its expression is also found in activated B 
cells, activated natural killer cells, and TIL from different cancers. PD-L1 and PD-L2 
are known as ligands for PD-1. PD-L1 is expressed in broad range of cell types 
including T and B cells, macrophages, dendritic cells, and tumor cells (60).  PD-L1 is 
constitutively expressed by tumor cells and IFN-γ was found to enhance PD-L1 
expression (183). Up-regulation of PD-L1 expression in tumor cells is thought to be a 
protective mechanism from T cell killing.  Basal expression level of PD-L2 is restricted 
in dendritic cells and macrophages at low level (64).  
Two cytoplasmic motifs of PD-1, ITIM and ITSM, were shown to suppress T 
cell function. Upon PD-1/PD-L1 ligation, SHP1/2 are recruited into ITIM and ITSM 
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motifs and attenuate proximal TCR activation. This inhibits T cell proliferation, 
cytotoxic function and cell survival (55). Downstream targets of PD-1 pathway are 
partially known. It has been demonstrated that the recruitment of SHP2 inhibited 
PI3K/AKT3, Ras, and MEK-ERK pathways (56). PD-1 pathway is known to exhibit 
an inhibitory function in CD8+ antigen-specific T cells, but instead enhances the 
generation of Treg cells. PD-1 expression is up-regulated following antigen exposure 
and down-regulated when stimuli no longer exists. Under chronic stimulation such as 
in cancer or latent infection, PD-1 expression can be maintained and affect the effector 
function of T cell. This condition is defined as “T cell exhaustion” (58). In tumor 
microenvironments, high PD-L1 expression by tumor cells and myeloid cells can 
suppress the effector function of T cells and prevent tumor killing. A novel strategy to 
block PD-1/PD-L1 engagement is the use of blocking anti-PD-1 antibodies. This 
approach led to improved tumor burden control and survival in several murine tumor 
models as well as multiple cancer types including melanoma, non-small cell lung 
carcinoma, and renal cell carcinoma. At present, anti-PD-1 agents have been FDA 
approved for the treatment of melanoma and lung cancer and more clinical trials are 
under investigation in multiple institutions to gain a better understanding about 
mechanisms involved in blockade of the PD-1 pathway and clinical response (62).   
CTLA-4 
CTLA-4 is known as a member of the Ig superfamily. CTLA-4 is highly 
expressed in T cells following activation, similar to PD-1. Constitutive expression of 
CTLA-4 was also reported in T regulatory cells. Interestingly, intracellular CTLA-4 is 
highly abundant in memory T cells and can translocate to the cell surface membrane 
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during T cell activation (184). CTLA-4 gene transcription is controlled by nuclear 
factor of activated T cells (NFAT). Down-regulation of CTLA-4 expression is 
enhanced when NFAT is inactivated by cylclosporine A. CTLA-4 shares amino acid 
sequence similarity with CD28, and also interact with CD28 ligands, CD80 and 86 
(44).  Initially, it was thought that CTLA-4 was a co-stimulatory molecule, as the 
YVKM motif has been demonstrated to interact with PI3K. Later, it was found that this 
motif can also interact with SHP2, which can recruit phosphatase and attenuate TCR 
activation (47). In addition, CTLA-4 was shown to inhibit lipid raft formation and 
prevent microcluster of Zap70 during T cell activation. Moreover, CTLA-4 was shown 
to attenuate CD28 signal by competitive binding to CD80 and 86, which prevent T cell 
from full activation during priming (45). In murine models, CTLA-4 deficient mice 
developed severe myocarditis, pancreatitis, and lymphadenopathy with massive 
infiltration of activated T cells with high expression of CD69 and CD44. In addition, 
CTLA-/- T cells exhibited high proliferative capacity upon activation and were also 
susceptible to FasL mediated apoptosis. Altogether, these finding support the inhibitory 
effect of CTLA-4 (28).  
CTLA-4 plays a critical role during T cell priming, which is critical for memory 
T cell generation. Thus, CTLA-4 blockade can be used to enhance the memory T cell 
pool generation under immunosuppressive environment in tumor bed. Several 
preclinical models have shown effectiveness in tumor control in both solid and 
hematological malignancies. The use of anti-CTLA-4 as a single agent in the clinic was 
very successful with the significant improvement in overall survival seen in melanoma 
patients leading to FDA approval in 2011 (185). 
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1.5 B and T lymphocyte attenuator (BTLA) 
1.5 a) Discovery of BTLA and its ligand 
B and T lymphocyte attenuator (BTLA) was first identified from the microarray 
analysis of T helper type 1 cells treated with IL-12 and IL-18 (186). BTLA transcripts 
were highly abundant in lymphoid organs such as the spleen and lymph node, but not 
in somatic tissues. BTLA is considered as the third co-inhibitory receptor found 
following the discovery of CTLA-4 and PD-1, respectively. BTLA belongs to the 
immunoglobulin superfamily as well as CD-28, ICOS, PD-1, and CTLA-4. The first 
report on the discovery of BTLA demonstrated that an orphan B7 (B7X) was a natural 
ligand for BTLA due to specific interaction between B7X-Ig fusion protein and with T 
cells overexpressing BTLA (186). Later, Sedy et al. found no direct interaction between 
NIHT3 cells overexpressing B7X and Fc fusion proteins of BTLA. A functional 
cloning strategy was used to indicate the actual ligand of BTLA. Cells transduced with 
retroviral cDNA libraries generated from mouse splenocytes were screened with 
tetramers of the extracellular domain of BTLA. Plasmon resonance imaging assay was 
used to confirm the direct interaction at the molecular level (187).  From these results, 
HVEM (Herpes Virus Entry Mediator) was found to have a specific interaction with 
BTLA, and defined as an actual BTLA ligand. In addition, engagement of BTLA and 
HVEM triggered phosphorylation of tyrosine residues and inhibited T cell function. 
This finding unveils a novel concept of cross interaction between receptor in the 
immunoglobulin family and TNFR superfamily. 
HVEM as well as other TNFR family members consists of three subunits of 
TNF ligands. The extracellular domain contains three cystein-rich domains (CRDs), 
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CRD1, CRD2, and CRD3, which can interact with its binding partners including 
LIGHT, lymphotoxin, Herpes virus 1 glycoprotien D (HSV1 gD), and BTLA. CRD2 
and CRD3 have been shown to interact with LIGHT and lymphotoxin, while HSV1 gD 
and BTLA bind to CRD1 and CRD2 subunits. BTLA and LIGHT can interact with 
HVEM at distinct areas in a non-competitive fashion. It is possible that BTLA and 
LIGHT can bind HVEM concomitantly. It is known that UL144, a viral protein derived 
from human cytomegalovirus (CMV) can also bind to BTLA due to the shared structure 
with the first two CRDs of HVEM (188, 189). It has been proved that UL144 
effectively suppresses T cell function upon ligation with BTLA, but recruitment of 
SHP1 and SHP2 has not been elucidated.  
BTLA and HVEM expression in immune cells 
BTLA expression was first observed in B and T cells, but later evidence was 
found that dendritic cells, macrophages, and NK cells also express BTLA. In mouse T 
cells, BTLA is up regulated upon T cell activation, particularly in Th1 cells, but not 
Th2 cells (190). It remains unclear what transcription factors controls BTLA expression 
in conventional T cells. On the other hand, it was indicated that transcription factor 
retinoid-related orphan receptor gamma (RORt) dampens the expression of BTLA, 
whereas IL-7 augments BTLA expression, which helps maintain homeostasis of the 
normal gamma delta T cell subset (191). BTLA is expressed at low level in early stages 
of B cell development (pro-B cells and pre-B cells) and gradually increases upon 
maturation stages. High expression of BTLA is generally found in circulating B cells. 
HVEM is highly expressed in naïve T cells, and its expression gradually decreases 
following T cell activation. High expression of HVEM is observed in naïve and 
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memory human B cells, but not on germinal center B cells (188). On the other hand, 
mouse B cells express HVEM at low level. Upon ligation with LIGHT, B cells become 
activated and down-regulate HVEM expression. In immature dendritic cells, HVEM 
expression decreases upon engagement with LIGHT. Typically, HVEM expression is 
high in naïve immune cells, but the expression declines following cell activation (190).  
1.5 b) BTLA structure and functions 
The cytoplasmic region of BTLA consists of three signaling motifs including 
Grb2, ITIM and ITSM. Grb2 motif is present in CD28, and ITIM and ITSM motifs are 
commonly found in other co-inhibitory molecules such as PD-1 (186). Based on the 
BTLA gene sequence analysis, the three signaling motifs are highly conserved across 
different species including humans, mice, rats, dogs, and non-human primates. It was 
shown that a few tyrosines in BTLA signaling motifs were phosphorylated following 
cross-linking of BTLA at the cell surface with anti-BTLA antibodies, suggesting that 
these motifs might contribute in regulating downstream signaling pathways during 
TCR activation (189). The Immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
Immunoreceptor tyrosine-based switch motif (ITSM) contain two tyrosine residues in 
both mice and humans. Similar to PD-1, ITIM and ITSM of BTLA could recruit and 
phosphorylate SHP1 and SHP2 tyrosine phosphatases, resulting in attenuation of TCR 
activation. It has been shown that T cell proliferation was suppressed following 
engagement of BTLA by HVEM, suggesting that BTLA functions as a co-inhibitory 
molecule by suppressing TCR activation (187).  
The downstream signaling pathway of BTLA inhibited by SHP1 and SHP2 
remains understudied. It has been suggested that the downstream targets of SHP1 and 
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SHP2 might be phosphorylated proteins involved in proximal TCR signals. A recent 
report has demonstrated that ITIM and ITSM motifs of PD-1 targeted the PI3K-AKT 
pathway, resulting in inhibition of T cell proliferation. Besides inhibitory motifs, BTLA 
also contains Growth factor receptor bound protein 2 (Grb2) motifs, commonly shared 
in co-stimulatory molecules like CD28. A biochemical assay using synthetic peptide 
demonstrated that Grb2 motifs of BTLA interacted with the p85 subunit of PI3K.  
Although using BTLA phosphotyrosile-containing peptide might not reflect the 
physiological binding of cellular protein during BTLA–HVEM interaction, it could 
provide indirect evidence leading to further study. The Grb2 motif of BTLA contains 
YXN, but not the YMNM sequence found in CD28. It has been well understood that 
Grb2 of CD28 could activate the PI3K-AKT pathway, resulting in an increased IL-2 
production and cell proliferation (192). Thus far, there is no direct evidence that 
supports a positive role for the Grb2 motif of BTLA. Immunoprecipication assay and 
functional studies in cell lines or primary immune cells are required to determine an 
actual interaction between phosphorylated Grb2 motifs and Grb2 protein or PI3K. This 
will aid in gaining a better understanding of the role and regulation of the positive and 
negative motifs resulting in the physiological function of BTLA in T cells.  
An early report on mouse and human BTLA indicated a highly conserved 
protein sequence in the three signaling motifs. In addition, inhibition of the function of 
BTLA on T cells and B cells were also consistent in both species. The study led by 
Riley’s laboratory showed that the conserved ITIM sequences in both human and 
mouse BTLA was necessary for the suppressive function of BTLA. BTLA expression 
at high levels is observed in human naïve and central memory T cells, with a gradual 
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decrease of BTLA expression as T cell differentiation occurs (193). In contrast, there 
is no BTLA expression in naïve mouse T cells, but up-regulation of BTLA is seen 
following TCR activation. These marked differences between the kinetics of BTLA 
expression between mouse and human T cells suggest that the gene regulation of BTLA 
in mice and humans is completely different.     
1.5 c) BTLA in murine disease models  
Multiple studies have been demonstrated the role of BTLA in innate immune 
response. A report in acute experimental sepsis induction in mice (CLP) has revealed 
the role of BTLA in the CD11C+ and CD11B+ innate immune cell subsets, which 
generally are macrophages, dendritic cells, and monocytes. An increase in 
BTLA+HVEM+ innate inflammatory cells in the peritoneum contributed to worsened 
mortality and morbidity in mice administered with lipopolysacccharide (LPS). BTLA 
expression hindered activation of innate inflammatory cells with increased IL-10, but 
not of other pro-inflammatory cytokine production. This resulted in inhibiting the 
recruitment of innate inflammatory cells and limiting bacterial clearance from the body 
(194). Furthermore, an increased BTLA expression by innate inflammatory cells such 
as macrophages, dendritic cells, and granulocytes was also observed in septic ICU 
patients, suggesting a link between mouse models and human studies. In agreement 
with another study, there was a significant increase in CD4+BTLA+ in peripheral blood 
of ICU patients with septicemia as compared with non-septic individuals. Furthermore, 
more than 80% of patients with high CD4+BTLA+ in circulation experienced extended 
hospital stays as they became more susceptible to nosocomial infections (195). Another 
study using a NOD (non-obese diabetic) murine model, BTLA was expressed by 
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dendritic cells and mediated CD8+ T cell tolerance which reduced the severity of 
diabetes. T cell proliferation and cytokine production were suppressed by dendritic 
cells overexpressing BTLA. In addition, NOD mice immunized with dendritic cells 
overexpressing BTLA reduced the incidence of diabetes. This results indicated 
inhibitory effect of BTLA on dendritic cell function (196, 197).  
In an experimental malaria models, BTLA was found to impair both adaptive 
and innate immune responses to Plasmodium yoelii strain 17NL during blood stage 
infection. Humoral immune response, considered as a key mechanism for controlling 
infection, was suppressed by BTLA expression. Furthermore, BTLA also inhibited the 
innate immune compartment, as double deficient RAG1 and BTLA improved the 
capability to control parasitemia over RAG1 deficient animals (198). On the other 
hand, another study demonstrated the favorable role of BTLA in preventing the 
pathogenesis of cerebral malaria. BTLA was shown to increase in peripheral blood as 
well as in the brain during the blood stage infection of Plasmodium berhei. The 
incidence of cerebral malaria significantly diminished when mice treated with agonistic 
anti-BTLA (clone 6A6), which correlated with the reduction of infiltrating T cells in 
brain tissue. It was confirmed that anti-BTLA agonist antibody attenuates the cytokine 
production including IL-6, IL-18, and IFN-γ (198). This suggests that the inhibitory 
function of BTLA helped prevent brain destruction due to strong immune reaction.  
Consistent with the graft-versus-host disease (GVHD) model, targeting BTLA 
with agonistic anti-BTLA (clone 6A6) has been shown to prevent GVHD regardless of 
the presence of HVEM. The agonistic anti-BTLA antibody was shown to directly 
inhibit cytokine production and cell proliferation of the donor effector CD4+Foxp3- T 
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cells, resulting in expansion of the pre-existing donor Treg population. This created a 
new balance between the effector and Treg population that helped prevent GVHD 
without global immunosuppression (199). In addition, the inhibitory function of BTLA 
has been shown to extend the survival of mice with partial MHC class I and II 
mismatches in cardiac allograft, whereas PD-1 played a critical role in full MHC 
mismatch settings. Both BTLA and PD-1 were up-regulated upon allogenic antigen 
stimulation and high expression of HVEM and PD-L1 were observed in cardiac 
transplant tissues. Engagement of BTLA and PD-1 to their ligands could attenuate T 
cell responses to alloantigen by inhibiting T cell proliferation and Th1 cytokine 
production, resulting in alleviation of allograft rejection (200).  
Interestingly, the role of BTLA in T cell survival has also been observed in the 
non-irradiated parental-into-F1 mouse model of acute GVHD. BTLA knockout (BTLA 
KO) donor lymphocytes were unsuccessfully engrafted in the host body. A similar 
finding was also observed when engagement of BTLA and HVEM was blocked using 
anti-BTLA antibody (clone 6A6). Donor lymphocytes lacking BTLA had less 
proliferative capacity prior to contraction as compared with wild type, resulting in 
engraftment failure. In addition, BTLA KO also impaired the re-expression of IL-7R 
alpha, considered as an important factor for homeostasis in naïve T cells. Another study 
has also shown that anti-HVEM antibodies specifically blocking HVEM and BTLA 
interaction ameliorated the graft versus host reaction in lethally irradiated parental-into-
F1 murine models of GVHD. Blockade of HVEM and BTLA dampened donor CD8+ 
T cell activation and IFN-γ secretion, which helped minimize donor anti-host rejection 
(201).    
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Previous studies in adaptive immune cells have shown that BTLA KO mice 
were able to produce more pro-inflammatory cytokine for the clearance of pathogen 
infections in several models such as malaria and listeria. However, it has been shown 
that macrophages lacking BTLA alleviated liver destruction in fulminant hepatitis 
models, caused by murine hepatitis virus strain-3. Macrophages were responsible for 
the pathogenesis of hepatitis as they carried and spread the virus during migration to 
the liver. A rapid increase in macrophage apoptosis mediated by the TRAIL receptor 
following virus infection was found to lower of the viral load and attenuate 
inflammatory response in the liver (202).  
It has been shown that MRL/Mp-Fas (MRL-Ipr) mice, a systemic autoimmune disease 
model for systemic lupus erythematosus (SLE) in humans, become exacerbated when 
lacking BTLA. High infiltration of lymphocytes in salivary glands, lungs, pancreas, 
kidneys, and joints was observed in BTLA-/-MRL-lpr/lpr mice as compared with the 
wild type counterparts. In addition, BTLA-/-MRL-lpr/lpr mice developed necrotizing 
hepatitis with increased autoantibodies, which was similar to autoimmune hepatitis 
(AIH)-like disease. This suggests that BTLA plays an important role in protection 
against autoimmune diseases (203).  
Although BTLA signaling itself is known to suppress immune cell function, a recent 
report has shown that BTLA could provide HVEM-dependent signals that harness T 
cell survival during bacterial infection. In Listeria monocytogenes infection models, 
engagement of HVEM expressed by CD8+T cells and BTLA expression in the host 
microenvironment was critical for CD8+T cell expansion and survival (204). This 
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suggests that BTLA can mediate positive signals through HVEM in trans con 
figurations, but inhibits HVEM signal in cis interactions.  
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1.6 Main theoretical questions posed in this dissertation 
An emerging checkpoint blockade strategy has successfully demonstrated ameliorated 
clinical outcomes for cancers in an advanced stage. Targetting co-inhibitory molecules 
using monoclonal antibodies clearly improves T cell function, resulting in tumor 
regression. It is known that CD8+T cells are prone to dysfunction in the tumor 
microenvironment due to high expression of  inhibitory receptors such as PD-1, BTLA, 
TIM-3, and LAG-3 on the cell surface. We have investigated a number of biomarkers 
in both T cells and the tumor microenvironment. These included T-lymphocyte subsets 
(CD4 and CD8), effector-memory differentiation markers (e.g., CD27, CD28, CD57, 
KLRG1, CD45RA, CD62L), positive (4-1BB, OX40, ICOS) and negative co-
stimulatory molecules (PD-1, BTLA, TIM-3, LAG-3). As expected, the total number 
of TIL and the frequency of CD8+ was associated with a favorable clinical response. It 
as a surprise when we found that BTLA, a negative co-stimulatory molecule appeared 
to be the only marker highly associated with clinical response, while other inhibitory 
molecules such as PD-1, TIM-3, and Lag3 did not. BTLA is known as a maker for T 
cell differentiation. BTLA is highly enriched in less differentiated T cells such as naïve 
and memory T cells, however its expression is progressively lost in CTL 
differentiation. This suggests that the association of patients receiving a high proportion 
of CD8+BTLA+ in TIL infusion products with favorable clinical response might be due 
to the multifunctional properties of less differentiated T cells. It has been reported that 
tumor-bearing mice adoptively transferred with minimally differentiated T cell 
phenotypes exhibited greater tumor control as these cells persisted much longer in the 
body when compared to more differentiated ones. Consistent with this data, we have 
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found that CD8+BTLA+TIL susbset is a less differentiated TIL subset that persists 
longer in vivo following TIL transfer in ACT treated patients. Thus far, it remains 
inconclusive whether the BTLA signaling pathway is also involved in the favorable 
clinical response to adoptive T cell therapy. The BTLA cytoplasmic domain consists 
of three signaling motifs including Grb2, ITIM, and ITSM. It is clearly known that 
ITIM and ITSM motifs are essential for BTLA to exert a suppressive effect by 
recruiting SHP1 and 2 during TCR activation. On the other hand, the BTLA 
cytoplasmic tail also contains a predicted recruitment site for Grb2, which is present in 
the cytoplasmic tail of costimulatory molecules such as CD28 and ICOS. Recent 
studies have shown that the predicted Grb2 binding site was not only able to recruit 
Grb2 protein, but also interacted with p85 PI3K even though there is no reported 
consensus motif for p85 recruitment.  
Previous studies have suggested the roles of BTLA in T cell differentiation and co-
inhibitory signal. However, it remains unclear how less differentiated T cell 
characteristics could contribute in improving the clinical outcome of ACT treated 
patients. In addition, several unanswered questions still remains concerning whether 
the Grb2 motif of BTLA could provide a positive signal. If so, mechanisms defining 
the integration of the inhibitory and positive signals during engagement of BTLA and 
HVEM remain to be elucidated.  
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1.7 Overall hypothesis and specific aims 
 
Our goal is to characterize the function of the CD8+BTLA+TIL subset and the 
molecular mechanism and function of BTLA upon HVEM ligation. We are 
hypothesizing that the less differentiated T cell phenotype of CD8+BTLA+ TIL together 
with BTLA signalling may provide a survival advantage and translate in a better 
persistence of TIL following antigen restimulation. In this dissertation, we tested our 
hypothesis under the following specific aims;   
 
Specific Aim #1: To characterize the survival and anti-tumor function of 
CD8+BTLA+TIL and CD8+BTLA-TIL subsets using in vitro assays and NSG 
mouse model for adoptive T cell therapy.  
Specific Aim#2: To dissect the function and downstream signals of BTLA using 
BTLA mutant retroviral constructs.  
Specific Aim #3: To investigate the role of BTLA in the generation of memory 
upon vaccination with gp100 in a Pmel-1 mouse model. 
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CHAPTER 2 
 
Transcriptional analysis of BTLA in metastatic melanoma patients 
and comparative study of the kinetics of BTLA expression in  
CD8+T lymphocyte 
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2.1 Rationale and Hypothesis 
Our phase II clinical trials of adoptive T cell therapy at MD Anderson Cancer 
Center using autologous ex vivo expanded tumor infiltrating lymphocytes (TILs) have 
demonstrated the great potential of this immunotherapy for stage IV metastatic 
melanoma. We have investigated a number of biomarkers in infused TIL for their 
association with clinical response. These included markers of T lymphocyte subsets, 
effector-memory differentiation markers, as well as positive and negative 
costimulatory molecules. Unexpectedly, we observed that BTLA is the only maker that 
is associated with positive clinical response in TIL treated patients (134).  
BTLA is characterized as a co-inhibitory receptor belonging to the Ig 
superfamily (186). It has been demonstrated that several co-inhibitory molecules 
including PD-1, CD160, TIM-3, LAG-3 are tightly associated with T cell exhaustion 
phenotype (205). As activated T cells progress toward exhaustion they gradually 
upregulate the expression of these co-inhibitory markers which results in a  gradual loss 
of T cell effector function defining T cell exhaustion. By the same token, T cells 
expressing one of these molecules, for example CD8+PD-1+ T cells in peripheral blood 
of healthy donors or antigen-specific T cells circulating in melanoma patients are not 
essentially functionally defective. A recent report has clearly demonstrated that the 
majority of co-inhibitory receptors such as PD-1, CD160, 2B4, as well KLRG1 were 
inducible upon T cells activation. On the contrary, BTLA is highly enriched in naïve T 
cells and gradually down-regulated following T cell activation, suggesting that BTLA 
marks a “young T cell phenotype” (141). It was demonstrated that human effector CD8+ 
T cells derived from naïve cells exhibit a minimally diferentiated phenotype with 
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superior ability to expand and retain longer telomere. These findings suggest that a less 
differentiated phenotype is tightly associated with enhanced proliferative capacity and 
persistence following T cell transfer, which is linked to an effective clinical response 
in ACT (206).  
Thus far, the study of BTLA has been largely restricted to its inhibitiory 
function in studieusing models such as autoimmune diseases and infectious diseases 
(191, 202, 207, 208). Our unexpected findings suggest that BTLA could play an 
important role in tumor immunology, particulary for adoptive T cell therapy. We have 
witnessed an improved clinical response in patients treated with high proportion of 
CD8+BTLA+ in their infusion products. However, our findings are based on the 
expression of BTLA on in vitro expanded TIL and it is unclear whether high expression 
of BTLA in the tumor tissue could be associated with improved survival in metastatic 
melanoma patients. Although BTLA expression was preliminarily reported in human 
and mouse T cells, the kinetic expression of BTLA in different T cell subsets has not 
yet been investigated, particularly in murine T lymphocytes.  
 In this study, we aimed to investigate the transcription level of BTLA in stage 
III metastatic melanoma patients to investigate the association between BTLA 
trancription and patient survival. In addition, we also determined the kinetics of 
expression of BTLA in both human and mouse to comparatively examine BTLA 
regulation between two species.  
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2.2 Results 
High CD8a and High BTLA gene expression strongly linked to an improved 
survival of stage III metastatic melanoma patients.  
 
We previously demonstrated that CD8+BTLA+ subset is highly associated with 
favorable clinical response in TIL treated metastatic patients, but not other co-
inhibitory molecules such as PD-1, TIM-3, as well as LAG-3 (141). It remains 
understudied whether metastatic melanoma patients with high expression of BTLA, 
CD8 or both markers, in the tumor tissue also conferred superior survival rate 
regardless of given therapy. 
To further examine whether CD8+BTLA+ is linked with better survival, we 
analyzed integrated data generated by The Cancer Genome Atlas (TCGA) Research 
Network. The data from 96 stage III metastatic melanoma patients were retrieved from 
the database for survival analysis using a Kaplan-Meier analysis method. A non-
parametric statistic was used to evaluate the fraction of patients alive for a period of 
time following therapeutic intervention. In this study, we performed transcription 
analysis by evaluating the association between transcripts of CD8a, CD19, NRC1, and 
BTLA, with survival in metastatic melanoma patients. Gene transcription level was 
categorized into high and low based on the expression being higher or lower than the 
median value respectively.   
We found that the patients with high transcripts of either CD8a or BTLA had 
much superior survival when compared with either CD8a low or BTLA low (Log Rank; 
CD8a high vs CD8a low, P=0.0007, N=42; BTLA high vs BTLA low, P=0.001, N=42) 
(Figure 2.1A and 2.1B). When both CD8a and BTLA were considered, high 
transcription level of CD8a and BTLA was the strongest link with better survival. 
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Interestingly, patients with low CD8 but high BTLA had better survival as compared 
to high CD8 paired with low BTLA. (Log Rank; CD8a high BTLA high vs CD8a low 
BTLA low, P =0.0007, N =98) (Figure 2.1C).  
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Figure 2.1. Association of high CD8a and high BTLA transcription level and 
improved patient survival in stage III metastatic melanoma.   
Kaplan-Meier survival curves in stage III metastatic melanoma from The Cancer 
Genome Atlas (TCGA) consortium depicts;  (A) CD8a expression; CD8a high versus 
CD8a low (B) BTLA expression; BTLA high versus BTLA low (C) Combined CD8 
and BTLA expression; CD8a high BTLA high versus CD8a low BTLA high versus 
CD8a high BTLA low versus CD8a low BTLA low. Total number of patients=98, 
(high- above median, low-below median). Statistical significance was determined 
using a log-rank. (P <0.001 and P <0.0001). CD8a high BTLA high, N=42; CD8a high 
BTLA low, N=7; CD8a low BTLA high, N=7; CD8a low BTLA low, N=42.  
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Since BTLA can be expressed by other cell types, we also further investigated 
the association of BTLA with other immune cells such as B cells (defined as CD19) 
and NK cells (defined as asNCR1). We found that high CD19 transcription level was 
linked with better survival, particularly in combination with low BTLA (Figure 2.2A). 
The worst survival was observed in the patients with low transcription level of both 
CD19 and BTLA; however, patients with low CD19 and high BTLA had much superior 
survival as compared with low CD19 and low BTLA P =0.024, N=40 (Figure 2.2B). 
Next, we determined the gene expression level of NK cells and BTLA, we observed 
that low NCR1 and high BTLA was correlated with the greatest survival. Within the 
BTLA high group, NCR1 expression defined worst survival. Overall the high 
expression of BTLA in conjunction with either high CD8, high/low CD19 or low NCR1 
was most predictive of best survival, indicating that BTLA might be a good predictor 
for stage III metastatic melanoma patients.   
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Figure 2.2. Correlation of CD19, NRC1, and BTLA transcription level with 
patients in stage III metastatic melanoma.  
Kaplan-Meier survival curves in stage III metastatic melanoma from The Cancer 
Genome Atlas (TCGA) consortium depicts (A) CD19 and BTLA expression in the 
following combinations; CD19 high and BTLA low (black), CD19 low and BTLA high 
(yellow), CD19 high and BTLA high (red), and CD19 low and BTLA low (green). (B) 
NCR1 (NK cell marker) expression and BTLA expression in the following 
combinations; NCR1 low and BTLA high (yellow), NCR1 high and BTLA high (red), 
NCR1low and BTLA low (green), and NCR1 high and BTLA low (black). Total 
number of patients=98 (high-above median, low-below median). Statistical 
significance was determined using a log-rank. CD19 high and BTLA low, N=9; CD19 
low and BTLA high, N=9;  CD19 high and BTLA high, N=40; and CD19 low and 
A 
B 
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BTLA low, N=40. NCR1 low and BTLA high, N=10; NCR1 high and BTLA high, 
N=39; NCR1low and BTLA low, N=39; and NCR1 high and BTLA low, N=10.  
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Human BTLA is downregulated upon cell differentiation and expansion.  
BTLA was first characterized as a co-inhibitory molecule expressed by B cells, 
T cells, dendritic cells, as well as NK cells (186). Several in vitro and in vivo studies 
have consistently shown that BTLA attenuated T activation through its inhibitory 
motifs, ITIM and ITSM. Unlike other inhibitory molecules, BTLA is down-regulated 
following T cell activation as opposed to the increased expression commonly seen with 
PD-1, TIM-3, and LAG-3. Transcriptional analysis of CD8+BTLA+ versus 
CD8+BTLA+ has indicated that CD8+BTLA+ T cell subset is highly enriched in genes 
associated with less differentiated T lymphocytes including CD28, whereas a gene 
signature typical of more differentiated T cells is highly up-regulated in  CD8+BTLA- 
T cell subset (142).  
Based on this finding, we further performed immunophenotypic analysis of T 
cells in PBMCs to determine the expression level of BTLA in different T cells subsets. 
Human PBMCs isolated from five donors were stained with CD3, CD8, CD45RA, 
CCR7, and BTLA. CD8+T cells were categorized into five subsets on the basis of the 
expression of CCR7 and CD45RA; Naïve (CD45RA+CCR7+), Central memory 
(CD45RA-CCR7+), Effector memory (CD45RA-CCR7-), Effector memory 
intermediate (CD45RAint, CCR7-), and terminally differentiated (CD45RA+, CCR7-) 
(Figure 2.3A). Highest BTLA expression was observed in naïve T cells (non-
differentiated cells), and terminally differentiated had the lowest BTLA expression. 
BTLA expression between naïve and central memory was comparable (P=0.06), but 
the expression was significantly higher than effector memory and terminally 
differentiated cells respectively (naïve versus effector memory, P= 0.028, N=6; naïve 
versus terminally differentiated, P =<0.001; central memory vs terminally 
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differentiated, P=0.03) (Figure 2.3B and C). This indicates that BTLA is highly 
enriched in less differentiated T cells, and that its expression level is down-regulated 
upon differentiation. Thus BTLA expression level marks T cell differentiation status.  
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Figure 2.3. BTLA expression correlates with differentiation status of T cells.  
PBMCs were isolated form five human donors. The cells were stained with anti-human 
CD3, CD8, CD45RA, CCR7, and BTLA. (A) Zebra plot depicts different CD8+ T cell 
subsets defined by the expression of CD45RA and CCR7; Naïve (CD45RA+CCR7+), 
Central memory (CD45RA-CCR7+), Effector memory (CD45RA-CCR7-), Effector 
memory intermediate (CD45RAint, CCR7-), and terminally differentiated (CD45RA+, 
CCR7-). (B) Histogram plot demonstrates mean fluorescence intensity (MFI) of BTLA 
expression in Naïve, Central memory (CM), Effector memory (EM), Effector memory 
intermediate (EMRAint), and Terminally differentiated (TEMRA). (C) Bar graph 
depicts percentage expression of BTLA in different CD8+T cell subsets. BTLA 
expression was down-regulated upon T cell differentiation.  
A B 
C 
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Upon T cell activation, T cells undergo proliferation as well as differentiation. 
Because BTLA expression correlates with T cell differentiation, we further 
investigated whether T cell expansion could lead to BTLA down-regulation. BTLA 
expression level was compared between pre and post-expansion of sorted BTLA+ TIL 
propagated using the REP protocol. BTLA was found to be significantly decreased in 
post-expansion of sorted BTLA TIL as compared to pre-expansion, indicating that 
BTLA is down-regulated upon T cell expansion and differentiation (P=0.001) (Figure 
2.4A and B).  
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Figure 2.4. BTLA is down-regulated upon T cell expansion and differentiation. 
CD8+BTLA+ TIL from four patients were sorted and propagated with the Rapid 
expansion protocol using irradiated PBMC, anti-human CD3, and IL-2 (6000 IU/ml) 
for 14 days. The cells were stained with anti-human CD8 and BTLA. The expression 
level of BTLA by CD8 TIL was assessed by flow cytometry. (A) BTLA expression 
was significantly decreased following TIL propagation using REP. (N=4, P=0.0131) 
(B) Pseudo color plots demonstrates BTLA expression. Representative example of 
CD8+TIL (TIL #2405) demonstrates post-sort purity (left panel) and a decreased BTLA 
expression following REP (right panel). 
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Mouse BTLA is up-regulated upon T cell activation. 
We previous demonstrated the expression of BTLA in different human T cell 
subset. In this study, we explored the kinetic of BTLA expression in different subset of 
mouse CD8+T lymphocytes. Mouse CD8+T cells were categorized into three subsets 
on the basis of the expression of CD62L and CD44; Naïve (CD44-CD62L+), Central 
memory (CD44+highCD62L+), Effector memory (CD44+CD62L-) (Figure 2.5A). 
Splenocytes from OT-1 mouse were stained with anti-CD3, anti-CD8, anti-CD44, anti-
CD62L, and anti-BTLA.  
High expression of BTLA was observed in CD44+CD8+ T cells, particularly in 
CD44high and CD62L+CD8+T cells, suggesting that BTLA expression correlates with 
T cell activation as CD44+ is highly expressed by activated T lymphocytes (Figure 
2.5B and C). Unlike human T cells, the expression of BTLA in mouse naïve T cells 
was undetectable.  
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Figure 2.5. High expression of BTLA correlates with CD44. 
Splenocytes were isolated from wild type OT-1 mouse, lysed with ACK buffer, then 
stained with anti-CD3, anti-CD8, anti-CD44, anti-CD62L, and anti-BTLA. (A) Mouse 
CD8+ T cell subset defined by the expression of CD44 and CD62L; Naïve (CD44-
CD62L+), Central memory (CM, CD44+CD62L+), and Effector memory (EM, 
CD44+CD62L-). (B) High expression of BTLA correlates with CD44. (C) The highest 
BTLA expression was found in Memory T cell subset (CD44 very hi and CD62Lhi), 
while CD44 low and CD62L subset had the lowest expression of BTLA.   
A B 
C 
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Next, we further examine the kinetic of BTLA expression in different mouse T 
cell subsets following T cell activation. Either sorted naïve T cells (CD44-CD62L+) or 
Memory T cells (CD44+CD62L+) were labeled with eflour®670 and stimulated by co-
culturing with bulk splenocytes of OT-1 mouse and anti-mouse CD3 (Figure 2.6A). 
BTLA expression was determined every other days following T cell activation. Down-
regulation of BTLA was observed in mouse T lymphocytes, which is similar to the 
kinetic of human T cells. In mouse naïve T cells, BTLA expression was inducible upon 
T cell activation, and gradually declined within five days (Figure 2.6B). Interestingly, 
re-stimulation with anti-mouse CD3 failed to trigger the expression of BTLA regardless 
of the dose of antibody (Figure 2.6C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
                   
 
                          
                        
 
 
                               
 
 
 
 
 
 
 
 
 
Figure 2.6. The kinetic of BTLA expression in mouse T cells.  
(A) Naïve (CD44loCD62Lhi) and Memory T cells (CD44very hi and CD62L hi ) were 
sorted from bulk splenocytes of OT-1 mouse, labeled with efluor670®, and activated 
by co-culturing with bulk splenocytes with mouse anti-mouse CD3 at concentration of 
300 µg/ml. Activated T cells were harvested and stained with anti-CD44, anti-CD62L, 
A 
B 
C 
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and anti-BTLA on day 0, 1, 3, and 5 respectively. (B) Sorted cells were gated on 
efluor670®+CD3+CD8+cells and analyzed for expression of BTLA, CD44, and 
CD62L. BTLA in naïve T cell was up-regulated shortly after activation and return to 
basal level within 5 days, while BTLA expression in memory T cell subset was 
continuously decrease within a day upon activation. (C) On day 7, the cells were re-
stimulated with antimouse-CD3 at concentration of 0.01, 0.25, and 1 mg/ml. There was 
no BTLA expression detected within 24 hours following re-stimulation.  
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2.3 Discussion 
Transcriptional analysis has demonstrated that the gene expression of CD8a and 
BTLA in the tumor tissue is associated with an extended survival of stage III metastatic 
melanoma patients, while no correlation of survival benefit was seen with the co-
expression of BTLA and other immune cells such as NK and DC cells. This finding is 
in agreement with our previous observation indicating that high proportion of 
CD8+BTLA+TIL in the infusion product associated with positive ACT clinical outcome 
(134). The association between the expression of BTLA and CD8 and survival from 
the TCGA data strengthens our results making the point that the co-expression of 
BTLA and CD8 is a good prognostic factor for patient survival regardless of the therapy 
they eventually receive.  
Our data on correlation of the high expression of human BTLA in less 
differentiated T cells is in agreement with a previous report from Speiser’s lab (142). 
A recent report also suggested that BTLA could be a maker for B cell differentiation 
as decreased BTLA expression was observed in aged B cells minimally responsive to 
influenza vaccination (209). Altogether, these results indicate that BTLA serves as a 
cell differentiation marker in both B and T cells.  
 We found that BTLA expression in mouse T cells did not correlate with cell 
differentiation. In fact, we did not observe BTLA expression in naïve T cells isolated 
from C57B6L mouse.  During T cell activation, mouse BTLA expression is up-
regulated rapidly within 24 hours, and the expression declines over 7 days. The kinetic 
of expression of BTLA in mouse is similar to the general expression pattern of co-
inhibitory molecules such as PD-1 and CTLA-4 (184, 210).   
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In conclusion, human BTLA serves as a cell differentiation maker in both B 
and T cells. In contrast, the kinetic of expression of BTLA in mouse is similar to other 
co-inhibitory molecules and not considered as a differentiation marker. This finding 
suggest BTLA gene regulation in mouse and human is different, possibly result from 
dissimilar epigenetic regulation of gene expression.  
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CHAPTER 3 
 
Characterization of the anti-tumor function of the CD8+BTLA+ TIL 
subset 
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3.1 Rationale and Hypothesis 
In the previous chapter, we and other have demonstrated that BTLA is considered as a 
marker for human T cell differentiation. BTLA is highly enriched in minimally 
differentiated T cells such as naïve and central memory T cells, while low expression 
is found in more differentiated phenotype (142). CD8+BTLA+TIL abundantly contains 
gene signature of less differentiated T lymphocyte including CD28, CD127 (also 
known as IL7R), and CX3CR1 (also known as CX3C chemokine receptor 1), while 
CD8+BTLA-TIL are highly enriched in more differentiated T lymphocyte gene cluster 
such as TYROBP (TYRO protein tyrosine kinase-binding protein), KIR2DL-1, -2, and-
3 (Killer cell immunoglobulin-like receptor) (141). It has been demonstrated that 
minimally differentiated CD8 T lymphocytes are less potent in effector cytokine 
production such as IFN-γ, perforin, and granzymes, as well as cytotoxic function as 
compared to the more differentiated CD8 T lymphocyte counterpart. Several studies 
have also indicated that more differentiated T lymphocyte are more effective in 
mediating cytotoxic killing (206). However, we have observed that our ACT treated 
patients who received high proportion of CD8+BTLA+ TIL subset achieved better 
clinical response relative to those who were infused with less proportion of 
CD8+BTLA+ TIL (141). Less differentiated T lymphocytes are thought to be less 
effective in effector mediating killing (141, 143). However, several studies have been 
reporting that less differentiated T lymphocyte subset have superior proliferative 
capacity and persistence as compared to more differentiated T lymphocyte (140, 143, 
206). We hypothesized that CD8+BTLA+ TIL may be less potent effectors but may be 
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able to proliferate and survive longer to repeatedly mediate tumor killing and therefore 
be able to better control tumor growth than their CD8+BTLA- counterpart.  
In this study, we aimed to perform an extensive investigation of the cytotoxic function 
of both CD8+BTLA+ TIL subset and CD8+BTLA-TIL subset. We utilize in vitro tumor 
killing assay as well as an in vivo model of immunodeficient NOD-scid IL2Rgammanull 
model for adoptive TIL transfer to evaluate tumor burden control. To extensively 
determine the dynamic interaction between tumor target cell and effector T cell in 
isolated killing events, we conducted single cell T cell/Tumor cell killing assay using 
TIME. This allowed us to gain a comprehensive understanding of the fate of the T cell 
after tumor killing at single cell level and helped us understand the outcome of the in 
vivo tumor challenge. 
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3.2 Results  
In vitro tumor killing capacity is relatively comparable between CD8+BTLA+ and 
CD8+BTLA- subsets regardless of tumor antigen restricted setting.  
It is known that more differentiated T lymphocytes are more effective in tumor killing 
relative to those of less differentiated T cell subset. Unexpectedly, we observed TIL 
treated patients who were infused with high percentage of less differentiated phenotype 
(CD8+BTLA+TIL subset) achieved superior clinical response instead of those patients 
who received high percentage of more differentiated phenotype (CD8+BTLA+TIL 
subset). We previously reported that the T cell repertoire of CD8+BTLA+TIL and 
CD8+BTLA-TIL subsets almost completely overlaps (>95% of the TCR CDR3 
sequences are shared) using high throughput CDR3 sequencing. This suggests that 
tumor-reactive T cells are not selectively enriched in one subset and the assumption is 
that they are equally distributed among two subset. With this bias removed, the overall 
killing capacity of each subset is determined on the basis of intrinsic cytotoxicity. We 
performed an in vitro killing assay to evaluate the killing capability of CD8+BTLA+ 
and CD8+BTLA- subsets in cultures where the antigen recognized by TIL are unknown 
(non-antigen restricted killing) and also with TIL that were sorted for HLA-A2 
restricted recognition of MART-1 tumor antigen (antigen-restricted killing). To 
investigate CTL-mediated tumor killing in tumor antigen restricted setting, we selected 
two TIL lines containing MART-1 recognizing TCR population (TIL#2559 and 2765). 
We co-incubated either sorted CD8+BTLA+MART-1 tetramer positive or CD8+BTLA-
MART-1 tetramer positive TIL with MEL526 (human melanoma tumor cells 
expressing the MART-1 antigen) at the ratio of effector T cells to target tumor cells of 
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1:1, 1:3, and 1:10 (Figure 3.1). Percentage of caspase-3 positive MEL526 tumor cells 
was used to compare tumor killing capacity between the two subsets. We found that 
the killing capability in two MART-1 antigen specific TIL lines were equally 
comparable (TIL# 2559; 1:1, BTLA+ (33%) vs BTLA-(29.1%), 1:3, BTLA+(13.95%) 
vs BTLA-(16.2%), 1:10, BTLA+(5.5%) vs BTLA-(5.6%), TIL#2765; 1:1, BTLA+ 
(2.5%) vs BTLA-(2%), 1:3, BTLA+ (7.7%) vs BTLA- (7%), 1:10, BTLA+ (11.8%) vs 
BTLA-(13.7%). Consistently, we did not observe any difference in tumor killing 
capacity in using bulk TIL from another patient in a non-antigen restricted setting (TIL# 
2549; 1:1, BTLA+ (64%) vs BTLA-(71%), 1:3, BTLA+(46%) vs BTLA-(63%), 1:10, 
BTLA+(38%) vs BTLA-(49%). In conclusion, CD8+BTLA+ and CD8+BTLA- exhibit 
equivalent in vitro tumor killing.    
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
 
 
 
 
 
 
 
Figure 3.1. Evaluation of in vitro killing capacity between CD8+BTLA+TIL and 
CD8+BTLA-TIL subset.  
MART1-reactive CD8+ TIL (left and mid panel) and TIL 2549 (right panel) were sorted 
into BTLA+ and BTLA- subsets. MEL 526 (melanoma tumor expressing MART-1 
antigen, left and mid graph) or autologous tumor line 2549 (right graph) were stained 
with eFluor670® and co-cultured with TIL at the following TIL-to-tumor cell ratios 
(1:10, 1:3, and 1:1). Tumor cell death is measured by the percentage of caspase-3 
positive cells. Comparable tumor killing capacity was found between two subsets.  
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CD8+BTLA+TIL subset confers superior tumor control in NSG mouse model for 
adoptive T cell therapy as compared to CD8+BTLA-TIL counterpart. 
Our results indicated comparable intrinsic tumor killing ability between CD8+BTLA+ 
and CD8+BTLA- subsets. This result disagreed with the previous knowledge 
demonstrating that more differentiated T cells are more effective in mediating tumor 
killing as compared to those less differentiated T lymphocyte phenotypes (211). 
Because in vitro killing capacity testing was conducted in short time (3 hours) and in a 
confined environment, this setting might not reflect an actual physiological interaction 
between tumor and TIL. We thus further determined the killing capability of TIL using 
an in vivo setting with the NOD-scid IL2Rgammanull (NSG) mouse model for adoptive 
T cell therapy. NSG mice lack immune cells including mature T cells, B cells, as well 
as NK cells. In addition, the innate immune system and multiple cytokines are also 
defective in NSG mice (212). The NSG mouse model is widely used to examine the 
function of human T cell for the therapy of cancer, particularly in genetic modified T 
lymphocytes. In this study, we compared the potency of in vivo tumor control between 
CD8+BTLA+TIL versus CD8+BTLA-TIL subsets in both a tumor-antigen restricted 
manner (MART-1 antigen) and a non-tumor restricted setting. In the tumor-antigen 
restricted setting, two TIL lines containing MART-1 recognizing TCR populations 
(TIL#2559 and 2765) were sorted on either CD8+BTLA+MART-1 subset or 
CD8+BTLA-MART-1 TIL subset, and further propagated using the REP for 14 days. 
These expanded cells were adoptively transferred into NSG animals that were engrafted 
with 10 x 106 cells of MEL526 human melanoma tumor line expressing MART-1 
antigen. IL-2 was administered immediately following T cell transfer and daily for 
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three days to support the in vivo TIL expansion. Tumor measurements were used to 
determine the potency of in vivo tumor control. Similarly, in the non-antigen restricted 
setting, TIL#2549 were sorted on either CD8+BTLA+ or CD8+BTLA-, propagated with 
the REP for 14 days, and adoptively transferred into NSG mice engrafted with 
autologous tumor generated from TIL#2549 patient. We found that the transfer of 
CD8+BTLA+ in tumor-bearing NSG mice conferred significantly better tumor control 
relative to those NSG mice infused with the CD8+BTLA- TIL counterpart in both 
tumor-antigen restricted (TIL#2559; P = 0.002, 2765; P=0.04) and non-tumor-antigen 
restricted setting (TIL#2549; P=0.049). This suggests that the CD8+BTLA+ subset has 
a superior capability to mediate in vivo tumor control from an equivalent TCR 
repertoire therefore implying intrinsic differences (Figure 3.2A). 
To evaluate the persistence of TIL in NSG mouse following TIL transfer, peripheral 
blood was collected every other day and stained with anti-human CD45 and anti-human 
CD8+. We observed that TIL were barely or no longer detected in peripheral blood of 
NSG mice approximately 6 to 8 days following TIL transfer. This could suggest that 
TIL do not efficiently engraft in the NSG host. We found that NSG treated with 
CD8+BTLA+MART+ had significant higher absolute number of CD45+CD8+ cells  than 
those treated with CD8+BTLA+MART+ (TIL#2559MART+; D4, P=0.0021, 
TIL#2765MART+; D2, P=0.0021, D4, P=0.02). In NSG treated with non-antigen 
restricted TIL, the absolute number of  CD45+CD8+ cells in peripheral blood are 
comparable in NSG mice treated with either CD8+BTLA+ or CD8+BTLA- (TIL#2549; 
D2, P=0.06) (Figure 3.2B).  
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Figure 3.2. CD8+BTLA+ exhibits superior in vivo tumor control potency as 
compared to CD8+BTLA-. 
(A) CD8+BTLA+TIL subset exhibited superior in vivo tumor control as compared to 
their CD8+BTLA-TIL counterpart. Ten million sorted CD8+BTLA+ or sorted 
CD8+BTLA- TIL were intravenously injected into tumor bearing mice previously 
subcutaneously implanted with either MEL526 or autologous melanoma tumor line 
2549. Tumor burden was measured for 15 days following TIL transfer using calipers 
and the diameter was graphed as mm2. (B). To determine TIL persistence following 
TIL transfer, peripheral blood was collected every other day and lysed with lysed with 
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ACK buffer, then stained with anti-human CD45 and anti-human CD8. Bar graphs 
demonstrate percentage of absolute number of CD45+CD8+. CD8+BTLA+TIL subset 
persisted significantly longer following adoptive transfer in antigen-restricted TIL lines 
(2559 MART-1+ and 2765 MART-1+).  
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Exploring the dynamic interaction between TIL and tumor cell at a single cell 
level using TIMING.  
We observed that CD8+BTLA+ displayed superior in vivo tumor control using 
NSG mouse model as compared with their CD8+BTLA- counterpart; however, no 
difference in in vitro tumor killing capacity was observed between these two subsets. 
The in vivo setting provides a broader picture relevant to an actual physiological 
situation and we chose to next look at the dynamic interaction between TIL and tumor 
at the cellular level over a longer period of time to elucidate functional differences 
between the two subsets. We utilized Timelapse Imaging Microscopy In Nanowell 
Grids (TIMING) to study the dynamic interactions between individual tumor targets 
and effector cells in a high-throughput setting. The nanofabricated array was used to 
restrict the effector TIL and tumor targets in small volumes. Functional features of TIL 
and tumor cells were sequentially monitored for 8 hours by automated time-lapse 
fluorescence microscope in each individual wells of nanofabricated array (213, 214).  
In this study, we evaluated the tumor killing capacity of TIL by measuring the 
survival of tumor cells following the interaction with TIL and we also determined the 
survival of TIL after a killing event. MART-1 recognizing TIL line was used to reduce 
the bias of heterogeneity of the tumor recognition capacity. TIL (either sorted 
CD8+BTLA+MART-1 TIL or CD8+BTLA-MART-1 TIL) and MEL526 human 
melanoma tumor line were labeled with Vybrant Violet and Cell Tracker Red 
respectively,  and loaded onto nanowell chip at two separate effector-to-target ratios of 
1:1 and 1:2. Dynamic interaction between TIL and tumor was monitored for 500 
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minutes using digital fluorescence microscope attached underneath the nanowell chip 
(Figure 3.3A and B) (213, 214).  
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Figure 3.3. Schematic diagram demonstrating single-cell cytotoxic analysis using 
nanofabricated array based analysis.  
Nanowell array-based cytolysis assay was used to determine tumor killing capacity at 
the single cell level. Effector cell and Tumor target are labeled in different colors and 
loaded into the nanowell at effector-to-target cell ratios of 1:1 and 1:2. Interaction 
between effector and target cells is monitored by automated time-lapse camera coupled 
with a fluorescence microscope. (A) Schematic diagram demonstrates nanowell chips 
loaded with effector cell and tumor target cells.  (B) Timelapse images depict effector 
cells and tumor target cell interaction over 8 hours following co-incubation; tumor cell, 
T cells, and apoptotic cells are labeled in red, blue, and green respectively.    
 
A 
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CD8+BTLA-TIL subset accelerates tumor cell death by shortening t contact and 
t death. 
The kinetics between TIL and tumor were evaluated using these three following 
sequential parameters (tseek, tcontact, and tdeath).1) Time needed to establish conjugation 
between the T cell and tumor target (tseek), 2) duration of the contact between the T cell 
and the tumor target (tcontact), and 3) time between the first T cell contact with the tumor 
cell and tumor cell apoptosis (tdeath) (Figure 3.4A). Intriguingly, the CD8
+BTLA+ 
subset was more effective in tumor seeking at effector-to-target cell ratios of 1:1 as 
time that T cell used to initiate first contact with tumor target was significantly less in 
CD8+BTLA+  as compared to CD8+BTLA-subset (N= 3319, tseek; ratio 1:1, P<0.0001) 
(Figure 3.4B). This difference was not observed when two targets were present in the 
well. (N= 3319, tseek; ratio 1:2, P<0.22) (Figure 3.4B). This finding could imply that 
CD8+BTLA+ TIL subset may be more bioenergetically efficient than the CD8+BTLA-
counterpart.  
However, the CD8+BTLA- subset was found to spend less time in contact with 
the tumor cell target (tcontact; 1:1 and 1:2, P<0.0001) and the time from first contact to 
apoptosis of the tumor target was considerably shorter for the CD8+BTLA- subset at 
both E:T ratios (tdeath; 1:1 and 1:2, P<0.0001) (Figure 3.4C and D). These findings 
support the functional role of BTLA in both signaling and cell differentiation. The co-
inhibitory role of BTLA signal attenuate TCR activation, resulting in extending the 
time used for TIL to reach and initiate interaction with a tumor. In addition, shortened 
tdeath observed in CD8+BTLA-TIL subset is in agreement with the previous knowledge 
demonstrating that more differentiated T lymphocytes are more potent in cytotoxic 
function relative to those of less differentiated phenotype. 
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In summary, CD8+BTLA+TIL subset are more active in seeking the tumor cell 
than CD8+BTLA-TIL subset, but perform tumor cell death with slower kinetics. These 
behavioral features might be explained from both distinct differentiation status and 
BTLA signaling.    
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Figure 3.4. CD8+BTLA-TIL subset extend t seek, but shorten t contact and t death. 
(A) Schematic diagram demonstrating the sequential events in which effector cells seek 
(tseek), contact (tcontact), and mediate tumor cell death (tdeath). Either 
CD8+MART1+BTLA+ or CD8+MART1+BTLA- subset was co-incubated with MEL 
526. Time (min) between each sequential event is evaluated. Dot plots depict tseek (B), 
tcontact (C), tdeath (D) in comparison between CD8+BTLA+ (blue) and CD8+BTLA- 
A 
B C 
D 
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(red) subsets. All error bars depicts the mean ± s.e.m. All P-values were calculated 
using a two-tailed Student’s t-test. (N=497). 
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CD8+BTLA+ subset conferred survival capacity that mediates tumor serial killing.    
We previously have shown that CD8+BTLA- TIL are effective in tumor killing 
as the time used to form contact (tcontact) and mediate tumor cell death (tdeath) was 
significantly less than CD8+BTLA+ subset. In contrast, we found that the two subsets 
had comparable tumor killing capacity when used for in vitro tumor killing in bulk 
setting.  
  We next examined whether the overall killing capacity between the two subsets 
was any different by evaluating tumor target cell survival following 8 hour of co-
incubation with TIL. In general, we found that both T cell subsets equally killed tumor 
target (Figure 3.5A, 18% of tumor target killed at an E:T ratio of 1:1). Interestingly, at 
the E:T ratio of 1:2 the CD8+BTLA+ subset was able to kill a total of 21% of tumor 
targets upon contact as compared to only 14% for the CD8+BTLA- (Figure 3.5A). 
When two tumor targets were in the presence of one effector T cell, the CD8+BTLA+ 
subset was twice as likely to kill both targets (Figure 3.5A, 14% for the BTLA+ versus 
7% for the BTLA-).  
Next, we evaluated tumor target cell survival through time following effector 
target cell killing over 500 minutes. In the first 250 minutes, we found that the 
CD8+BTLA- TIL subset was more potent in tumor killing capacity as survival of tumor 
cells being killed by CD8+BTLA- TIL was significantly less than tumors co-incubated 
with the CD8+BTLA+ TIL counterpart at both effector TIL to target tumor cell ratio of 
1:1 and 1:2 (Figure 3.5B and C, survival of contacted tumor target cells; 1:1, P<0.03, 
1:2, P<0.0001). In the last 250 minutes, we found that the two subsets had comparable 
tumor killing capacity at effector TIL to target tumor cell ratio of 1:1; however, 
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CD8+BTLA+ became more effective in tumor killing when effector TIL to target tumor 
cell ratio increased to 1:2 (Figure 3.5D and E, survival of contacted tumor target cells; 
1:1, P<0.54, 1:2, P<0.0001).  
When we cautiously determined the survival capability of T cells following 
tumor killing events, we found that the CD8+BTLA- subset was more susceptible to 
undergo apoptosis in comparison with the CD8+BTLA+ counterpart (Figure 3.5D, 
survival of effector cells following target tumor cell killing; ratio 1:1, P<0.01). This 
demonstrates that the CD8+BTLA+ subset is prone to survive better after tumor killing, 
and thus is able to repeatedly kill additional tumor cells.  
 Overall, our results suggest that CD8+BTLA- is more effective in tumor killing, 
but also more susceptible to undergo apoptosis following killing as compared to 
CD8+BTLA+.  
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Figure 3.5. CD8+BTLA+ TIL subset exhibit improved survival following tumor 
target killing. 
(A) Donut charts demonstrate the frequency of tumor cell death following effector cell 
killing by either CD8+BTLA+ (left) or CD8+BTLA-(right) subset. Inner circle and outer 
circle depict E:T ratio of 1:1 and 1:2 respectively. Kaplan-Meier survival curves of T 
cell-contacted tumor targets resulting in a killing event in the first 250 minutes in 
comparison between CD8+BTLA+ and CD8+BTLA-subsets at effector-to-target cells 
ratios of 1:1 (B) and 1:2 (C). Kaplan-Meier survival curves of T cell-contacted tumor 
target resulting in a killing event in the last 250 minutes; comparison between 
CD8+BTLA+ and CD8+BTLA-subset at effector-to-target cells ratios of 1:1 (D) and 1:2 
(E). Statistical significance was determined using a log-rank. (N=3319). (***P 
<0.0001). (F) Kaplan-Meier survival curves of tumor-contacted effector cells 
following tumor cell death in comparison between CD8+BTLA+ and CD8+BTLA- 
subsets at an effector-to-target ratio of 1:1. Statistical significance was determined 
using a log-rank. (N= 3319) (*P<0.05). 
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Discussion  
Previous knowledge indicates that more differentiated T lymphocytes are more 
potent at performing effector function, suggesting that CD8+BTLA- subset (more 
differentiated T cell) might be endowed with better tumor killing capacity as compared 
to the CD8+BTLA+ counterpart. However, we observed comparable in vitro tumor 
killing capacity between these two subsets regardless of tumor antigen recognition 
ability. A recent report showed that the BTLA blockade in γδ T cells had no effect on 
tumor killing (215). Because we did not observe difference in killing capacity between 
these two subset, we thus further examined the potency of in vivo tumor burden control 
using NSG mouse model. We observed that the CD8+BTLA+ TIL subset was 
significantly more potent at controlling in vivo tumor growth than its CD8+BTLA- 
counterpart. In addition, we found that CD8+BTLA+TIL tended to persist longer 
following adoptive transfer. This finding is in accordance with our clinical observation 
indicating that CD8+BTLA+TIL persisted longer following TIL transfer (141).  
 Discerning the difference between the two BTLA subsets required to carry out 
the killing assay for a long period of time (8h) and looking at the fate of both T cells 
and tumor cells. Utilizing Timelapse Imaging Microscopy In Nanowell Grids 
(TIMING), we demonstrated that CD8+BTLA+ TIL subset has a heightened capability 
of killing multiple tumor targets through enhanced T cell survival. This finding 
provides a rationale for the improved in vivo efficacy of the CD8+BTLA+ TIL subset.  
 We previously demonstrated that CD8+BTLA+ TIL subset has superior 
mitochondrial function and spare respiratory capacity (SRC) as compared to its 
CD8+BTLA- counterpart. It has been shown that memory CD8+ T cells manifested high 
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SRC with increased number of mitochondria, which is distinct from naïve and effector 
T cell subset (216). This unique bioenergetic attribute was shown to play a role in cell 
survival and establishment of the memory T cell pool.  
 Overall, our findings suggest that BTLA signaling itself might not affect the 
tumor killing capability. In fact, the intrinsic attributes of the less differentiated 
phenotype of the BTLA+ subset provide a pro-survival signal enhancing the “serial 
killing” capacity.   
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CHAPTER 4 
 
Functional study of B and T lymphocyte attenuator in murine model 
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4.1 Rationale and Hypothesis 
BTLA is well characterized as an inhibitory molecules belonging to the Ig 
superfamily. Its cytoplasmic domains composes of three motifs (Grb2, ITIM, and 
ITSM), which are highly conserved between mouse and human. As mentioned before 
the inhibitory role of ITIM and ITSM motifs of BTLA through recruitment of SHP1/2 
is well documented (186, 189, 192, 207). BTLA also contains the Grb2 motif, which 
also exists as a cytoplasmic motif in CD28. It is known that Grb2 motif contributes to 
CD28 signaling pathway to promote T cell proliferation. However, the function of the 
Grb2 motif of BTLA has not been addressed. Evidence suggest that it might transduce 
a positive signal. An in vitro binding assay first demonstrated the potential interaction 
of the Grb2 binding motif with the Grb2 adaptor protein and the p85 subunit of 
phosphatidylinositol 3-kinase (p85 PI3K). Moreover gene expression analysis of 
mouse T cells following activation of anti-CD3 and anti-BTLA demonstrated a highly 
overlapping transcription profile with that produced by anti-CD3 in combination with 
positive co-stimulators but not inhibitory molecules (192). 
We hypothesize that the Grb2 motif might exert positive signal that could 
contribute to BTLA’s function besides transducing an inhibitory signal from 
ITIM and ITSM motifs. Previous studies demonstrated that BTLA inhibited T cell 
function by suppressing effector cytokine production and cell proliferation upon TCR 
triggering. Thus far, no study has focused on comprehensively understanding BTLA 
signaling on CD8 T cell function in both human and murine setting.  
In this study, we generated retroviral constructs containing wild type BTLA 
(WT BTLA), BTLA with inactivating mutation of ITIM and ITSM motifs (∆ITSM), 
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and BTLA with an activating mutation of Grb2 motif (∆Grb2), and overexpressed those 
constructs in BTLA knockout OT.1 mouse T cells (BTLA-KO-OT.1). To dissect the 
function of BTLA, we performed tumor killing assays to investigate the role of BTLA 
in mediating cytotoxic function. In addition, we also evaluated intracellular effector 
cytokine production and secretion during antigen re-stimulation using either dendritic 
cells pulsed with OVA peptide or anti-mouse CD3 with HVEM-Fc fusion protein. 
Furthermore, we assessed the impact of BTLA signaling on the T cell proliferation 
induced upon antigen re-stimulation using dendritic cells pulsed with OVA peptide to 
determine proliferative capacity following T cell re-stimulation.  
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4.2 Results  
Generation of retroviral vectors containing wild type BTLA and BTLA mutants 
for functional study using BTLA-KO-OT.1 mouse T cells. 
The functional role of BTLA signaling motifs remains understudied; therefore, site 
directed mutagenesis was conducted to inactivate BTLA signaling motifs.  This was 
achieved by substitution of tyrosine for phenylalanine in the two different motifs of 
WT BTLA cytoplasmic tail to generate two different BTLA mutants; the Grb2 mutant 
∆Grb2 (Y245F) and the ITIM and ITSM mutant ∆ITSM (Y274 and Y299F) (Figure 
4.1A). We utilized pRVKM retroviral vector with GFP reporter as a gene delivery 
system to overexpress WT BTLA or its mutants in BTLA-KO-OT.1 mouse T cells 
(Figure 4.1B). Briefly, the splenocytes of BTLA-KO-OT.1 mouse were stimulated 
with anti-mouse CD3. After 24 hours, the cells were transduced with the retroviruses 
containing either WT BTLA or the inactivating mutations of BTLA. On day 3, GFP+ 
T cells were sorted and expanded for 7 days prior to functional studies (Figure 4.1C). 
Comparable expression of BTLA was observed in BTLA WT and its mutants (Figure 
4.1D) 
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Figure 4.1. Generation of retroviral vector containing wild type BTLA and 
inactivating mutations of BTLA for functional study using BTLA-KO-OT.1 
mouse model. 
Substitutions of tyrosine for phenylalanine in three different motifs of the cytoplasmic 
tail of BTLA generated 2 mutant constructs; the Grb2 mutant ∆Grb2 (Y226F), as well 
as the ITIM and ITSM mutant ∆ITSM (Y274 and Y299F) (A) Schematic diagram 
depicts the structure of BTLA WT (Top), BTLA ∆Grb2 (middle), and BTLA ∆ITSM 
(bottom). (B) Schematic diagram demonstrates the pRVKM retroviral construct 
containing GFP and BTLA genes (left). Signaling motifs with Tyrosine and 
Phenylalanine are indicated in blue and red respectively (right). (C) Schematic diagram 
depicts viral transduction and generation of BTLA-KO-OT.1 mouse T cells 
overexpressing either BTLA or its mutants. (D) Histogram plots showing BTLA 
expression in BTLA-KO-OT.1 mouse T cells. The cells were gated on GFP positive 
and AQUA negative cells (live cells). BTLA WT (Yellow), BTLA ∆Grb2 (Green), and 
BTLA ∆ITSM (Blue) positive cells, were gated using empty vector controls (tinted 
red).   
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BTLA signaling motifs have no effect on tumor killing capacity.  
Our previous result unveiled that the CD8+BTLA+ TIL subset have superior survival 
benefit following tumor target killing as opposed to CD8+BTLA- subset therefore is 
able to repeatedly mediate killing of additional tumor targets. This superior serial 
killing attribute can result from either 1) properties of less-differentiated T cell 
phenotype or 2) BTLA signaling itself.  We set out to further determine whether BTLA 
signaling pathway might be involved in the superior killing capacity. Here, we 
conducted in vitro assays using murine T lymphocytes and B16 melanoma tumor cells, 
which express high levels of HVEM (Figure 4.2A and B).   
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Figure 4.2. Expression level of HVEM in B16 melanoma cell lines. 
Histogram plots showing HVEM expression in (A) B16 OVA and (B) B16F10 mouse 
melanoma tumor cells. Live tumor cells were defined as AQUA negative. HVEM 
positive cells (red) were gated using FMO controls (tinted gray).   
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Virally transduced BTLA-KO-OT.1 mouse T cells overexpressing of WT 
BTLA, BTLA with mutation of the Grb2 motif (∆Grb2), BTLA with mutation of ITIM 
and ITSM motifs (∆ITSM), or empty vector control (EM) were incubated with either 
B16F10 (negative for OVA antigen) or B16OVA cells (positive for OVA antigen) that 
were labeled with efluor 670 at an effector to target ratio of 1:1, 1:3, and 1:10. After 
three hours, apoptotic tumor cells were determined by intracellular staining for cleaved 
capase-3. We found comparable levels of OVA-specific tumor killing regardless of the 
presence of WT BTLA or BTLA mutants (T cell: B16OVA, ratio 1:1, P=0.67; ratio 
1:3, P=0.46; ratio 1:10, P=0.29; T cells: B16F10; ratio 1:1, P= 0.43; ratio 1:3, P=0.69; 
ratio 1:10, P=0.47) (Figure 4.3).  
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Figure 4.3. In vitro tumor killing capacity of BTLA-KO-OT.1 mouse T cells 
overexpressing of WT BTLA and it mutants.  
B16 OVA (mouse melanoma tumor positive for OVA) or B16F10 (mouse melanoma 
tumor negative for OVA) were stained with eFluor670® and co-cultured with OT-1 
BTLA KO T cells overexpressing WT BTLA or BTLA mutants at the following T cell-
to-tumor cell ratios (1:10, 1:3, and 1:1). Tumor cell death is depicted by the percentage 
of caspase-3 positive cells. N=3 independent experiments.  
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Decrease in TNF-α production in BTLA-KO-OT.1 mouse T cells overexpressing 
WT BTLA or its mutants.  
Because we found the comparable in vitro killing tumor capacity of BTLA-KO-OT.1 
mouse T cells regardless of BTLA expression, we sought to determine whether 
overexpression of WT BTLA or its mutants could affect effector cytokine production. 
In this experiment, we re-stimulated virally transduced T cells overexpressing WT 
BTLA or its mutants with either dendritic cells alone or pulsed with OVA peptide at an 
effector to target ratio of 1 to 40. After five hours, the cells were intracellularly stained 
with IFN-γ and TNF-α. We found almost all effector T cells produced IFN-γ and TNF-
α, and comparable percentage of the effector T cells that produced IFN-γ and TNF-α 
was observed (% of IFN-γ positive cells; P=0.11, % of TNF-α positive cells; P=0.59) 
(Figure 4.4A). However, the quantity of effector cytokines being made by WT BTLA 
was significantly less than that produced by BTLA negative cells (empty vector) alone 
when re-stimulated with dendritic cells pulsed with OVA peptide (IFN-γ MFI; EM vs 
WT, P=0.04, TNF-α MFI; EM vs WT, P=0.0045) (Figure 4.4B). This suggests that 
BTLA signaling negatively impacts effector cytokine production. The suppressive 
effect of BTLA was completely reverted by the inactivation of ITIM and ITSM motifs, 
which implies that those motifs are responsible for the BTLA-mediated decrease in 
IFN-γ and TNF-α effector cytokines upon TCR activation. 
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Figure 4.4. Decrease in TNF-α production in BTLA-KO-OT.1 mouse T cells 
overexpressing of WT BTLA and it mutants.  
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were re-stimulated 
with dendritic cells pulsed with OVA peptide. TNF-α and IFN-γ production by virally 
transduced OT-1 BTLA KO T cells was evaluated by intracellular staining. Bar graph 
depicts the percentage of positive cells (A) and mean fluorescence intensity (MFI) (B). 
Each bar represents three independent experiments. (Two-way ANOVA; *P<0.05). 
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BTLA signaling motifs affect T cell proliferation.  
We have previously demonstrated that CD8+BTLA+TIL are more proliferative in 
response to IL-2 and less differentiated. It has been shown that less differentiated T 
cells were more metabolically active and superior in proliferative capacity. However 
several studies have demonstrated that BTLA inhibited T cell proliferation upon 
ligation with HVEM. It was shown that both ITIM and ITSM motifs were required for 
the full function of BTLA to inhibit T cell proliferation and cytokine production 
including IFN-γ, IL-2, and IL-10 (193, 217). A recent report indicated that the PD-1 
receptor, which consisted of ITIM and ITSM motif, selectively inhibited the Akt and 
Ras-MEK-ERK pathways. So far, it remains inconclusive whether BTLA utilizes a 
similar mechanism as PD-1 to inhibit T cells as ITIM and ITSM motifs are commonly 
shared between these two receptors. Thus, we sought to further determine whether 
BTLA signaling motifs could play a role in proliferation of CD8+ TIL. BTLA-KO-
OT.1 T mouse cells overexpressing BTLA WT or its mutants were labeled with the cell 
proliferation dye efluor670® and re-stimulated with dendritic cells pulsed with OVA 
peptide for two days. Upon re-stimulation with dendritic cells pulsed with the cognate 
peptide most T cells underwent proliferation. However, subtle differences are 
appreciable between T cells expressing the different BTLA constructs. We observed 
that BTLA-KO-OT.1 mouse T cells expressing a non-functional inhibitory domain 
(∆ITSM) had lower mean intensity of fluorescence (MFI) as compared with empty 
vector control  (MFI: ∆ITSM versus EM; P=0.012, ∆ITSM versus WT; P=0.0057) 
(Figure 4.5A and B). WT BTLA and EM control showed comparable proliferation as 
no significantly different MFI was observed (MFI: WT versus EM; P=0.30). On the 
contrary, attenuation of T cell proliferation was observed in T cells expressing a 
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disrupted Grb2 domain (∆Grb2), (MFI: ∆Grb2 versus ∆ITSM; P=0.0003, ∆Grb2 versus 
EM; P=0.0008, ∆Grb2 versus WT; P= 0.0009) (Figure 4.5A and B). Our findings 
suggests that Grb2 motif plays a role in enhancing cell proliferation, while ITIM and 
ITISM motif suppress the proliferative capacity of T cells.  
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Figure 4.5. ITIM and ITSM motifs of BTLA attenuated T cell proliferation.  
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were labeled with 
eFluor670® and re-stimulated with dendritic cells pulsed with OVA peptide. Cell 
proliferation was determined by the dilution of eFluor670®. (A) Histogram plots of 
eFluor670® demonstrate proliferation of OT-1 BTLA KO T cells overexpressing WT 
BTLA or its variants. (B) Bar graph depicts MFI of virally transduced T cells in the 
same experiment shown in the left panel. N=3 *P <0.05, **P <0.001, ***P<0.0001.  
All error bars depicts the mean ± s.e.m. All P-values were calculated using a two-tailed 
Student’s t-test. 
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Grb2 motif of BTLA enhanced IL-2 production.  
Our previous study demonstrated that CD8+BTLA+TIL subset had increased 
proliferative capacity due to enhanced IL-2 responsiveness (141). In mouse CD4+T 
cells, however, it has been shown that engagement of BTLA and HVEM suppressed 
cytokine production including IFN-γ, IL-2, and IL-10 (193). Thus far, the role of BTLA 
in cytokine production of CD8 T cells remains unclear. To further investigate whether 
BTLA signaling motifs might affect the cytokine production, we overexpressed in OT-
1 BTLA KO T cells the WT BTLA or its mutants, and re-stimulated with anti-CD3 in 
the presence of HVEM-Fc fusion protein to engage the BTLA molecules. The 
supernatants were collected after 24 hours to assess the cytokine secretion using a 
MILLPLEX multiplex assay.  
  When ∆Grb2 T cells were re-stimulated with anti-CD3 and HVEM, we found 
a significant decrease in GM-CSF, IL-6, and IL-10 production as compared with empty 
vector control (GM-CSF; P=0.0004, IL-6; P=0.02, IL-10; P=0.002), but we did not 
observe a significant increase in these cytokines in ∆ITSM T cells when compared with 
empty vector control (GM-CSF; P=0.30, IL-6; P=0.72, IL-10; P=0.59) (Figure 4.6A).  
The only cytokine induced to high levels by the introduction of BTLA was IL-
2. The BTLA-dependent IL-2 production was abrogated by the inactivating mutation 
of Grb2 but unaffected by the inactivating mutations to ITIM/ITSM (WT versus EM; 
P=0.02, ∆ITSM versus EM; P=0.005, WT versus ∆Grb2; P=0.02, ITSM versus∆ Grb2; 
P=0.01, EM versus Grb2; P=0.79, WT versus ∆ITSM; P=0.32) (Figure 4.6B). Our 
data show that BTLA signaling augments the TCR-driven IL-2 production and 
highlight that Grb2 signaling on BTLA significantly contributes to the IL-2 production 
following BTLA ligation during T cell activation.  
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Figure 4.6. Grb2 motif of BTLA augment IL-2 production upon HVEM ligation. 
Virally transduced OT-1 BTLA KO T cells were stimulated with plate-bound anti-
mouse CD3 and HVEM Fc. Supernatants were assessed for cytokine production 
including (A) GM-CSF, IL-6, IL-10, and (B) IL-2 using by MILLIPEX MAP Mouse 
A 
B 
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CD8+ T Cell Magnetic Bead Panel Assays. Each bar graph represents two independent 
experiments.  *P <0.05, **P <0.001.  All error bars depicts the mean ± s.e.m. All P-
value were calculated using a two-tailed Student’s t-test.   
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Discussion 
It is known that ITIM and ITSM signaling motifs are required for BTLA to 
inhibit T cell function through the recruiting of phosphatases, SHP-1 and -2. Evidence 
suggests that Grb2 motif of BTLA might transduce positive signal as an in vitro binding 
assay demonstrated an interaction between Grb2 and p85 subunit of PI3K, suggesting 
it may happen in physiological conditions. Thus far, it remains inconclusive whether 
Grb2 motif could play a positive role on T cell function.  
Our current study demonstrated that BTLA signaling has no effect on tumor 
killing capacity even though subtle decreased in TNF-α and IFN-γ was found in BTLA 
WT. In line with these observations, a recent report showing that BTLA blockade did 
not improve T cell mediated tumor killing (215). This suggests that BTLA signaling 
motif might not be directly involved in killing capacity.  
We have shown that inactivated ITIM and ITSM motif ameliorated T cell 
proliferation while malfunction of Grb2 decreased T cell proliferation. Interestingly, 
we did not observe a significant impact of T cell proliferation when overexpressing 
BTLA WT. Previous reports demonstrated that CD8+ T cells were less susceptible to 
BTLA-mediated T cell inhibition as compared to CD4+ T cells in both mouse and 
human contexts. This may explain our observation of the subtle inhibitory effect of T 
cell proliferation when overexpressing BTLA WT.  
Intriguingly, our result first unveil the importance of Grb2 motif of BTLA in 
CD8+ T cells. We found that the Grb2 motif of BTLA mediates IL-2 secretion and 
might not or minimally be affected by SHP1/2-mediated signaling attenuation. 
Previous report have shown that Grb2-linked SLP-76 and Vav interaction is involved 
in IL-2 production (218). Of note, Grb2 recruitment was found to be critical for CD28 
124 
 
in mediating IL-2 production. Our work thus demonstrates that BTLA shares features 
of a co-stimulatory molecule (CD28) as well as inhibitory properties of checkpoint 
regulators such as PD-1 through its ITIM/ITSM motifs.  
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CHAPTER 5 
 
Dissecting BTLA signaling pathway in murine T lymphocytes  
and human tumor infiltrating lymphocytes (TIL) 
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5.1 Rationale and Hypothesis 
Very little is known about the downstream signaling pathways triggered by BTLA. 
From its structure it is anticipated that ITIM and ITSM motifs will recruit SHP1 and 2 
and that Grb2 binding motif will recruit Grb2, but beyond that much is to be learned. 
Several studies demonstrated that ligation of BTLA and HVEM suppressed T cell 
proliferation as well as cytokine production such as IL-6, IL-18, and IFN-γ (193, 219). 
The downstream signaling protein targets of SHP1 and SHP2 of BTLA are not well 
characterized, but it is suggested that protein involved in proximal TCR activation 
might be attenuated by BTLA. A recent report has demonstrated that ITIM and ITSM 
in PD-1 inhibited cytoplasmic proteins of the cell cycle, Cdk-activating phosphatase 
Cdc25A, PI3K-Akt and Ras-MEK-ERK signaling axis, leading to T cell proliferation 
inhibition (56). Unlike PD-1, BTLA also harbors Growth factor receptor bound protein 
2 (Grb2) motif, commonly shared in co-stimulatory molecules like CD28 with 
commonly shared YXN sequence. An in vitro binding assay using synthetic peptide 
suggested that Grb2 motif of BTLA could interact with the p85 subunit of PI3K (192, 
220). It is known that Grb2 motif of CD28 can activate PI3K-AKT signaling pathway 
and result in increased cell proliferation and IL-2 production (218, 221). However, it 
cannot be directly extrapolated that Grb2 motif of BTLA would function similar to that 
of CD28 as an in vitro biochemical assay binding does not reflect physiological binding 
of cellular protein during BTLA-HVEM interaction. Our previous chapter has 
demonstrated that mouse BTLA signaling pathway did not affect tumor killing capacity 
of T cells, but subtly inhibits TNF-α cytokine and IFN-γ production. In addition, an 
increased proliferation of T cells was observed when ITIM and ITSM motifs were 
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disrupted, while inactivated Grb2 motifs attenuated T cell proliferation. We observed 
that IL-2 production was enhanced in WT BTLA as well as with an intact Grb2 motif 
in the ITIM/ITSM mutant but totally abrogated when a non-functional Grb2 motif was 
introduced, indicating that Grb2 motif of BTLA could play a role in IL-2 production 
and cell proliferation. Because we have witnessed that Grb2 motif of BTLA exhibited 
positive function, we sought to gain a better understanding of the underlying 
mechanism that might be responsible for its favorable functions. We hypothesized 
that the Grb2 motif could exhibit positive signal(s) that are not targeted by ITIM 
and ITSM during HVEM ligation. In this study, we further elucidated the 
downstream signaling pathway of BTLA in BTLA-KO-OT.1 mouse T cells 
overexpressing WT BTLA and BTLA mutants during TCR activation and HVEM 
ligation. We used RPPA (Reverse Phase Protein Array) as a high-through put method 
to determine differential changes in protein production as well as protein 
phosphorylation. To exclude the bias of the overexpression of WT BTLA and 
genetically modified BTLA in BTLA knockout mouse, we also investigated the 
downstream signaling pathway of BTLA in non-modified human TIL.  
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5.2 Results  
Dissecting downstream signaling pathway of mouse BTLA upon HVEM ligation. 
We have previously demonstrated the positive effect of Grb2 motif on T cell 
proliferation and IL-2 production. These findings prompted us to further dissect 
signaling pathway of BTLA in each signaling motif. We overexpressed WT BTLA and 
BTLA mutant for either Grb2 or ITIM and ITSM in BTLA-KO-OT.1 murine T cells. 
Empty vector (EM) was used as a control to determine the basal level of CD3 activation 
alone. Murine T cells were re-stimulated with plate-bound anti-CD3 with or without 
the presence of HVEM-Fusion protein. The cell lysates were harvested for protein 
extraction at 12 hours following re-stimulation. We performed Reverse Phase Protein 
Array (RPPA), a high-throughput method developed for functional proteomic studies, 
to evaluate protein changes in both quantity and phosphorylation status upon TCR 
activation either with or without HVEM ligation.   
When we compared the differential protein changes in ∆ITSM versus WT BTLA and 
∆Grb2 versus WT BTLA, we found that a higher number of the surveyed proteins were 
significantly changed in ∆ITSM as opposed to ∆Grb2. (Figure 5.1A) (16 versus 2; 
P<0.05). This analysis was complicated by the fact that each mutant construct bears a 
mutated (inactivated) motif as well as a functional motif e.g. ∆Grb2 represents the 
overexpression of an inactive Grb2 motif along with an active ITIM/ITSM motif while 
∆ITSM construct overexpresses an inactive form of ITIM and ITSM paired with a WT 
Grb2 motif. We found that the phosphorylation of Akt and a known substrate of AKT, 
pPRAS40, were significantly attenuated in ∆Grb2 (pAkt S473; P=0.045, pRAS40 
T246; P=0.007) (Figure 5.1B). This suggests that the Akt pathway was targeted by the 
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SHP1/2 recruited by the active ITIM/ITSM motif of ∆Grb2 as the net result was a 
dephosphorylation of these targets, not likely to be influenced by the effect of the Grb2 
motif. In contrast, a remarkable enhancement of the phosphorylation levels of multiple 
targets such as of pSrc at S527, Chk1 at S286, Chk2 at T68, GSK-3b at S9, and of Beta-
Catenin at T41 and S45 were observed in ∆ITSM (pSrc at S527; P=0.005, pA-Raf at 
S299; P=0.01, and pC-Raf at S338; P=0.02, pChk1 at S286; P=0.01, pChk2 at T68; 
P=0.02, GSK-3b at S9; P=0.04, Beta-Catenin at T41 and S45; P=0.04) (Figure 5.1C). 
An increased number of phosphorylated proteins in ∆ITIM and ITSM is likely to 
mainly be due to the defect in recruitment of SHP1 and SHP2 into BTLA cytoplasmic 
domain caused by the disruption of ITIM and ITSM motifs rather than to the presence 
of the functional Grb2 motif. To further elucidate whether increased phosphorylation 
levels of specific targets are due solely to the presence of the Grb2 motif rather than to 
the deficient ITIM and ITSM motifs, we then compared differential protein changes in 
∆ITSM (which bears an intact Grb2 motif) versus EM (No BTLA) to isolate the effect 
of Grb2 on the TCR stimulation alone. We found that only pSrc at S527 and JNK2 
were remarkably higher in ∆ITSM (Figure5.1D). This indicated that those two 
downstream signaling molecules may be activated through the Grb2 motif and may not 
be targeted by SHP1 and SHP2. The list of differential protein changes with the 
following comparisons; ∆Grb2 versus WT, ∆ITSM versus WT, and ∆ITSM versus EM 
is demonstrated in Table 1.  
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Figure 5.1. Dissecting downstream signaling pathway of mouse BTLA upon 
HVEM ligation. 
OT-1 BTLA KO T cells overexpressing WT BTLA or its variants were re-stimulated 
with plate-bound anti-CD3 and HVEM-Fc for 8 h prior to harvest. Cells were lysed and 
the protein supernatant was collected to perform RPPA. (A) Bar graph depicts the 
differential protein expressions with the following comparisons: ∆Grb2 versus WT 
A B 
C D 
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(red) and ∆ITSM versus WT (blue). Volcano plots depicts fold changes of proteins 
with the following comparisons: ∆ITSM versus EM (B) ∆Grb2 versus WT (C), and 
∆ITSM versus WT (D). Data shown represent two independent experiments. P <0.05. 
P-value were calculated using Linear models and empirical Bayes methods. 
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Table 1. Differentially expressed proteins in OT-1 mouse T cells overexpressing 
either WT BTLA or BTLA mutant re-stimulated with CD3 and HVEM Fc fusion 
protein at 8 h. 
Table demonstrates the list of differential protein changes with the following 
comparisons; ∆Grb2 versus WT, ∆ITSM versus WT, ∆ITSM versus EM.  Data shown 
represent two independent experiments. P <0.05. P-value were calculated using Linear 
models and empirical Bayes methods. 
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Table 1. Differentially expressed proteins in OT-1 mouse T cells overexpressing 
either WT BTLA or BTLA mutant re-stimulated with CD3 and HVEM Fc 
fusion protein at 8 h.  
 
 
 
 
Log fold change 
 
P-value 
∆Grb2 versus WT   
PI3K-p110-alpha-R-C_GBL1115582  -1.0537676 5.836064e-05 
PRAS40_pT246-R-V_GBL1115574     -0.2976067 7.643870e-03 
MIF-R-C_GBL1116364              -0.2667402 1.815897e-02 
AMPK-alpha-R-C_GBL1115509       -0.3295237 1.889904e-02 
EGFR-R-V_GBL1115620             -0.4283460 1.969070e-02 
Hif-1-alpha-M-C_GBL1116504       0.1131972 3.083201e-02 
TFAM-R-V_GBL1116333             -0.4439703 3.552049e-02 
C-Raf_pS338-R-V_GBL1115523       0.1775591 4.003768e-02 
YB1-R-V_GBL1115569              -0.5434096 4.322444e-02 
Akt_pT308-R-V_GBL1116492         -0.3454098 4.509359e-02 
∆ITSM versus WT                                        
PI3K-p110-alpha-R-C_GBL1115582     -1.09610694 4.178212e-05 
RBM15-R-V_GBL1115629                0.77592249 3.194537e-04 
Raptor-R-V_GBL1115625               0.25530383 2.185063e-03 
Gys-R-V_GBL1116482                  0.32602047 2.216354e-03 
Stat3-R-C_GBL1116311                0.52531068 2.539887e-03 
Src_pY527-R-V_GBL1115563            0.36285815 5.045994e-03 
Gys_pS641-R-V_GBL1115603            0.34757270 1.207815e-02 
LDHA-R-C_GBL1115596                 0.35131897 1.222602e-02 
FAK_pY397-R-V_GBL1116461           -0.20031315 1.257107e-02 
YB1_pS102-R-V_GBL1115584           -0.59051723 1.298821e-02 
Bcl2A1-R-V_GBL1116330              -0.15537524 1.530438e-02 
Chk1_pS296-R-V_GBL1116335           0.28491931 1.675901e-02 
A-Raf_pS299-R-C_GBL1115605          0.32200036 1.787957e-02 
Chk2_pT68-R-C_GBL1115522            0.19753223 2.076754e-02 
ATM_pS1981-R-V_GBL1116464            0.59568985 2.429322e-02 
SDHA-R-V_GBL1116334                -0.23145741 2.537912e-02 
C-Raf_pS338-R-V_GBL1115523          0.19658953 2.590506e-02 
CD31-M-V_GBL1116506                -0.13128423 2.918579e-02 
Pdcd4-R-C_GBL1115583               -0.16554607 2.927126e-02 
PKC-delta_pS664-R-V_GBL1115593      0.27087240 2.956589e-02 
ATR-R-C_GBL1115590                 -0.13505418 3.098111e-02 
UQCRC2-M-C_GBL1116412              -0.14721028 3.312001e-02 
HER2_pY1248-R-C_GBL1115612         -0.19768054 3.388986e-02 
Mitochondria-M-V_GBL1116387         0.14868332 3.679310e-02 
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Table 1 (continued). Differentially expressed proteins in OT-1 mouse T cells 
overexpressing either WT BTLA or BTLA mutant re-stimulated with CD3 and 
HVEM Fc fusion protein at 8 h.  
∆ITSM versus WT 
 
Log fold change 
 
P-value 
GSK-3b_pS9-R-V_GBL1115615           0.12487282 4.193362e-02 
Jak2-R-V_GBL1116307                 -0.13055136 4.349372e-02 
b-Catenin_pT41_S45-R-
V_GBL1116494   
0.35325496 4.731829e-02 
CDK1-R-V_GBL1115598                 0.36169900 4.952413e-02 
∆ITSM versus EM   
PI3K-p110-alpha-R-C_GBL1115582     -0.7194512 0.001134154 
Raptor-R-V_GBL1115625                0.2645821 0.001720536 
Gys-R-V_GBL1116482                  0.3146227 0.002795612 
RBM15-R-V_GBL1115629                0.5571886 0.003298385 
b-Catenin_pT41_S45-R-
V_GBL1116494   
0.5471095 0.005618371 
Notch3-R-C_GBL1116354              -0.2137534 0.007785951 
Vimentin-M-C_GBL1116421             -0.3850135 0.034672688 
Stat5a-R-V_GBL1115565               -0.2380353 0.040673318 
MMP2-R-V_GBL1115540                -0.2629724 0.040863077 
YB1_pS102-R-V_GBL1115584           -0.4568981 0.042068010 
ACC_pS79-R-V_GBL1115507             0.1714040 0.043934614 
Src_pY527-R-V_GBL1115563            0.2308867 0.046698220 
PLK1-R-C_GBL1115575                  0.1276333 0.049231222 
GCN5L2-R-V_GBL1116463              -0.1807406 0.049610757 
JNK2-R-C_GBL1116442                 0.1424863 0.049987949 
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BTLA-HVEM axis in human TIL selectively suppresses MAPK, Akt, and NF-kB 
pathways, but enhances Src pathway.  
Thus far, our data uncovered the positive role of the Grb2 motif of BTLA in mouse T 
cells in contributing to T cell proliferation and IL-2 production. In addition, RRPA 
analysis in mouse suggested that Grb2 motif signals through Src at pY527 as a 
significantly increased level of this phosphorylated protein was present in ∆ITSM when 
compared with both WT and EM. On the other hand, we found that Akt at pT308 and 
PRAS40, proteins in Akt signaling pathway, were suppressed when Grb2 was mutated 
as compared to WT BTLA. This suggested that ITIM and ITSM motifs do not suppress 
all downstream signaling pathways. It has been shown that mouse BTLA signaling 
motifs are highly conserved with human BTLA. Overexpressing WT BTLA and BTLA 
mutants allowed us to dissect BTLA signaling at each BTLA motifs. However, 
downstream signaling pathway of genetically modified BTLA in BTLA might not be 
physiologically relevant to human T cell signaling pathway. To exclude the bias of 
BTLA KO mouse T cells, we further investigated BTLA signaling pathway in human 
BTLA TIL, which is more clinically relevant to our observation in favorable clinical 
outcome of TIL treated patients with high proportion of CD8+BTLA+ TIL subset.  
In this study, we sorted the CD8+BTLA+ human TIL subset from five cultured human 
TIL lines (pre-REP) isolated from melanoma patients treated at M.D. Anderson Cancer. 
Because TIL from different patients might be variable in their susceptibility to TCR 
activation, and because the strength of TCR activation could lead to different signaling 
outcome, we then stimulated with increasing concentration of plate-bound anti-human 
CD3 at concentrations of 10, 30, 100, 300, and 1000 ng alone or in the presence of 
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HVEM-Fc, to look at TCR activation with or without BTLA engagement. After 
activation for two hours, proteins were extracted from the cell lysates, and used to 
perform RPPA to determine the differential proteins expression in both quantity and 
phosphorylation status upon T cell activation.  
We observed a general decrease in phosphorylation levels of proteins phosphorylated 
in response to TCR engagement in the presence of HVEM-Fc. We found that the 
MAPK kinase pathway (pP38 at T180; P=2.08 x 10-9, pP90RSK at T573; P=3.26 x 10-
4, pS6 at S235; P= 1.68x10-2), NF-Kb pathway (pNF-Kb p65 at S536; P=3.15 x 10-2), 
the mTOR pathway (pP70-6K at T389; P=1.7 x 10-4), the Akt pathway (pAKT at S473; 
P=9.6x10-3), the JNK pathway (pC-Jun at S73; P= 9.38x10-3 ), and the Beta-catenin 
pathway (GSK-3a-b pS21; P=9.6x10-3) were significantly decreased in HVEM in 
comparison to CD3 activation alone. (Figure 5.2A). Inhibition of these positive 
signaling pathways clearly supported the role of BTLA as a co-inhibitory molecule.   
Consistent with downstream targets of PD-1, we also found that AKT and MAPK 
pathways were attenuated in BTLA. However activation of specific signaling pathways 
were also observed when T cell activation happened in the presence of HVEM.   
Interestingly, we found that the Src signaling pathway was activated due to an increase 
in pSrc at S416 during HVEM ligation (pSrc at S416; P= 3.36 x 10-6) (Figure 5.2A). 
Our results suggest that the TCR signaling pathway is not completely suppressed by 
BTLA, but is specifically attenuated in certain pathways as indicated above and 
specifically potentiated in very select pathways. Unexpectedly, we found that 
phosphorylation of HER2 at tyrosine 1248 was prominently increased in an anti-CD3 
dose-dependent manner regardless of the presence of HVEM (Figure 5.2B and C). 
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This strengthens the notion that not all proteins are affected by the BTLA and HVEM 
signaling axis. To further comprehensively understand the downstream signaling 
pathway of human BTLA, we mapped a signaling network with Ingenuity pathway 
analysis (IPA) utilizing the proteins that were differentially expressed during HVEM 
ligation (Figure 5.2D). We observed that Src signaling node was exclusively separated 
from Akt, mTOR, and NF-kB pathway nodes (Figure 5.2E). This likely suggests that 
some downstream signals from the Grb2 motif and TCR activation are likely not 
interfered by SHP1/2. The list of differential protein changes in with the following 
comparisons; CD3+HVEM versus CD3 alone (Dose 100), CD3+HVEM versus CD3 
alone (Dose300), CD3+HVEM versus CD3 alone (Dose1000), CD3 alone (Dose 0 
versus 30), CD3 alone (Dose 0 versus 100), CD3 alone (Dose 0 versus 300), CD3 alone 
(Dose 0 versus 1000), CD3+HVEM (Dose 0 versus 30), CD3+HVEM (Dose 0 versus 
100) CD3+HVEM (Dose 0 versus 300) CD3+HVEM (Dose 0 versus 1000) is 
demonstrated in the Table 2 A, B, and C. 
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Figure 5.2. BTLA-HVEM axis in human TIL selectively suppresses Akt, and 
NF-kB pathways, but enhances Src pathway.  
Sorted CD8+BTLA+ TIL were stimulated with plate-bound anti-CD3 at following 
concentrations (0, 10, 30, 100, 300, and 1000 ng/ml) alone or with HVEM-Fc for 8 h 
prior to harvest. Cells were lysed and the protein supernatant was collected to perform 
RPPA. Volcano plot depicts fold changes of proteins in CD8+BTLA+TIL upon T cell 
activation with (A) anti-CD3 alone, (B) anti-CD3 + HVEM, and (C) anti-CD3 in 
comparison with anti-CD3 + HVEM. (D) Bar graph demonstrates proteins that 
significantly change in comparison between anti-CD3 activation alone (red) and anti-
CD3 + HVEM ligation (blue). (E) Signaling network from the proteins that 
significantly change in (D) were clustered by Ingenuity Pathway Analysis.  N=5, P 
<0.05. P-value were calculated using Linear models and empirical Bayes methods.  
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Table 2. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with 
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h 
 
Table demonstrates the list of differential protein changes in with the following 
comparisons; CD3+HVEM versus CD3 alone (Dose100), CD3+HVEM versus CD3 
alone (Dose300), CD3+HVEM versus CD3 alone (Dose1000), CD3 alone (Dose 0 
versus 30), CD3 alone (Dose 0 versus 100), CD3 alone (Dose 0 versus 300), CD3 alone 
(Dose 0 versus 1000), CD3+HVEM (Dose 0 versus 30), CD3+HVEM (Dose 0 versus 
100) CD3+HVEM (Dose 0 versus 300) CD3+HVEM (Dose 0 versus 1000). Data 
shown represent five TIL lines. N=5, P <0.05. P-value were calculated using Linear 
models and empirical Bayes methods.  
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Table 2A. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with 
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Log fold change 
 
P-value 
CD3+HVEM versus CD3 alone 
(Dose100) 
  
GPBB.R.V_GBL1122116             0.8555653 0.01800838 
p38_pT180_Y182.R.V_GBL1121998  -0.4030583 0.03829165 
CD3+HVEM versus CD3 alone 
(Dose300) 
  
p38_pT180_Y182.R.V_GBL1121998   -0.6544899 5.908173e-05 
NF.kB.p65_pS536.R.C_GBL1121996  -0.9045702 3.154015e-02 
CD3+HVEM versus CD3 alone 
(Dose1000) 
  
p38_pT180_Y182.R.V_GBL1121998    -1.0040382 2.089641e-09 
PKC.b.II_pS660.R.V_GBL1122088    -0.4154961 3.921504e-05 
YB1_pS102.R.V_GBL1122037         -0.5119427 3.268774e-04 
p90RSK_pT573.R.C_GBL1122101      -0.5823908 3.268774e-04 
Bad_pS112.R.V_GBL1121957         -0.3764103 7.738640e-04 
Hif.1.alpha.M.C_GBL1122215       -0.2835044 3.368133e-03 
Src_pY416.R.V_GBL1122013          0.3219323 3.368133e-03 
c.Jun_pS73.R.V_GBL1122272        -0.3778729 9.382127e-03 
GSK.3a.b_pS21_S9.R.V_GBL1122282  -0.6958194 9.619107e-03 
Akt_pS473.R.V_GBL1122267         -0.4338686 9.619107e-03 
S6_pS235_S236.R.V_GBL1122011     -0.8881963 1.685525e-02 
CD3 alone (Dose 0 versus 30)   
HER2_pY1248.R.C_GBL1122070  0.4855243 4.248393e-09 
CD3 alone (Dose 0 versus 100)   
HER2_pY1248.R.C_GBL1122070  0.3855653 1.438851e-06 
GPBB.R.V_GBL1122116          -0.8828316 1.188161e-02 
CD3 alone (Dose 0 versus 300)   
HER2_pY1248.R.C_GBL1122070     0.3577353 7.798521e-06 
p38_pT180_Y182.R.V_GBL1121998  0.6541823 2.982066e-05 
p16INK4a.R.V_GBL1122112         -0.2825169 2.159478e-02 
HES1.R.V_GBL1122148             -0.2216701 2.631820e-02 
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Table 2B. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with 
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h 
 
 
  
 
 
Log fold change 
 
P-value 
CD3 alone (Dose 0 versus 1000)   
p38_pT180_Y182.R.V_GBL1121998      1.0757191 3.002318e-10 
HER2_pY1248.R.C_GBL1122070        0.4240169 7.277417e-08 
p90RSK_pT573.R.C_GBL1122101          0.7340010 5.278553e-06 
FAK.R.C_GBL1121979                0.4678432 1.294449e-04 
YB1_pS102.R.V_GBL1122037           0.5055596 2.426017e-04 
Bad_pS112.R.V_GBL1121957           0.3991817 2.426017e-04 
HER2.M.V_GBL1122226                0.6678777 2.426017e-04 
Akt_pS473.R.V_GBL1122267           0.5425173 5.814298e-04 
S6_pS235_S236.R.V_GBL1122011       1.1279666 8.810221e-04 
p16INK4a.R.V_GBL1122112           -0.3265606 8.810221e-04 
Src_pY416.R.V_GBL1122013            -0.3429326 8.810221e-04 
PKC.b.II_pS660.R.V_GBL1122088      0.3052046 1.206663e-03 
Hif.1.alpha.M.C_GBL1122215         0.2850831 1.464922e-03 
MEK1_pS217_S221.R.V_GBL1122071     0.2810258 2.243427e-03 
c.Jun_pS73.R.V_GBL1122272          0.3869022 3.748423e-03 
Bid.R.C_GBL1122269                -0.2585016 4.012587e-03 
Pdcd4.R.C_GBL1122036               0.3287594 5.809354e-03 
GSK.3a.b_pS21_S9.R.V_GBL1122282    0.6531518 1.033092e-02 
FAK_pY397.R.V_GBL1122111          -0.3464483 1.706239e-02 
Annexin.VII.M.V_GBL1122204         0.3889564 1.706239e-02 
p70.S6K_pT389.R.V_GBL1122001       0.2603769 1.706239e-02 
MEK1.R.V_GBL1122290               -0.1943432 1.706239e-02 
Cox2.R.C_GBL1122107               -0.1705135 2.006613e-02 
Myosin.IIa_pS1943.R.V_GBL1122096  -1.3589428 2.242156e-02 
Myosin.11.R.V_GBL1122090          -0.2640302 2.659773e-02 
MCT4.R.V_GBL1122301               -0.2318147 3.155032e-02 
Chk1_pS345.R.C_GBL1122046          0.2649744 3.529039e-02 
HER3.R.V_GBL1122170               -0.1859548 3.995997e-02 
MEK2.R.V_GBL1122113               -0.1887894 4.325005e-02 
Rictor_pT1135.R.V_GBL1122087       0.2460314 4.366397e-02 
MIG6.M.V_GBL1122201               -0.1615994 4.856163e-02 
CD31.M.V_GBL1122218                0.1874872 4.856163e-02 
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Table 2C. Differentially expressed proteins in CD8+BTLA+TIL re-stimulated with 
either CD3 or CD3 and HVEM at concentration of 0, 30, 100, 300, and 100 at 8 h 
 
 
 
 
 
 
  
 
 
Log fold change 
 
P-value 
CD3+HVEM (Dose 0 versus 30)   
HER2_pY1248.R.C_GBL1122070   0.3899450 1.105288e-06 
Rab11.R.E_GBL1122074        -0.2834234 1.713254e-04 
EGFR_pY1068.R.C_GBL1122278   0.5953123 3.704580e-02 
CD3+HVEM (Dose 0 versus 100)   
HER2_pY1248.R.C_GBL1122070 0.3146506 0.000110571 
CD3+HVEM (Dose 0 versus 300)   
HER2_pY1248.R.C_GBL1122070   0.4133938 2.725237e-07 
LC3A.B.R.C_GBL1122300       -0.4248823 7.798027e-03 
Dvl3.R.V_GBL1122051          0.3864097 2.657925e-02 
HES1.R.V_GBL1122148         -0.2175110 3.269281e-02 
Cyclin.E1.M.V_GBL1122219    -0.5887974 3.810823e-02 
E.Cadherin.R.V_GBL1122077    0.3640928 4.438662e-02 
CD3+HVEM (Dose 0 versus 1000)   
HER2_pY1248.R.C_GBL1122070  0.3735338 2.979160e-06 
FAK.R.C_GBL1121979           0.4586727 3.676352e-04 
p16INK4a.R.V_GBL1122112    -0.2893436 1.604959e-02 
LC3A.B.R.C_GBL1122300       -0.3517036 4.125150e-02 
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Discussion 
 
BTLA is a unique co-stimulatory molecule that contains both positive (Grb2) 
and negative (ITIM and ITSM) signaling motifs. Although a previous study 
demonstrated that Grb2 displayed potential interaction with Grb2 and p85 subunit of 
PI3K, downstream signaling pathway of BTLA remains under investigation.  
 Because we have shown that Grb2 motif enhanced IL-2 production and T cell 
proliferation, we then sought to gain in depth in downstream signaling pathway in both 
human and mouse CD8+T cells. When we compared differential protein expression of 
BTLA mutants (∆Grb2 and ∆ITIM and ITSM) using WT as a reference, we observed 
that Akt signaling was remarkably suppressed when Grb2 was mutated. This suggests 
that the intact effect of ITIM and ITSM specifically targets Akt pathway. In previous 
study, it has been suggested that PD-1, which also consists of ITIM and ITSM motifs, 
inhibited Akt and MAPK signaling pathways during TCR activation (56). This suggests 
that an inhibitory effect of BTLA similarly shares downstream targets with PD-1. 
However, we found that Src phosphorylation was enhanced when ITIM and ITSM 
malfunction. Because Src might be enhanced due to either unleashed TCR activation 
through disrupted negative regulation or through Grb2 activation, ∆ITIM and ITSM 
differential protein expression was then also compared with both WT and EM to 
distinguish these two effects. We found that Src phosphorylation remains consistently 
present when using WT and EM as a reference, suggesting that Grb2 could activate Src 
signaling pathway. In fact, a recent report has provided a direct interaction between 
Grb2 and Src in NIH3T3 cells upon stimulated with Fibronectin. Additionally, it has 
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been shown that overexpression of Grb2 augments phosphorylation of Src at 416, but 
the opposite result was obtained when Grb2 expression was disrupted (222). 
 Consistently, we found that Src enhancement was also observed in human 
CD8+BTLA+ TIL activated with anti-CD3 and HVEM. In fact, we also observed an 
attenuation of MAPK, NF-κB, and Akt signaling pathways in CD8+BTLA+ TIL during 
engagement with anti-CD3 and HVEM as compared to anti-CD3 alone. This data 
suggests that BTLA signaling pathways in both human and mouse share common 
downstream targets.  
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CHAPTER 6 
 
Investigating the functional role of BTLA signaling pathway in  
in vivo tumor control  
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6.1 Rationale and Hypothesis 
We have uncovered that CD8+BTLA+TIL subset exhibited superior tumor 
control in tumor bearing NSG mouse when compared with CD8+BTLA-TIL subset, but 
no difference in tumor killing capacity was observed  in in vitro setting. It remains 
unclear whether persistence of CD8+BTLA+TIL results from either the intrinsic 
function of less differentiated phenotype or BTLA signaling itself.  
We observed that BTLA signaling pathway did not contribute in tumor killing 
capacity regardless of the changes introduced in BTLA signaling motifs.  However, the 
effector cytokine production such as IFN-γ and TNF-α were attenuated when Grb2 
motif was attenuated. Intriguingly, we found an increased IL-2 production and T cell 
proliferation when ITIM and ITSM were defective, suggesting the positive function of 
the Grb2 motif.  
Consistently, we observed an attenuation of the Akt pathway with enhanced Src 
phosphorylation in CD8+ activated with anti-CD3 and HVEM in both human and 
mouse setting, suggesting that BTLA provides dual signals both positive and negative. 
We hypothesize that positive signal transduced by Grb2 motif could improve TIL 
function and lead to better tumor control.  
To determine to the functional role of the Grb2 and ITIM/ITSM motifs of 
BTLA in human CD8+TIL, we used the NSG mouse model for adoptive transfer to 
investigate the role of CD8+BTLA-TIL overexpressing WT BTLA, BTLA with 
mutation of Grb2 or ITIM and ITSM during a study of in vivo tumor challenge.  
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6.2 Results  
Generation of retroviral vectors containing wild type human BTLA and human 
BTLA mutants for functional study using NSG mouse model. 
Because we have witnessed a dual role for BTLA as a co-stimulatory and co-inhibitory 
receptor in human and mouse T cells, we next sought to dissect the potential 
contributions of the Grb2 motif and the ITIM/ITSM motifs of BTLA in CD8+ TIL 
mediated in vivo tumor control. To study the functional role of human BTLA signaling 
motifs, we generated WT BTLA and mutants of the human Grb2 and ITIM/ITSM 
motifs by substitution of tyrosine for phenylalanine using a site directed mutagenesis 
method and thus generated ∆Grb2 mutant (Y226F and Y243F) and ∆ITIM and ITSM 
mutant (Y257F and Y282F) (Figure 6.1A). We used pRVKM retroviral vector with 
GFP reporter as a gene delivery system to overexpress WT BTLA and its mutants in 
human CD8+BTLA-TIL. Comparable expression of BTLA was observed in BTLA WT and 
its mutant (Figure 6.1B). Briefly, sorted CD8+BTLA-TIL were activated with anti-
human CD3 for 2 days. The cells were transduced with either WT BTLA or BTLA 
mutants (∆Grb2 or ∆ITIM and ITSM). Over the next 14 days the cells were propagated 
using the rapid expansion protocol (RFP). Because not all cells were transduced with 
retroviruses, the GFP positive cells were further sorted and propagated for another 14 
days prior to perform in vitro functional assays and adoptive TIL transfer (Figure 
6.1C).  
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Figure 6.1. BTLA singling motifs had no effect on in vitro tumor killing capacity. 
Substitutions of tyrosine for phenylalanine were made in three different motifs of 
human BTLA cytoplasmic tail; ∆Grb2 mutants (Y226F and Y243F), ∆ ITIM and ITSM 
mutants (Y243F, Y257F, and Y282F) (A) Schematic diagram depicts the structure of 
BTLA WT (Top), BTLA ∆Grb2 (middle), and BTLA ∆ITSM (bottom). (B)  
(C) Schematic diagram depicts NSG mouse model for adoptive T cell transfer. 
CD8+BTLA-were virally transduced with WT BTLA or its variants, and propagated by 
A 
C 
B 
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REP protocol for 14 days. The cells were then sorted based on GFP expression and 
further expanded by REP protocol for another 14 days. Ten million virally transduced 
TIL were intravenously injected into tumor bearing mice previously subcutaneously 
implanted with autologous tumor line. 
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BTLA signaling motifs have no effect on in vitro tumor killing capacity.  
We previously showed the comparable in vitro tumor killing capacity between 
CD8+BTLA+TIL and CD8+BTLA-TIL; however, we observed superior in vivo tumor 
control of CD8+BTLA+TIL using the NSG mouse model. In addition, we also found 
that CD8+BTLA+TIL subset circulated in the peripheral blood at higher frequency as 
compared to CD8+BTLA-TIL subset counterpart. This finding is consistent with our 
clinical observation demonstrating that the CD8+BTLA+TIL subset persisted longer in 
the body following adoptive transfer in comparison to the CD8+BTLA-TIL subset. 
Using BTLA-KO mouse T cells overexpressing WT BTLA or its mutants, we also 
found that BTLA signaling motifs did not affect tumor killing capacity even though 
effector cytokine production (IFN-γ and TNF-α) were significantly decreased when 
Grb2 motif was mutated, in the presence of high levels of ITIM/ITSM. To further 
determine whether BTLA signaling motif could contribute to the in vitro tumor killing 
capacity, we co-incubated sorted CD8+BTLA-TIL (TIL#2549) overexpressing either 
WT BTLA or mutant BTLA with the autologous tumor. We consistently observed that 
the in vitro tumor killing capacity was comparable regardless of the presence of BTLA 
or its mutants (Figure 6.2). (1:1, BTLA-EM (23.2%) vs BTLA-WT (23.8%) BTLA-
∆Grb2 (28.0%) vs BTLA- ∆ITIM and ITSM (26.5%); 1:3, BTLA-EM (8.2%) vs 
BTLA-WT (8.5%) vs BTLA-∆Grb2 (14.8%) vs BTLA- ∆ITIM and ITSM (10.5%); 
1:10, BTLA-EM (4.5%) vs BTLA-WT (3.2%) vs  BTLA-∆Grb2 (5.6%) vs BTLA- 
∆ITIM and ITSM (4.7%). 
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Figure 6.2. BTLA signaling motifs had no effect on in vitro tumor killing capacity.  
Autologous melanoma tumor line 2549 labeled with eFluor670® was co-cultured with 
TIL at the following TIL-to-tumor cell ratios (1:10, 1:3, and 1:1). Tumor cell death is 
evaluated by the percentage of caspase-3 positive tumor cells. 
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Overexpression of inactivated ITIM and ITSM motifs in TIL enhanced tumor 
burden control in NSG mouse model. 
Because we found the comparable in vitro killing tumor capacity of cells 
regardless of WT BTLA and it BTLA mutant expression, we sought to determine 
whether overexpression of WT BTLA and its mutant could affect in vivo tumor control.  
For in vivo tumor experiment, TIL overexpressing BTLA WT or BTLA mutants 
were adoptively transferred into NSG tumor-bearing mice, and tumor burden was 
measured every other day. We found that the transfer of TIL transduced with empty 
vector (BTLA-) or TIL transduced with BTLA WT did not control the tumor and were 
not significantly different from the non-treated group (NTx). However, the transfer of 
TIL with a disrupted ITIM/ITSM domain (∆ITSM) resulted in greater tumor control 
than the empty vector or non-treated groups early on day 2 (EM vs NTx; P= 0.08, ∆ 
ITSM vs NTx; P= 0.01, WT vs NTx; P=0.24, ∆Grb2 vs NTx; P= 0.92) (Figure 6.3A, 
B, and C). However, the group that received TIL transduced with BTLA bearing a 
malfunctioning Grb2 motif (∆Grb2) exhibited significantly worst tumor control as 
opposed to those receiving TIL with empty vector control (EM) (EM VS WT; P=0.48, 
EM VS ∆Grb2; P=0.04) (Figure 6.3A, B, and C). We found that only BTLA- 
overexpressing ∆ITIM and ITSM and empty vector control exhibited significantly 
higher frequency in the blood on day 2 following transfer, while ∆Grb2 and WT 
overexpressing TIL were not detected following TIL transfer.  
Our result suggests that malfunction of Grb2 attenuated TIL function and 
impaired tumor control. We observed that MEL526 tumor cells grown in NSG mice 
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were explanted and stained for HVEM expression which was found to be still present 
(Figure 6.4). In addition, HVEM expression is highly abundant in 2549 tumor cells as 
well as other primary melanoma tumor cells (Figure 6.5A and B). This indicated that 
melanoma tumor cells potentially provided a suppressive signal through BTLA 
expressed by TIL in the tumor bed.  
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Figure 6.3. Overexpression of inactivated ITIM and ITSM motifs in TIL enhanced 
tumor burden control in NSG mouse model. 
Ten million virally transduced TIL were intravenously injected into tumor-bearing 
mice previously implanted subcutaneously with autologous tumor line 2549. Tumor 
burden was measured using calipers and diameter graphed as mm2.  N= 5-8 animals per 
group. *P <0.05 and **P <0.001. Error bars are expressed as mean ± s.e.m. P-values 
were calculated using a two-tailed Student’s t-test. The graphs show tumor volumes in 
NSG mice adoptively transferred with TIL with following comparison; (A) ∆ ITSM 
versus EM versus No Tx (B) ∆ Grb versus EM versus No Tx (C) WT versus EM versus 
No Tx.  
A B 
C 
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Figure 6.4. Sustained expression of HVEM following injection into NSG mice. 
Histogram plots demonstrating HVEM expression in MEL526 tumor cells (blue) and 
MEL526 tumor cells isolated from NSG mice following engraftment for 10 days (red). 
Live tumor cells were defined as AQUA negative and MCSP positive. The HVEM 
positive population was gated using an FMO control (black).  
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Figure 6.5. HVEM expression in 10 primary melanoma cell lines derived at 
MDACC. 
(A) Bar graph demonstrates the percentage of HVEM expression in 10 primary 
melanoma cell lines derived at MDACC. Live tumor cells were defined as AQUA 
negative and MCSP positive. HVEM expression was determined using fluorescence 
minus one controls. (B) Representative immunohistochemistry (IHC) of HVEM 
expression in paired melanoma tumor biopsies (TIL# 2420 and 2371).  
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Discussion  
 
We have shown that BTLA can provide positive function through Grb2 motif. 
In this study, we have demonstrated that use of TIL overexpressing a disrupted 
ITIM/ITSM motif to treat NSG tumor-bearing mice resulted in superior tumor control 
as compared to EM control and non-treated group. Moreover, the mice received a 
malfunctioned Grb2 motif had worse tumor control than the control groups. This result 
indicates that Grb2 could play a role in mediating tumor control.  
Although we have also shown that BTLA WT also transduced positive co-
signaling function of T cells such as boosting IL-2 secretion, it remains unclear why 
WT BTLA transduced TIL failed to exhibit tumor control in the NSG tumor bearing 
mice. It is possible that the repetitive expansion of TIL for two consecutive 14-day 
rapid expansions naturally triggers TIL to further differentiate. Thus, overexpression 
of BTLA in TIL containing a large proportion of late-differentiated attributes might not 
reflect the normal biology of human CD8+T cell. As such, the high levels of SHP-1 
present in late differentiated CD8+T cells potentially gain more interaction with ITIM 
and ITSM and result in skewing BTLA toward its inhibitory function. 
Generally, co-stimulatory molecules expressed by T cells receive signals from 
their ligands presented by APCs, but not the tumor cells since it usually lacks 
expression of these ligands. Instead, high expression of ligands for co-inhibitory 
molecules by tumor cells can suppress T cell function upon ligation with co-inhibitory 
molecules highly presented by T cell upon activation. Since overexpression of modified 
BTLA mediated superior tumor control, this is a proof of concept suggesting that 
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engagement of BTLA by HVEM on tumor cells could improve TIL function at the 
tumor site.  
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CHAPTER 7 
 
Functional role of BTLA in T cell priming and memory recall 
response 
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7.1 Rationale and Hypothesis 
Unlike human BTLA, mouse BTLA is not considered as a differentiation maker as its 
expression is not detected in mouse naïve T cell, but up-regulated upon TCR 
stimulation in a similar fashion than other co-inhibitory molecules such as PD-1 and 
CTLA-4. Although the kinetic of expression of mouse BTLA is different from human, 
we have showed that expression of BTLA was highly enriched in memory T cell in 
both human and mouse. A recent study in patients with active pulmonary tuberculosis 
showed that BTLA is highly expressed by the memory T cell subset and linked with a 
protective immune response against mycobacterial infection. A survival role of BTLA 
has been indicated in a mouse model for acute graft versus host disease (GVHD) (201). 
BTLA KO donor lymphocytes failed to engraft in host body due to impaired re-
expression of IL-7R, a critical receptor for homeostasis of naïve T cells and memory T 
cell development. Additionally, BTLA-HVEM ligation was shown to promote T cell 
expansion and survival during bacterial infection in a listeria model (204). From these 
findings, we hypothesize that BTLA could play a role in memory T cell development. 
To this end, we utilize a mouse model for vaccination to examine the generation of 
memory T cells and the memory recall response following vaccination. In this study, 
we vaccinated C57BL/6 mice with gp100 melanoma peptide following the adoptive 
transfer of bulk splenocytes from either Pmel-1 BTLA WT or Pmel-1 BTLA KO 
mouse, transgenic for the TCR recognizing the gp100 peptide used for vaccination. 
Pmel-1 T cells were tracked in peripheral blood following priming and boosting to 
determine memory recall response following vaccination.  
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7.2 Results  
Memory recall response is defective in BTLA deficient T cells. 
We and others showed that BTLA is mainly expressed by the memory T cell subset in 
both human and mouse. Previous studies have implied the association of BTLA and 
memory T cell generation in several disease models including GVHD, bacterial 
infection, and cancer. In this study, we sought to conduct an experiment to determine 
the role of BTLA in memory recall response using mouse model for vaccination. Pmel-
1 mice were crossed with C57BL/6 BTLA KO mice to generate Pmel-1 BTLA KO 
mice. Half million of splenocytes from either Pmel-1 WT or Pmel-1 BTLA KO were 
adoptively transferred into c57BL/6 recipient mice. On the following day, mice were 
vaccinated with gp100 peptide together with anti-mouse CD40. Imiquimod cream 5% 
was also applied on the vaccination site to boost the innate immune response. 
Additionally, IL-2 was also provide to support in vivo T cell proliferation following 
vaccination. The frequency of Pmel-1 T cells was determined in peripheral blood every 
other day after vaccination (Figure 7A and B).  On day 20 following the first priming, 
we observed significantly higher frequency of Pmel-1 WT in peripheral blood when 
compared with Pmel-1 BTLA KO. The frequency of both Pmel-1 WT and Pmel-1 
BTLA KO declined and disappeared by day 30. Boost vaccination was performed on 
day 60 following the first priming. We observed that Pmel-1 WT T cells were detected 
in the peripheral blood within two days following boosting. However, the frequency of 
Pmel-1 BTLA KO T cells remained unchanged (Figure 7C). To determine the long 
term memory response, we determined the existence of Pmel-1 T cells in the spleen on 
day 120. We found significantly higher percentage of Pmel-1 WT T cells in spleen as 
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compared to Pmel-1 BTLA KO T cells (Figure 7D). This result suggests that BTLA is 
critical for generation of a memory T cell pool in both priming and memory recall 
response. Our finding has strengthen the notion that BTLA is not only a T cell 
differentiation marker, but its function is also important in memory T cell development.  
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Figure 7. Defect of memory recall response of BTLA deficient T cells. 
Schematic diagram depicting experimental design of mouse model for vaccination. A 
non-myeloablative dose (350 cGy) of radiation is given to induce lymphopenia. The 
next day, half a million of either (A) Pmel-1 Thy 1.1. wild type splenocytes or (B) 
Pmel-1 BTLA KO splenocytes were adoptively transferred into C57BL/6 mouse 
recipients (i.v.). On the following day, the recipients were vaccinated with gp100 
peptide (100µg) together with anti-CD40 (50 µg) and imiquimod (50 mg). 
A 
B 
C D 
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Recombinant human IL-2 at 1.2 X106 IU was administered once, and 6 x 105 IU twice 
daily for the next 2 days (i.p.). Peripheral blood was collected every other day to 
determine the frequency of circulating Pmel-1 Thy 1.1 T cells. On day 60, the mice 
were vaccinated with gp100 peptide, and peripheral blood was collected every other 
day until Pmel-1 T cells were no longer detected. On day 120, the mice were 
euthanized, and spleens were collected to determine the presence of Pmel-1 Thy 1.1 T 
cells. (C) Plot graph depicts the percentage of CD3+CD8+Pmel+ T cells in the peripheral 
blood following the priming (first peak from day 15 to day 30) and boosting (second 
peak from day 60 to 70). The frequency of CD3+CD8+Pmel+T cells was significantly 
higher in C57BL/6 mouse recipients receiving Pmel-1 Thy 1.1. wild type splenocytes 
as compared to those receiving Pmel-1 Thy 1.1. BTLA KO splenocytes. (D) 
Comparison of the percentage of CD3+CD8+Pmel+ T cell in spleen on day 120 of mice 
receiving either Pmel-1 Thy 1.1. wild type splenocytes or Pmel-1 Thy 1.1. BTLA KO 
splenocytes. Pmel-1 Thy 1.1. BTLA KO splenocytes failed to develop memory recall 
response following vaccination and boosting.  
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Discussion 
 
Generation of memory T cells is critical for highly effective immune response. 
In this study, we found that mouse transferred with BTLA deficient splenocytes before 
vaccination failed to develop antigen-specific CD8+ memory T cells, suggesting that 
BTLA plays a pivotal role in memory T cell development. It is known that BTLA is a 
co-inhibitory molecule; however, our data has shown that BTLA can also mediate 
positive signal through its Grb2 motif. It has been clearly shown that optimal antigenic 
and co-stimulatory signals are involved in memory T cell development, particularly 
during naïve T cell priming. The weak TCR signal has been shown to inhibit memory 
T cell development; on the contrary, extremely strong signal resulted in skewing toward 
terminally differentiated effector T cell development (138). We have shown that BTLA 
contains motifs that can transduce both positive and negative signal. This data suggest 
that BTLA (unlike PD-1) induces both pro-survival positive signals but also inhibitory 
signals through the recruitment of SHP1 and 2. Thus, BTLA acts more like a rheostat 
reducing TCR signaling during strong antigenic stimulation while also inducing cell 
survival signaling. This rheostat property of BTLA could play an important role for 
memory T cell development in producing a balanced TCR signal favoring memory T 
cell generation.  
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CHAPTER 8 
 
Overall discussion and future directions 
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8.1 Overall discussion 
Our clinical observation on the association of an improved outcome to TIL ACT in 
melanoma patients with the infusion of higher numbers of CD8+BTLA+ TIL has 
brought up an intriguing question of how this co-inhibitory molecule could benefit TIL 
therapy as its known function is to inhibit T cell function. Recent literature uncovered 
another role of BTLA as a T cell differentiation marker. It has been shown that BTLA 
is highly enriched in naïve and central memory T cells, but down-regulated upon T cell 
expansion and differentiation (142). Several studies in T cell therapy and cancer 
immunology clearly demonstrated that adoptive transfer of less differentiated T cell 
improves T cell persistence, resulting in superior anti-tumor immunity and tumor 
burden control. Similarly, we also observe that CD8+BTLA+TIL subset persisted in the 
peripheral blood longer than its CD8+BTLA-TIL subset counterpart, indicating that the 
less differentiated CD8+BTLA+TIL subset indeed play a role in clinical outcome (121, 
141, 143, 223-227).  
In this study, while we have demonstrated that CD8+BTLA+TIL and CD8+BTLA-TIL 
subsets had comparable in vitro tumor killing capacity, CD8+BTLA+TIL displayed 
superior in vivo tumor control using NSG tumor bearing mouse model with increased 
persistence following transfer in MART-1 antigen-specific setting, which reproduced 
the exclusive advantage of CD8+BTLA+ in ACT treated patients. We did not fully 
understand why the in vitro tumor killing observations did not agree with the in vivo 
tumor burden control. We hypothesized that in vitro tumor killing was performed in a 
bulk setting between tumor cells and T cells during such a short time (3 h) that it might 
not fully predict the fate of T cell following subsequent killing of multiple tumor 
targets, which occurred in mouse model as well as in melanoma patients. To this end, 
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we sought to use a nanowell array-based cytolysis assay conducted at the single cell 
level in order to study the dynamic interactions between tumor targets and effector T 
cells at high-throughput setting. Our data demonstrated that CD8+BTLA+TIL were 
more active at seeking the tumor, but once a contact is established with the target they 
took more time than their BTLA- counterpart to produce apoptosis of the target cell. In 
fact, we observed that CD8+BTLA-TIL subset was more effective in tumor killing only 
at early time point (first 250 mins) as compared to CD8+BTLA+TIL counterpart. 
However, after careful analysis of the ability of the T cells to kill more than one target, 
we found that the CD8+BTLA+TIL subset conferred superior ability for repetitive 
killing of multiple tumor targets.  
We have demonstrated that CD8+BTLA+TIL manifested enhanced mitochondrial 
function and spare respiratory capacity (SRC) and preferentially used an oxidative 
phosphorylation (OXPHOS) pathway for energy generation, which was more efficient 
than the glycolysis pathway utilized by T effector cells (228, 229). A recent study 
indicated that increased SRC was strongly associated with a superior bioenergetic 
capacity, which helped improve T cell survival and motility under hypoxic conditions 
(230). This property could help explain both the decreased time in finding a tumor 
target and increased resistance to apoptosis following engagement and subsequent 
killing of multiple tumor targets. Our result demonstrates for the first time that 
CD8+BTLA+ subset is a “serial killing T cell”. The potentially intrinsic property of this 
subset provides an intriguing possibility for why infusion of large numbers of 
CD8+BTLA+TIL positively correlates with clinical response to TIL ACT in metastatic 
melanoma patients. This supports the notion that the minimally differentiated 
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phenotype of CD8+BTLA+TIL has less capacity for rapid tumor cytolysis as compared 
with more differentiated, and short-lived, CD8+BTLA-TIL, but is more 
bioenergetically efficient. 
The use of CD8+BTLA+ and CD8+BTLA- is impossible to discrete the intrinsic 
property of less differentiated T cell from BTLA signaling pathway. Because gene 
silencing of BTLA using lentiviral vector exhibits relatively low efficiency of gene 
delivery in TIL, this obstacle limits our understanding of the role of BTLA signaling 
pathway in less differentiated T cells. 
Thus, we utilize the genetically modified BTLA constructs to dissect the dichotomy of 
positive and negative signaling motifs of BTLA, Grb2 and ITIM and ITISM 
respectively.  We did not observe any major differences in the in vitro killing capacity 
and cytotoxic cytokine production between BTLA KO T cells versus BTLA KO T cells 
overexpressing BTLA WT or its mutants, this suggests that BTLA signaling does not 
affect tumor killing capability. Our findings are consistent with the previous report 
showing that the BTLA blockade in gamma delta T cells had no effect on the tumor 
lysis.                          
We observed a slight decrease in T cell proliferation in WT as compared with EM, and 
the inhibitory effect was even more pronounced when the Grb2 motif was defective. In 
contrast, malfunction of ITIM and ITSM motifs significantly enhanced T cell 
proliferation. Previous studies in both human and mouse settings indicated that CD8+ 
T cells were intrinsically less susceptible to BTLA-mediated inhibition as compared to 
CD4+ T cells. This might explain the minimal inhibition of WT as compared to EM in 
CD8+ T cells in terms of proliferation. In addition, we noticed that T cells with deficient 
171 
 
Grb2 motifs remarkably decreased IL-2 production. Interestingly, we found that 
production of IL-2 in BTLA WT was significantly higher than empty vector control. A 
previous report has shown that Grb2-linked SLP-76 and Vav interaction was involved 
in IL-2 production. This suggested that the presence of Grb2 is potentially linked to IL-
2 production without influence from ITIM and ITSM (218, 231, 232). Our previous 
work had shown higher IL-2 production in BTLA+CD8+ TIL and the current study 
reveals that the Grb2 motif of BTLA is responsible for the BTLA-dependent IL-2 
production which makes the Grb2 motif functionally active and critically important in 
T cell proliferation.  
Because we found a positive role for the Grb2 motif of BTLA, we further wondered 
whether there was a distinct downstream signaling pathway exhibited from Grb2 motif. 
When comparing the differentially expressed proteins in activated T cells transduced 
with the different BTLA constructs and comparing with BTLA WT, we noticed that 
the Akt signaling pathway was remarkably attenuated in BTLA ∆Grb2, while the 
phosphorylation of Src was enhanced in BTLA ∆ITSM. A previous report 
demonstrated that ITIM and ITSM motifs of PD-1 inhibited signals through Akt and 
MAPK. This suggested that the Akt pathway in BTLA was likely targeted by SHP1/2, 
similar to what was found in PD-1. From our data, it is clear that the phosphorylation 
of Src increased when ITIM and ITSM domain is abrogated, but this could result from 
either the effect of Grb2 signal transduction or the deficient dephosphorylation of 
SHP1/2 recruited through ITIM and ITSM motifs. It was not possible to distinguish the 
overlapping downstream signaling pathway when BTLA WT was used as a reference 
to compare with ∆ITSM. Instead, we found an increased phosphorylation of Src when 
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directly comparing ∆ITSM to EM, suggesting that Grb2 motif is potentially responsible 
for the increased Src phosphorylation. It has been demonstrated that the interaction 
between cells stimulated with Fibronectin (222). Overexpression of Grb2 in osteoclasts 
was also shown to promote phosphorylation of Src at Y416 and the opposite result was 
obtained when Grb2 expression was disrupted.  
Our data in mouse BTLA signaling are in line with signaling in human TIL as we 
observed attenuation of MAPK, NF-kB, and Akt signaling proteins, but 
phosphorylation of Src was enhanced when stimulated with anti-CD3 and HVEM as 
compared to CD3 alone. This suggested that the downstream signaling pathway of 
BTLA in mice and humans possibly share similar targets.  
As is consistent with the positive function of the Grb2 motif, we demonstrated that TIL 
overexpressing disrupted ITIM and ITSM had superior in vivo tumor burden control 
while the disruption of Grb2 domain led to the least effective tumor control. It is 
possible that the signals from the Grb2 motif helped mediate tumor control at tumor 
sites where TIL interacted with melanoma cells highly expressing HVEM. The fact that 
the BTLA WT group in this experiment did not control the tumor better than the empty 
vector group may have to do with the preparation of the cells. The TIL need to undergo 
two 14-day rapid expansions successively to allow for vector transduction first 
following by sorting and secondary expansion of the vector positive population. At the 
end of this four week expansion process the T cell product will be more differentiated 
whereby we will have late differentiated TIL expressing BTLA and therefore trump the 
usual “less differentiated” phenotype of the BTLA+ TIL.  
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Our study sheds light on a dual role of BTLA as both a co-stimulatory and co-inhibitory 
molecule. The integration of the positive and negative signals transduced by BTLA will 
promote survival and IL-2 secretion while reducing proliferation and effector cytokine 
production. In addition, inherited properties of minimally differentiated phenotype of 
BTLA+ subset display enhanced apoptosis resistance and efficient bioenergetics 
provide survival advantage following subsequent tumor killing. Since BTLA 
expression is regulated by the differentiation status of the T cell such that it is only 
expressed at early stages of differentiation, it is not expected to impact the survival or 
function of late effector T cells. This places BTLA in a different category than other 
checkpoint blockade molecules such as PD-1 or CTLA-4, which are up-regulated 
following T cell activation (184, 233). In general, co-stimulatory molecules expressed 
by T cells receive signals from their ligands presented by antigen-presenting cells 
(APCs). Tumor cells generally lack expression of those co-stimulatory molecule 
ligands. In contrast, tumor cells highly expressing co-inhibitory ligands can suppress T 
cell function in tumor environments upon ligation with co-inhibitory molecules such 
as PD-1 and TIM-3. In contrast, BTLA’s ligand, HVEM, is expressed widely by 
melanoma tumor cells. This findings support the concept that intrinsic attribute of less 
differentiated CD8+BTLA+ subset together with engagement of HVEM on melanoma 
cells could provide a costimulatory signal to BTLA+CD8+ TIL to promote IL-2 
secretion, survival and anti-tumor function.   
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8.2 Future directions  
Our data reveal that BTLA provides advantage in both intrinsic attribute of less 
differentiated T cells as well as signaling pathway. These properties help T cell to resist 
apoptosis and mediate killing of multiple tumor targets with enhanced IL-2 production 
and cell proliferation. Overall our findings partially explain the observation of better 
clinical outcome of melanoma patients infused with high proportion of 
CD8+BTLA+TIL subset (134).  Both intrinsic properties of BTLA and its positive 
signaling pathway through Grb2 motif could contribute to superior clinical responses. 
On the basis of this finding, I propose two strategies that might potentially improve the 
efficacy of ACT; I) De-acceleration of T cell differentiation during REP II) 
Overexpression of BTLA or other inhibitory molecules with genetically modified endo 
domain.    
De-acceleration of T cell differentiation during REP 
Several studies have demonstrated that the transfer of less differentiated T cells 
improved in vivo tumor control. In consistent with our clinical observation, patients 
treated with TIL of a less differentiated T cell phenotype (CD8+BTLA+) exhibited 
superior clinical response with enhanced persistence following TIL transfer as 
compared to CD8+BTLA- counterpart. During massive T cell expansion, the effect of 
anti-CD3 activation together with IL-2 promote T cells to undergo proliferation and 
differentiation (234). Repetitive T cell activation can initiate terminal differentiation 
resulting in telomere shortening and defect in proliferation, and become clonal deletion 
eventually (137).  This could explain our findings demonstrating that less differentiated 
TIL subset with high expression of BTLA persist longer than those of more 
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differentiated phenotype. Thus, an approach to attenuate T cell differentiation during T 
cell expansion is desirable for T cell therapy. Several strategies have been reported to 
target cellular signaling pathways that promote T cell differentiation. It has been shown 
that sustained Akt activation enhanced mTOR phosphorylation and down-regulation of 
IL-7R expression (235). This resulted in promoting terminal differentiation of effector 
CD8+ T cells and impaired development of memory T cell pools. On the other hand, 
inhibition of Akt signaling pathway has been shown to up-regulate CD62L expression 
and enhance gene signature of human memory T cell (236). In addition, Akt inhibition 
also altered T cell metabolism by augmenting mitochondrial spare respiratory capacity 
and oxidative phosphorylation pathway, which is mainly utilized by memory T cells. 
Adoptive transfer of human TIL previously expanded with Akt inhibitor has 
demonstrated superior in vivo persistence and tumor burden control using NSG mouse 
model. Consistently, another study also demonstrated that inhibition of Akt signaling 
pathway can attenuate differentiation of minor histocompatibility antigens (MiHAs) 
specific CD8+ T cells following rapid expansion for 14 days. In addition, Akt-inhibited 
MiHA specific CD8+ T cells also exhibited superior anti-tumor capacity following 
adoptive T cell transfer (237). This suggest that sustained Akt signaling pathway can 
promote terminal differentiation of T cell by altering transcriptome, metabolism, 
phenotype, and function.  
It has been shown that inhibition of mammalian Target of Rapamycin complex 1 
(mTORC1) and activation of Wnt signaling pathway can promote the in vitro 
generation of stem cell-like memory T cells (Tscm). CD4+Tscm cells expanded with 
mTORC1 inhibitor (Rapamycin) conferred longer term persistence following adoptive 
176 
 
transfer. Furthermore, expanded Tscm also preferentially utilized mitochondria fatty 
oxidation rather than glycolysis, which is preferably used by effector T cells. The study 
of mTORC1 gene silencing using siRNA also showed enhanced differentiation of 
CD8+ T cells into memory phenotype and augmented potent antitumor effect. 
Interestingly, the combination of 4-1BB aptamer with mTORC1 gene silencing, was 
found to be synergistically inhibiting mTOR activity and resulted in improved 
antitumor immunity (238). In vaccination model, it has been demonstrated that using 
OX-40 agonist in combination with mTOR inhibitor (Rapamycin) boosted the 
generation of memory T cell pool and protective immunity following Vaccinia Vaccine 
challenge (239).  
Overall current studies demonstrate the advantage of suppressing Akt-mTOR pathway 
in the generation of less differentiated T cell phenotype and stem-cell like phenotype. 
It appears that the inhibition of Akt and mTOR can alter the metabolic pathway to 
mitochondria oxidative phosphorylation, which is much more bioenergetically efficient 
as compared to the glycolysis pathway. More importantly, expanded T cell with either 
Akt inhibitor or mTOR inhibitor exhibited superior persistence following adoptive 
transfer with enhanced antitumor immunity. Therefore, targeting Akt and mTOR could 
be an effective strategy to help generate less differentiated TIL and stem cell like 
phenotype.  
Overexpression of co-inhibitory molecules with modified endodomain 
 
Less differentiated T cells have intrinsic attributes that enhance survival following 
tumor cell killing such as apoptosis resistance, superior IL-2 production, and enhanced 
replicative proliferation. We have demonstrated that the transduction of BTLA bearing 
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non-functional ITIM and ITSM motifs transduced positive signals with enhanced IL-2 
production and T cell proliferation. Thus, intrinsic attribute and positive signaling of 
BTLA are critical to TIL function and linked to positive clinical response in ACT 
treated patients. It is known that tumor microenvironment is immunosuppressive. 
Engagement of co-inhibitory molecules on T cell and their ligand expressed by tumor 
cells attenuates T function. Using tumor NSG mouse model for adoptive transfer, we 
have shown that CD8+BTLA- overexpressing BTLA with inactivated ITIM and ITSM 
motifs conferred superior in vivo tumor control, while overexpression of BTLA WT in 
TIL failed to improve tumor control as compared to non-treatment group. This suggests 
that engagement of BTLA and HVEM in tumor site affect TIL function in mediating 
tumor control (Figure 8A). This proof of principle allows us to generate a strategy to 
modify the endodomain of inhibitory molecules by substitution with endodomain of 
positive co-stimulatory molecule such as CD40, CD27, CD28, 4-1BB, and etc. (Figure 
8B). Because co-stimulatory molecule only transduces its downstream signal during 
TCR activation, this context acts selectively and specifically upon engagement of T 
cell and tumor cell.   
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Figure 8. Overexpression of co-inhibitory molecules with modified endodomain. 
(A) Schematic diagram depicts the interaction between TIL and melanoma tumor cell 
targets. Engagement between BTLA expressed by TIL and HVEM expressed by 
melanoma tumor cells exhibits both a positive and negative signal. (B) Schematic 
diagram demonstrates interaction between the TIL and melanoma tumor cell targets. 
Engagement between co-inhibitory molecules with modified endodomain expressed by 
TIL and HVEM expressed by melanoma tumor cells exhibits positive signals that 
promote TIL effector function.  
A 
B 
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Materials and Methods 
Reagents.  
Cell lines. Platinum E cell line, 526 Melanoma tumor line, and autologous tumor cell 
line #2549 were maintained in  Roswell Park Memorial Institute (RPMI) supplemented 
with 10% fetal bovine serum (FBS) (Gemini bio product), 10 mM HEPES (Gibco™), 
10 mM Penicillin-streptomycin (Gibco™), and 10 mM Glutamine (Gibco™), and 0.05 
mM Beta-mercaptoethanol(Gibco™). Platinum-E retro packing cell line was purchased 
from Cellbiolabs. MEL 526 tumor line was obtained from Dr Steven A. Rosenberg at 
the National Cancer Institute. B16F10 and B16OVA cell lines were generously 
provided by Dr. Willem Overwijk (MD Anderson Cancer Center). Autologous primary 
melanoma tumor cell line #2549 was generated at M.D. Anderson Cancer Center from 
a tumor sample of a patient enrolled on an ongoing adoptive T cell therapy study (IRB 
#2004-0069, lab06-0755). 
Patient tumor sample acquisition. Tumor samples were obtained from patients with 
Stage IIIc and Stage IV melanoma undergoing surgery at The University of Texas MD 
Anderson Cancer Center according to an Institutional Review Board-approved protocol 
and with patient consent (IRB# LAB06-0755) 
Generation of tumor infiltrating lymphocytes (TIL). Fragments from melanoma 
tumors were cut into 1 to 2 millimeters. Each fragment was placed into a single wells 
in 24-well-culture plates (Falcon) and maintained with RPMI supplemented with 10% 
heat inactivated Human AB serum (Gemini bio product), IL-2 6000 IU/ml 
(Aldesleukin, Novartis), 10 mM HEPES, 10 mM Penicillin-streptomycin (Gibco™), 
and 10 mM Glutamine (Gibco™).  
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Animal. The NOD/SCIDγc-/- (NSG) mice were obtained from the Jackson Laboratory. 
NOD/SCIDγc-/- (NSG) mice were given autoclaved food and acidified autoclaved 
water. The BTLA-OT.1 KO mouse were kindly provided from Dr. Roza Nurieva (MD 
Anderson Cancer Center). All mice were housed in a specific pathogen-free facility at 
The University of Texas M.D. Anderson Cancer Center.  
Retroviral constructs of BTLA wild type and mutants. Human BTLA and murine 
BTLA were amplified from MGC fully sequenced human BTLA and murine BTLA 
(Open biosystem) respectively by PCR with primers hBTLA-F and R and mBTLA-F 
and R. The PCR products were cloned into pRVKM retroviral vectors. To generate 
BTLA mutants, we substituted tyrosine for phenyl alanine in either Grb2 motifs or 
ITIM and ITSM motifs of BTLA cytoplasmic tails. These included human ∆Grb2 
mutants (Y226F and Y243F), human ∆ ITIM and ITSM mutants (Y243F, Y257F, and 
Y282F), murine ∆Grb2 mutants (Y245F), and murine ∆ ITIM and ITSM mutants 
(Y274F, and Y299F). Sequence of all constructs were validated by DNA sequencing. 
DNA sequencing of mouse and human BTLA and their mutants 
TAT and TTC are genetic codes of tyrosine and phenylalanine respectively. Red, Blue, 
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs 
respectively. 
Wild type human BTLA 
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
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TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
TACTGCTATCAGAAACTGGAATTTATGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTATTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTATGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATATGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA 
 ∆ITIM and ITSM human BTLA 
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
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ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
TACTGCTATCAGAAACTGGAATTTATGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTATTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTTCGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATTCGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA 
∆Grb2 human BTLA  
ATGAAGACATTGCCTGCCATGCTTGGAACTGGGAAATTATTTTGGGTCTTC
TTCTTAATCCCATATCTGGACATCTGGAACATCCATGGGAAAGAATCATG
TGATGTACAGCTTTATATAAAGAGACAATCTGAACACTCCATCTTAGCAG
GAGATCCCTTTGAACTAGAATGCCCTGTGAAATACTGTGCTAACAGGCCT
CATGTGACTTGGTGCAAGCTCAATGGAACAACATGTGTAAAACTTGAAGA
TAGACAAACAAGTTGGAAGGAAGAGAAGAACATTTCATTTTTCATTCTAC
ATTTTGAACCAGTGCTTCCTAATGACAATGGGTCATACCGCTGTTCTGCAA
ATTTTCAGTCTAATCTCATTGAAAGCCACTCAACAACTCTTTATGTGACAG
ATGTAAAAAGTGCCTCAGAACGACCCTCCAAGGACGAAATGGCAAGCAG
ACCCTGGCTCCTGTATAGTTTACTTCCTTTGGGGGGATTGCCTCTACTCAT
CACTACCTGTTTCTGCCTGTTCTGCTGCCTGAGAAGGCACCAAGGAAAGC
AAAATGAACTCTCTGACACAGCAGGAAGGGAAATTAACCTGGTTGATGCT
CACCTTAAGAGTGAGCAAACAGAAGCAAGCACCAGGCAAAATTCCCAAG
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TACTGCTATCAGAAACTGGAATTTTCGATAATGACCCTGACCTTTGTTTCA
GGATGCAGGAAGGGTCTGAAGTTTTCTCTAATCCATGCCTGGAAGAAAAC
AAACCAGGCATTGTTTATGCTTCCCTGAACCATTCTGTCATTGGACTGAAC
TCAAGACTGGCAAGAAATGTAAAAGAAGCACCAACAGAATATGCATCCA
TATGTGTGAGGAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAA
GTAA 
Wild type mouse BTLA 
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAATGCCTCAGG
ACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGCTTTACACCT
TGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTGCCTGCTCTG
CTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTGACTTGGCAG
GAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGGACAAATCAC
CAAGCACTGCCATCAGGAACTGGAATTTATGATAATGATCCCTGGTCTAG
CATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAGAGAGAAACA
ACCAGGGCATTGTTTATGCTTCTTTGAACCATTGTGTTATTGGAAGGAATC
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CAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATATGCATCCAT
TTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAAG
TAA 
∆ITIM and ITSM mouse BTLA 
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAATGCCTCAGG
ACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGCTTTACACCT
TGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTGCCTGCTCTG
CTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTGACTTGGCAG
GAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGGACAAATCAC
CAAGCACTGCCATCAGGAACTGGAATTTATGATAATGATCCCTGGTCTAG
CATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAGAGAGAAACA
ACCAGGGCATTGTTTTCGCTTCTTTGAACCATTGTGTTATTGGAAGGAATC
CAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATTCGCATCCAT
TTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACGATGACAAG
TAA 
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∆Grb2 mouse BTLA  
ATGAAGACAGTGCCTGCCATGCTTGGGACTCCTCGGTTATTTAGGGAATT
CTTCATCCTCCATCTGGGCCTCTGGAGCATCCTTTGTGAGAAAGCTACTAA
GAGGAATGATGAAGAGTGTCCAGTGCAACTTACTATTACGAGGAATTCCA
AACAGTCTGCCAGGACAGGAGAGTTATTTAAAATTCAATGTCCTGTGAAA
TACTGTGTTCATAGACCTAATGTGACTTGGTGTAAGCACAATGGAACAAT
CTGTGTACCCCTTGAGGTTAGCCCTCAGCTATACACTAGTTGGGAAGAAA
ATCAATCAGTTCCGGTTTTTGTTCTCCACTTTAAACCAATACATCTCAGTG
ATAATGGGTCGTATAGCTGTTCTACAAACTTCAATTCTCAAGTTATTAATA
GCCATTCAGTAACCATCCATGTGACAGAAAGGACTCAAAACTCTTCAGAA
CACCCACTAATAACAGTATCTGACATCCCAGATGCCACCAAT 
GCCTCAGGACCATCCACCATGGAAGAGAGGCCAGGCAGGACTTGGCTGC
TTTACACCTTGCTTCCTTTGGGGGCATTGCTTCTGCTCCTTGCCTGTGTCTG
CCTGCTCTGCTTTCTGAAAAGGATCCAAGGGAAAGAAAAGAAGCCTTCTG
ACTTGGCAGGAAGGGACACTAACCTGGTTGATATTCCAGCCAGTTCCAGG
ACAAATCACCAAGCACTGCCATCAGGAACTGGAATTTTCGATAATGATCC
CTGGTCTAGCATGCAGGATGAATCTGAATTGACAATTAGCTTGCAATCAG
AGAGAAACAACCAGGGCATTGTTTATGCTTCTTTGAACCATTGTGTTATTG
GAAGGAATCCAAGACAGGAAAACAACATGCAGGAGGCACCCACAGAATA
TGCATCCATTTGTGTGAGAAGTGGTGGCGGAAGTGACTACAAGGACGACG
ATGACAAGTAA 
TAT and TTC are genetic codes of tyrosine and phenylalanine respectively. Red, Blue, 
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs 
respectively. 
187 
 
Amino acid sequencing of mouse and human BTLA and their mutants 
Wild type human BTLA 
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVYASLNHSVI
GLNSRLARNVKEAPTEYASICVRSGGGSDYKDDDDK. 
∆ITIM and ITSM human BTLA 
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIYDNDPDLCFRMQEGSEVYSNPCLEENKPGIVFASLNHSVI
GLNSRLARNVKEAPTEFASICVRSGGGSDYKDDDDK. 
∆Grb2 human BTLA 
MKTLPAMLGTGKLFWVFFLIPYLDIWNIHGKESCDVQLYIKRQSEHSILAGDP
FELECPVKYCANRPHVTWCKLNGTTCVKLEDRQTSWKEEKNISFFILHFEPVL
PNDNGSYRCSANFQSNLIESHSTTLYVTDVKSASERPSKDEMASRPWLLYSLL
PLGGLPLLITTCFCLFCCLRRHQGKQNELSDTAGREINLVDAHLKSEQTEAST
RQNSQVLLSETGIFDNDPDLCFRMQEGSEVFSNPCLEENKPGIVYASLNHSVI
GLNSRLARNVKEAPTEYASICVRSGGGSDYKDDDDK. 
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Wild type mouse BTLA 
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIYDNDPWSSMQDESELTISLQS
ERNNQGIVYASLNHCVIGRNPRQENNMQEAPTEYASICVRSGGGSDYKDDD
DK. 
∆ITIM and ITSM mouse BTLA 
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIYDNDPWSSMQDESELTISLQS
ERNNQGIVFASLNHCVIGRNPRQENNMQEAPTEFASICVRSGGGSDYKDDDD
K. 
∆Grb2 mouse BTLA  
MKTVPAMLGTPRLFREFFILHLGLWSILCEKATKRNDEECPVQLTITRNSKQS
ARTGELFKIQCPVKYCVHRPNVTWCKHNGTICVPLEVSPQLYTSWEENQSVP
VFVLHFKPIHLSDNGSYSCSTNFNSQVINSHSVTIHVTERTQNSSEHPLITVSDI
PDATNASGPSTMEERPGRTWLLYTLLPLGALLLLLACVCLLCFLKRIQGKEK
KPSDLAGRDTNLVDIPASSRTNHQALPSGTGIFDNDPWSSMQDESELTISLQSE
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RNNQGIVFASLNHCVIGRNPRQENNMQEAPTEYASICVRSGGGSDYKDDDD
K. 
Y and F are amino acid codes of tyrosine and phenylalanine respectively. Red, Blue, 
and Green represent either tyrosine or phenylalanine of Grb2, ITIM, and ITSM motifs 
respectively. 
Amino acid sequencing of human co-stimulatory molecules containing Grb2 motif 
Human CD28 
MLRLLLALNLFPSIQVTGNKILVKQSPMLVAYDNAVNLSYNEKSNGTIIHVKG
KHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSD
YMNMTPRRPGPTRKHYQPYAPPRDFAAYRS 
Human ICOS 
MKSGLWYFFLFCLRIKVLTGEINGSANYEMFIFHNGGVQILCKYPDIVQQFK
MQLLKGGQILCDLTKTKGSGNTVSIKSLKFCHSQLSNNSVSFFLYNLDHSHA
NYYFCNLSIFDPPPFKVTLTGGYLHIYESQLCCQLKFWLPIGCAAFVVVCILGC
ILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL 
Amino acid sequencing of co-inhibitory molecule containing ITIM and ITSM 
motif 
Human PD-1 
MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNAT
FTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNG
RDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAH
PSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQ
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PLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTS
SPARRGSADGPRSAQPLRPEDGHCSWPL 
 
Table 3. Primers used to amplify mouse and human BTLA 
 
Retrovirus generation and transduction of human TIL.  Plate-E cells were 
transfected with pRVKM retroviral vectors and RD114 plasmids using PolyJet 
(Signagen Laboratories) according to manufacturer’s protocol for 60 h. The 
supernatants were harvested and concentrated using Vivaspin-20 (Vivaproducts), then 
added onto a plate pre-coated with Retronectin (Takara clontech) and centrifuged at 
2000 g for 2 h. Pre-activated CD8+BTLA- with anti-human CD3 at a concentration of 
300 ng/mL (Clone OKT3, BD PharmingenTM) were then added and centrifuged at 1000 
g for 10 min. On the next day, the cells were propagated using the Rapid expansion 
protocol (REP) with irradiated PBMC and hIL-2 (Proleukin, Novartis) at 6000 IU for 
14 d as previously described (141). Transduced cells were then sorted based on GFP 
expression and propagated with the REP protocol.  
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Retroviral transduction in mouse T cells. pRVKM retroviral vectors and pEco 
plasmids were co-transfected into Plate-E cells using using PolyJet (Signagen 
Laboratories). The supernatants were harvested 60 h later and concentrated using 
Vivaspin-20 (Vivaproducts). Splenocytes from BTLA-KO OT.1 mice were cultured 
with RPMI1640 with 10% FBS and hIL-2 at 300IU/ml, and activated with anti-mouse 
CD3 at concentration of 0.3 ug/ml (Clone 145-2C11, BD PharmingenTM) for 24 h. The 
cells were then infected with a concentrated retrovirus and further expanded in 
RPMI1640 with 10% FBS and hIL-2 for 3 days. The cells were sorted based on the 
expression of GFP using a FACSAria (BD Bioscience) and propagated with hIL-2 at 
300 IU/ml for 5 days.  
Reverse phase protein array. Murine BTLA KO OT.1 cells overexpressing BTLA 
WT or mutants were re-stimulated with either 10 ng/ml anti-mouse CD3 (Clone 145-
2C11, BD PharmingenTM) alone or with recombinant Fc mouse HVEM (R&D systems) 
plate-bound for 12 h prior to harvest with cell lysis buffer (kindly provided by RPPA 
core facility at The University of Texas M.D. Anderson Cancer Center). The cell 
lysates were centrifuged at 14,000 rpm for 10 minutes at 4C.  For human TIL, four 
TIL lines were stained with anti-CD8 (clone RPA-T8, BD Biosciences), anti-BTLA 
(clone J168, BD Bioscience), and Sytox blue (Molecular ProbeTM) under aseptic 
condition. The cells were sorted based on expression of CD8+BTLA- using FACSAria 
(BD Biosciences). On the next day, sorted TIL were re-stimulated with anti-human 
CD3 (clone OKT-3, BD Bioscience) with or without recombinant Fc mouse HVEM 
(R&D systems) for 30 minutes. The cells were harvested as previously described 
above.  
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Surface marker staining 
TIL were washed twice with 2 ml FWB for 5 minutes at 1400 rpm.  The cell were 
stained with T cell surface markers with the cocktail antibody of anti-human CD3 
(clone BD Pharmingen), anti-human CD8( clone BD Pharmingen), anti-BTLA (clone 
J168, BD Pharmingen). Amcyan Aqua (Molecular Probes, Life Technologies) was 
used to selectively gate live cells. Staining was performed on ice for 25 minutes. The 
cells were washed twice with FWB to remove an excessed unbound antibodies for 5 
minutes at 1400 rpm. The samples were fixed with 1% para-formaldehyde solution 
prior to acquire acquire using a BD FACScanto II flow cytometer machine. For 
tetramer staining, the cells were washed with FWB previously described, and stained 
with a MART-1 peptide HLA-A0201 tetramer (Beckman-Coulter) prior to normally 
stain with surface markers. 
Intracellular cytokine staining. Overexpressing BTLA WT or mutants in BTLA-/- 
OT-1 T cells were re-activated with either DC pulsed with OVA peptide (SIINFEKL) 
(Polysciences) or DC alone at a ratio of 1 to 40 in the presence of BD™ GolgiStop™ 
according to the manufacturer’s instruction. After 4 hours, cells were fixed and 
permeabilized using BD Cytofix/CytopermTM kits (BD Biosciences Cat: 554722) and 
subsequently stained with anti-mouse IFN-γ and anti-mouse TNF-α (BD Pharmigen).  
Cytokine multiplex assays. Murine BTLA KO OT.1 cells overexpressing BTLA WT 
or mutants were re-stimulated with either 10 ng/ml anti-mouse CD3 (Clone 145-2C11, 
BD PharmingenTM) alone or with recombinant Fc mouse HVEM (R&D systems) plate-
bound for 24 h. Supernatants were collected to quantify the secreted cytokines using a 
MILLPLEX multiplex assay according to manufacturer protocol (Millipore).  
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Killing assays. T cells were co-cultured with tumor cells labeled with efluor670® at 
ratio of 1 to 1, 1 to 3, and 1 to 10. After 3 h, the cells were fixed and permeabilized 
(BD Cytofix/Cytoperm), then stained with anti-cleaved caspase-3 (clone CPP32, BD 
Biosciences), and analyzed by a BD FACSCanto II (BD Biosciences). The data was 
analyzed using FlowJo software (TreeStar). 
Cell proliferation assay. Murine BTLA-/- OT-1 expressing BTLA WT or mutants 
were labeled with efluor670® and re-stimulated with DC alone or DC pulsed with 
OVA peptide (SIINFEKL) at a ratio of 1 to 40 for 48 h prior to being analyzed using a 
BD FACSCanto II (BD Biosciences). The data was analyzed using FlowJo software 
(TreeStar). 
Nanowell array-based cytolytic assay. TIL and Tumor cells were labeled with 1 
µmol/L of red fluorescence dye (PKH26, Sigma) and 1 µl of green fluorescence dye 
(PKH68, Sigma) respectively. The cells were loaded onto nanowell at concentration of 
1x106/mL. Target cell cytolysis mediated by TIL was monitored using a Carl Zeiss 
Axio Observer fitted with Hamamatsu EM-CCD camera using 10 x 0.3 NA objective. 
Apoptotic cells became green when stained with Annexin V conjugated with Alexa 
647as previously described.  
Adoptive Transfer and IL-2 treatment. The NOD/SCIDγc-/- (NSG) mice in each 
experiment contained 5 to 8, 10-12 week-old female mice per group. We were 
subcutaneously engrafted with either 10 x 106 526 melanoma tumors or 10 x 106 
autologous melanoma tumors. On day 12, either 5 x106 sorted CD8+BTLA+ or sorted 
CD8+BTLA- were adoptively transferred into tumor-bearing mice through the tail vein. 
In the virally transduced TIL experiment, either sorted CD8+GFP+WT, CD8+GFP+∆ 
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Grb2, CD8+GFP+∆ ITSM, or CD8+GFP+empty vector controls were transferred 
instead. Recombinant human IL-2 (Proleukin, Novartis) was administered 
intraperitoneally at a concentration of 6 x105 I.U. immediately after TIL transfer twice 
daily for three day. Tumor size was measured every other day using calipers. Mice were 
sacrificed when tumors exceeded 15 mm diameter. Peripheral blood was collected 
every other day, washed with 1X PBS twice, and lysed with ACK lysis buffer. The 
cells were stained for human surface markers, CD45, CD8, and Aqua (viability) for 20 
minutes on ice. After, the cells were washed with 1XPBS twice prior to acquire using 
a BD FACScanto II flow cytometer machine.  The data was analyzed using FlowJo 
software (TreeStar). 
Statistical Analysis 
For all survival curve analysis data, we used the log rank test to compare distribution 
of two groups. We applied Linear Models and Empirical Bayes Methods to compare 
the differential protein expression from RPPA data sets. Difference in the percentage 
of positive cells producing IFN-γ and TNF-α was analyzed using an ANOVA, and a 
two-tailed Student’s t-test was used to determine statistical significance for other 
analyses. 
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